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SUMMARY 
 
 It is estimated that 8.5 million new tuberculosis cases occurred in the year 2001 
and that 1.8 million people died of TB. Operational research to improve the use of 
existing tools is vital. Studies in Manila, Philippines were carried out to exami ne TB 
illness experience and help seeking of TB patients. Apart from patient interviews, 
focus group discussions with non-affected urban poor residents and group discussions 
with public health care providers were carried out. The TB illness burden was found 
to be substantial; ill-defined suffering, such as emotional and social distress as well as 
social stigma, was common. Non-affected urban poor residents expressed 
ambivalence towards TB patients: fear of getting infected contrasted with feelings of 
concern and support. Interaction with the health care providers was found to be 
problematic. Misconceptions have the potential to increase the burden of TB. Giving 
health information, interpersonal skills and other aspects of clinical care need to be 
improved.  
 
   The patient interviews also inquired about case finding. Only 29% of the 
respondents had gone first to a health centre after onset of TB-related symptoms, and 
53% had initially consulted a private doctor. Two-thirds of the patients (66%) had 
received a prescription for drugs, and 29% had purchased and taken anti-TB drugs for 
at least three weeks before they came to a public health centre. The health seeking 
delay after symptom onset was relatively short – 64% of the respondents said they 
went to a health facility within one month. 
 
  With these findings as a background, we examined the TB-related practices of 
the private practitioners and approaches to public-private collaboration and assessed 
the feasibility, acceptability and effectiveness of thrice-weekly therapy in comparison 
to daily therapy. Forty-five private practitioners of Malabon who treat adult TB 
Summary 
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patients were interviewed in their clinics. For diagnosis, most private practitioners 
relied on clinical presentation and result of an X-ray and 96% used X-ray as a tool to 
monitor treatment. Sixty percent of the respondents prescribed in accordance to 
international guidelines a regimen consisting of isoniazid, rifampicin, pyrazinamide, 
and ethambutol. However, over-dosage was common and length of treatment not 
always correct. For re-treatment cases, none prescribed the recommended re-
treatment regimen. The private practitioners perceived the main reasons for patient 
non-adherence to be the patients' lack of finances to buy drugs and patients' perceived 
well-being after a certain period of treatment. Patients' lack of money was seen as the 
main obstacle to treatment adherence. The only case holding mechanism mentioned 
was occasional visits of the TB patients to the clinic. Our findings of the private 
practitioner's unsatisfactory quality of care and of the limitations of the public sector 
indicate the need for collaboration between public and private sectors. The private 
practitioners were therefore asked about their felt needs for additional knowledge on 
clinical management of tuberculosis and their views on the public TB programme and 
collaboration with the public health sector. And discussions with personnel of the 
public health centres inquired about collaboration with private practitioners. The 
private practitioners' most frequently mentioned needs for updated clinical knowledge 
were about appropriate use of sputum microscopy, how to tell patients that household 
contacts need a check-up, and motivating the patients to adhere to treatment. There 
was considerable interest to receive and follow the national TB guidelines. The main 
perceived problems they identified with the public TB programme were insufficient 
drug supply, poor quality of the TB drugs, and lack of health education. Two 
suggestions on how to establish public-private collaboration (mandatory referral of 
poor TB patients to the public TB programme and allowing private practitioners to 
use the governmental TB drugs) were generally welcome, but they expressed 
reservation concerning feasibility of the latter suggestion. The personnel of the public 
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health centres were positive about mandatory referral of poor TB patients to the 
public TB programme but sceptical about allowing private practitioners to use the 
governmental TB drugs. Our findings suggest steps to facilitate public-private 
collaboration. The public programme needs to be strengthened and collaboration 
prioritised. Public-private collaboration has great potential to make TB care that is 
based on the principles of DOTS, the internationally recommended treatment 
strategy, accessible to more people with TB.  
 
  While our studies on the private practitioners and public-private collaboration 
aimed to see DOTS being used more widely, the randomised controlled trial that 
compared thrice weekly with daily therapy aimed to make the main tool of DOTS, 
namely short-course chemotherapy, more efficient and patient- as well as provider-
friendly. Intermittent regimens (twice weekly and thrice weekly regimens) are 
recommended, but the evidence base regarding their effectiveness in comparison to 
daily therapy is not very strong. We carried out a randomised controlled trial: thrice-
weekly therapy was randomly assigned to 10 of the 20 health centres of a 
municipality in Manila. All TB patients of the other 10 health centres received daily 
therapy. Patients were interviewed three times. Drug susceptibility tests were 
performed. A total of 806 patients (451 under thrice-weekly and 355 under daily 
therapy) were interviewed shortly after treatment start. 18.5% were re-treatment 
cases. Multidrug-resistant TB was found among 2% of the new and 26% of the 
previously treated patients. Under thrice-weekly therapy, directly observed therapy in 
the health centres was more common than when treatment was daily. Thrice-weekly 
therapy was more popular among patients and health personnel and resulted in 
savings of about 40% of the cost of drugs. There were also some disadvantages of 
thrice-weekly therapy compared to daily therapy: gastro-intestinal disturbances were 
reported more frequently. And sputum conversion rate assessed after two months of 
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treatment was lower (74% vs. 81%; p = 0.03). Treatment outcome was similar, but 
treatment failure and default due to side effects was more common among those 
treated thrice weekly (p = 0.08 and p = 0.04, respectively). In a multivariate model, 
adverse treatment outcome (failure and relapse) was not associated with mode of 
treatment (p = 0.7). In the light of the potential benefits of intermittent therapy, its 
equivalence to daily therapy should be established more firmly and if confirmed, 
fully thrice-weekly therapy should be used more widely.    
 
   Our research indicated approaches of how to improve TB control in terms of 
more appropriate practices in the private sector, better access to proper TB care, and 
more efficient and patient-friendly use of treatment. Resources and commitment for 
further operational research and for pilot projects are needed to further test and 
implement outlined approaches to public-private collaboration and to clarify the role 
of intermittent therapy. 
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ZUSAMMENFASSUNG 
 
Es wird geschätzt, daß im Jahr 2001 rund 8,5 Millionen neue Tuberkulosefälle 
aufgetreten und 1,8 Million Leute an Tuberkulose (TB) gestorben sind. Angewandte 
Forschung, die das Ziel hat, den Einsatz der bestehenden Instrumente zu verbessern, ist 
sehr wichtig. In Manila, Philippinen wurden Studien durchgeführt, um TB-
Krankheitserfahrungen (‚TB illness burden’) und das Suchen nach 
Gesundheitsdienstleistung (‚help seeking’) von TB Patienten zu erfassen. Abgesehen von 
einer Befragung von TB Patienten wurden ‚Focus Group Discussions’ mit nicht-
erkrankten städtischen armen Bewohnern und Gruppendiskussionen mit öffentlichen 
Gesundheitsversorgern durchgeführt. Es wurde gefunden, daß die TB-
Krankheitsbelastung erheblich ist. Schwer zu definierendes Leiden, wie emotionale und 
soziale Not und soziales Stigma, war verbreitet. Nicht-erkrankte städtische arme 
Bewohner drückten Ambivalenz gegenüber TB-Patienten aus: Furcht vor dem infiziert 
Werden stand im Kontrast zu Gefühlen der Anteilnahme und Hilfsbereitschaft. Die 
Interaktion mit den Versorgern des Gesundheitsdienstes wurde als problematisch 
empfunden. Mißverständnisse haben das Potential, die TB-Krankheitsbelastung zu 
erhöhen. Das Vermitteln von Gesundheitsinformationen, Kompetenz im Umgang mit 
Patienten und andere Aspekte der klinischen Versorgung müssen verbessert werden.  
 
Die Patienteninterviews untersuchten auch den Prozess der Identifizierung der 
Krankheit (‚case finding’). Nur 29% der Antwortenden waren nach dem Ausbruch von 
Symptomen, die mit TB in Verbindung standen, zuerst zu einem öffentlichen 
Gesundheitszentrum gegangen und 53% hatten zuerst einen Arzt im privaten Sektor 
aufgesucht. Zweidrittel der Patienten (66%) hatten eine Verordnung für Medikamente 
und 29% hatten TB-Medikamente für mindestens drei Wochen eingenommen, bevor sie 
zu einem öffentlichen Gesundheits zentrum gingen. Die Verzögerung der Suche nach 
Gesundheits-dienstleistung (‚help seeking delay’) war eher gering; 64% der 
Antwortenden sagten, daß sie innerhalb eines Monats zu einer Gesundheitseinrichtung 
gegangen waren.  
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Mit diesen Befunden als Hintergrund untersuchten wir sich auf TB beziehende 
Handhabungen der Ärzte im privaten Sektor und Ansätze zur Zusammenarbeit des 
öffentlichen und privaten Sektors (’public-private collaboration’). Wir untersuchten auch 
die Machbarkeit, Akzeptanz und Wirksamkeit der dreimal-wöchentlichen Therapie im 
Vergleich zur täglichen Therapie. In Malabon befragten wir 45 Ärzte des privaten 
Sektors, die erwachsene TB-Patienten behandeln, in ihren Kliniken. Für die Diagnose 
verliessen sich die meisten Ärzte des privaten Sektors auf die klinische Erscheinung und 
auf das Resultat einer Röntgenschirmbilduntersuchung; 96% benutzten Letzteres, um die 
Behandlung zu überwachen. Sechzig Prozent der Antwortenden verschrieben in 
Übereinstimmung mit den internationalen Richtlinien eine Behandlung, die aus Isoniazid, 
Rifampicin, Pyrazinamide und Ethambutol bestand. Jedoch war Überdosierung verbreitet 
und die Länge der Behandlung nicht immer korrekt. Für schon zuvor behandelte Fälle 
verschrieb niemand die empfohlene Wiederholungs-Therapie. Die Ärzte im privaten 
Sektor empfanden, daß die Hauptgründe für die Nichtbefolgung der Therapie von Seiten 
der Patienten der Mangel an Geld für das Kaufen der Medikamente und die von den 
Patienten empfundene Gesundung nach einer Weile der Behandlung sind. Der 
Geldmangel der Patienten wurde als das Haupthindernis zur Befolgung der Therapie 
gesehen. Die einzige Massnahme, die Therapietreue zu fördern, bestand darin, den TB 
Patienten von Zeit zu Zeit in die Klinik zu bitten. Unsere Befunde, daß die Dienstleistung 
der Ärzte im privaten Sektor von unbefriedigender Qualität war und daß der öffentliche 
Sektor an Grenzen stiess, deuten auf die Notwendigkeit der Zusammenarbeit zwischen 
dem öffentlichen und dem privaten Sektor. Die Ärzte im privaten Sektor wurden folglich 
gefragt, welches ihre Bedürfnisse nach zusätzlichen Wissen betreffend klinischer 
Handhabung der Tuberkulose waren und was ihre Ansichten über das öffentliche TB 
Programm und die Zusammenarbeit mit dem öffentliche n Sektor des Gesundheitswesens 
waren. Und Diskussionen mit dem Personal der öffentlichen Gesundheitszentren 
erörterten die Zusammenarbeit mit den Ärzten des privaten Sektors. Passender Gebrauch 
von Sputummikroskopie, wie man Patienten erklärt, daß Haushaltkontakte eine 
Gesundheitsüberprüfung benötigen und das Motivieren von Patienten, die Therapie 
korrekt zu befolgen, wurden am häufigsten erwähnt in Bezug auf Bedürfnisse nach 
zusätzlichem klinischen Wissen. Es gab beträchtliches Interesse, die nationalen TB-
Richtlinien zu erhalten und zu befolgen. Als Hauptprobleme des öffentlichen TB-
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Programms wurden unzulängliche Versorgung mit TB-Medikamenten, unbefriedigende 
Qualität der TB-Medikamenten und Mangel an Gesundheitsausbildung (‚health 
education’) erwähnt. Zwei Vorschläge, wie man Zusammenarbeit zwischen dem 
öffentlichen und dem privaten Sektor erreichen könnte (obligatorisches Weiterleiten von 
armen TB-Patienten an das öffentliche TB-Programm und den Ärzten des privaten 
Sektors erlauben, TB-Medikamente der Regierung zu verwenden) waren im Allgemeinen 
willkommen, aber Vorbehalte hinsichtlich der Machbarkeit des zweiten Vorschlages 
wurden formuliert. Das Personal der öffentlichen Gesundheitszentren war positiv 
eingestellt gegenüber obligatorischem Weiterleiten von armen TB-Patienten an das 
öffentliche TB-Programm, aber skeptisch gegenüber dem Vorschlag, den Ärzten des 
privaten Sektors die Verwendung von TB-Medikamenten der Regierung zu erlauben. 
Unsere Befunde führen zu Vorschlägen, wie Zusammenarbeit zwischen dem öffentlichen 
und dem privaten Sektor gefördert werden kann. Das öffentliche TB-Programm muß 
gestärkt und die Zusammenarbeit eine Priorität werden. Die Zusammenarbeit zwischen 
dem öffentlichen und dem privaten Sektor hat grosses Potential, die Behandlung von TB, 
welche auf den Grundsätzen von DOTS (der international empfohlenen 
Behandlungstrategie) beruht, mehr Patienten zugänglich zu machen.   
 
Während unsere Untersuchungen über die Ärzte des privaten Sektors und über 
eine Zusammenarbeit zwischen dem öffentlichen und dem privaten Sektor zum Ziel 
hatte, DOTS zu umfassenderer Anwendung zu bringen, hatte die randomisierte 
kontrollierte Studie zum Ziel, einen Bestandteil von DOTS, nämlich die 6-bis 8-Monate 
dauernde Chemotherapie, effizienter und gebrauchsfreundlicher (sowohl für Patienten als 
auch für das Gesundheitspersonal) zu machen. Die Studie verglich ein 
Behandlungsschema, bei der die Medikamenteneinnahme nur dreimal pro Woche 
stattfindet (‚thrice-weekly therapy’) mit täglicher Behandlung (‚daily therapy’). Nicht-
tägliche Behandlungsschemen (‚intermittent therapy’), sei es zweimal oder dreimal pro 
Woche, werden empfohlen, aber die vorhandene Evidenz betreffend ihrer Wirksamkeit 
im Vergleich zu täglicher Medikamenteneinnahme ist nicht sehr robust. Wir führten eine 
randomisierte kontrollierte Studie durch: dreimal-wöchentliche Therapie (‚thrice-weekly 
therapy’) wurde nach dem Zufallsprinzip 10 der 20 Gesundheitszentren eines 
Stadtbezirkes in Manila zugewiesen. Alle TB-Patienten der anderen 10 
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Gesundheits zentren empfingen tägliche Therapie. Die Patienten wurden dreimal 
interviewt.  Die TB Bazillen in den Sputa wurden in Bezug auf Medikamentenresistenz 
getestet. Insgesamt wurden 806 Patienten (451 unter dreimal-wöchentlicher Therapie und 
355 unter täglicher Therapie) kurz nach dem Beginn der Behandlung interviewt. 18,5% 
waren schon früher mindestens einmal wegen TB behandelt worden. Zwei Prozent der 
Patienten, die erstmals TB hatten, und 26% der schon zuvor behandelten Patienten hatten 
TB Bazillen, die zumindest gegen Isoniazid und Rifampicin resistent waren (‚multidrug-
resistant TB’). Mit dreimal-wöchentlicher Therapie war in den Gesundheitszentren 
durchgeführtes Beobachten der Medikamenteneinnahme häufiger als mit täglicher 
Therapie. Dreimal-wöchentliche Therapie war unter Patienten und dem medizinischen 
Personal populärer und ergab Einsparungen von ungefähr 40% der 
Medikamentenausgaben. Es gab auch einige Nachteile der dreimal-wöchentlichen 
Therapie verglichen mit täglicher Therapie: gastro-intestinale Störungen wurden häufiger 
gemeldet.  Und nach zwei Monaten der Behandlung war ein Sputum, in dem sich noch 
immer TB-Bazillen mit dem Lichtmikroskop finden liessen, häufiger (26% im Vergleich 
zu 19%;  p = 0.03).  Der Ausgang der Behandlung war ähnlich, aber erfolglose 
Behandlung und das Abbrechen der Therapie wegen Nebenwirkungen waren häufiger mit 
der dreimal-wöchentlichen Therapie (p = 0,08 und p = 0,04, beziehungsweise). In einem 
multivariaten Modell war ein nachteiliger Ausgang der Behandlung (erfolglose 
Behandlung und Rückfall) nicht mit dem Modus der Behandlung assoziiert (p = 0,7). 
Angesichts der potenziellen Vorteile der nicht-täglichen Behandlungsschemen sollte 
seine Gleichwertigkeit zur täglichen Therapie eingehender untersucht werden und (falls 
die Gleichwertigkeit bestätigt ist) durchgehend dreimal-wöchentliche Therapie 
verbreiteter eingesetzt werden.  
 
Unsere Forschung wies auf Strategien für eine bessere Bekämpfung der TB auf 
drei Ebenen hin: Bessere Handhabungen im privaten Sektor, besserer Zugang zu 
korrekter Behandlung der TB und effizienterer und patientenfreundlicherer Gebrauch der 
Medikamente. Mittel und echter Einsatz für weitere angewandte Forschung und für 
Pionierssprojekte sind nötig, um die erwähnten Strategien für eine Zusammenarbeit 
zwischen dem öffentlichen und dem privaten Sektor weiter zu testen und einzusetzen und 
um die Rolle der nicht-täglichen Behandlungsschemen zu klären.  
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CHAPTER 1: BACKGROUND  
 
1.1. Motivation for the thesis and overview  
 
In 1997 and 1998 operational research on tuberculosis (TB) control was carried out in 
Malabon and to a lesser degree also in Navotas, two municipalities of Metro Manila, 
Philippines. The main components were: 
   
1.  An evaluation of the public TB programme of Malabon. This included questionnaires 
for health centre staff and community health volunteers. Countless encounters with people 
responsible for TB control (the range was from the municipal TB co-ordinator to the 
community health volunteers) were part of this evaluation.  
 
2.  Extensive patient interviews (319 patients were interviewed) that covered topics such 
as health seeking behaviour, treatment adherence (Auer, 1998), the socio-emotional burden 
of having TB, and stigma.  
 
3.  Focus group discussions with poor urban residents. Chapters 4 and 5 presents parts of 
the findings from the health provider questionnaires, the patient interviews, and the focus 
group discussions.  
 
4. Record reviews and interviews with public health providers and with TB patients from 
Malabon and from Navotas regarding DOT (directly observed therapy). 
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Three findings became important for the development of further research: 
 
One, as presented in Chapter 5, it was found that more than half of the TB patients 
being treated in the public health centres had made use of private practitioners (66% had 
received a prescription for drugs, and 29% had purchased and taken anti-TB drugs for at 
least three weeks before they came to a public health centre).  
 
Two, availability of TB drugs in the health centres was not always guaranteed.  
 
Three, proper DOT (daily supervision of drug intake) was hard to implement. The 
burden for the patients and/or for the health providers could be substantial.  
 
Also, a review of the international literature made clear that intermittent therapy 
(thrice-weekly or twice-weekly intake of drugs) resulted in reduced costs for buying drugs 
and suggested that it was effective, facilitating treatment supervision, and of advantage to 
patients and providers.  
 
   This lead to the conviction that the two following approaches have considerable 
potential to improve TB control and TB care:  
 
· One, collaboration between the private practitioners and the public health providers 
would significantly reduce the burden of having TB, mainly by simplifying the health 
seeking process and by making proper treatment more likely. 
 
· Two, intermittent therapy would enable the government to treat more TB patients with 
the same amount of money earmarked for TB drugs, would facilitate proper 
implementation of DOT and would reduce the burden of treatment, especially DOT, 
for patients and providers.  
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Thus, further research in Manila was carried out as a PhD project. The main goal 
of the project is to contribute to the development of more effective strategies for TB 
Control. One part of the research project looks at the TB-related practices of the private 
practitioners of Malabon and at approaches to public-private collaboration. The other part 
compares thrice-weekly with daily therapy in the public health centres of Taguig, another 
municipality of Metro Manila. 
 
While the two parts do not have obvious links apart from their common goal to 
find a more effective and efficient approach to TB control, it can be argued that the second 
part facilitates the goal of the first part, namely public-private collaboration. If the public 
health providers use a more efficient and more attractive treatment approach (and the 
hypothesis is that intermittent therapy is more efficient and patient- as well as provider-
friendly) then collaboration with the private practitioners, for instance timely referral of 
private patients with limited financial resources to the health centres, is more likely. The 
better the public TB programme works, the more willing people with TB are to get treated 
in public health clinics and the easier facilitation of public-private collaboration is.  
 
After first giving an overview of the burden of tuberculosis in the world, and 
outlining as well as critically discussing the internationally recommended treatment 
approach, this thesis then reports some of the findings of the work of 1997 and 1998 
(Chapters 4 and 5) that help to understand the TB patient.  This understanding lays a ground 
for aspiring to improve TB control. The findings of the two tested strategies to improve TB 
control are then presented. First the findings regarding public-private collaboration and 
then the findings from the randomised controlled trial that compares thrice-weekly with 
daily therapy in the public health centres of Taguig.  
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1.2. The burden of tuberculosis 
1.2.1.  Public health indicators  
 
"The conquest of the 'Great White Plague', undreamt of less than ten years ago, 
is now virtually within sight." 
 
and 
 
"…  the ancient foe of man, known as consumption, the great white plague, tuberculosis, 
or by whatever other name, is on the way to being reduced to a minor ailment of man. 
The future appears bright indeed, and the complete eradication of the disease is in sight." 
 
Selman A. Waksman, co-discoverer of streptomycin, in his Nobel Lecture 1952 
and in his book of 1966 "The Conquest of Tuberculosis" (Waksman, 1952 and 1966) 
 
 
 
"Tuberculosis currently kills three million people a year. Unless immediate action is 
taken it will claim more than 30 million lives during the coming decade. The disease is 
out of control in many parts of the world." 
 
Hiroshi Nakajima in 1993, then the Director-General of the WHO (Nakajima, 1993) 
 
     * * * 
 
In the nineteenth century, TB was responsible for nearly one in ten deaths in 
Europe (Preston et al., 1972, cited in Murray et al., 1990). Another estimate is that in the 
middle of the nineteenth century, TB accounted for 15-20% of all deaths in industrialised 
countries. In many countries of the South, particularly in sub-Saharan Africa, TB had not 
yet spread widely and was mostly confined to urban areas. It is further estimated that in 
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the mid-1800’s, TB killed 1.9 million people per year, more than half of these deaths 
occurring in Europe and North America (Dubos & Dubos, 1952, cited in Kochi, 1994). 
 
Over the next 150 years, the TB mortality rate in Europe, North America and 
Oceania declined from more than 300 per 100,000 to 1-2 per 100,000 and the absolute 
number of people dying of TB declined from more than one million to less than 50,000 in 
spite of a more than tripling of the population. In the countries of the South, the death rate 
declined from more than 100 to less than 50 per 100,000. But because of a more than 
fivefold population increase and poorly implemented TB control programmes, the 
absolute number of TB deaths increased from less than one million to 2.7 million in 1992 
(Kochi, 1994). The estimate for 1995 was that 3 million people died of tuberculosis 
globally and that 8.9 million new cases of tuberculosis occurred (WHO, 1996). It is 
further estimated that 98% of TB mortality and 95% of the new cases of TB occur in the 
so-called developing countries (WHO, 2001, p. 29). 
 
A paper of 1994 stated that without improvement of treatment, 3.5 million people 
were expected to die of tuberculosis in the year 2000 (Dolin et al., 1994). For 1997, it 
was estimated that 1.87 million TB deaths and 7.96 million new cases of TB occurred in 
the world (Dye et al., 1999) and an estimated 1.66 million people died of TB in the year 
2000 (WHO, 2001a). This much lower figure compared to the expected number of 3.5 
million is mostly due to more accurate estimates (some assumptions about TB case 
fatality rates were altered - Dye et al., 1999) but partly also due to the effects of a 
growing implementation of the DOTS strategy (see chapter 1.3.1. regarding DOTS). For 
instance, it is estimated that the successful implementation of the DOTS strategy in India 
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has prevented the death of 200,000 people, mostly in the years 1999 to 2001 (Khatri & 
Frieden, 2002).  
 
In terms of global burden of disease (expressed in DALYs - disability-adjusted 
life years lost), it is estimated that in 1990, TB ranked seventh (Murray & Lopez, 1997) 
and in the year 2000 TB tenth (WHO, 2002). In the year 2001, an estimated 2.5% of the 
global burden of disease was due to TB (WHO, 2002a).    
 
1.2.2.  Economic indicators 
 
 The economic impact of TB can be severe. Studies in Asian countries such as 
Thailand (Kamolratanakul et al., 1999), Bangladesh (Croft & Croft, 1998) and India 
(Rajeswari et al., 1999; Nair et al., 1997) and in African countries such as Uganda 
(Saunderson, 1995), Zambia (Needham et al., 1998; Needham & Godfrey-Faussett, 
1996), Malawi (Pocock et al., 1996), Sierra Leone (Gibson et al., 1998) and Tanzania 
(Wyss et al., 2001) revealed that before and during treatment substantial patient costs 
often occur, direct and indirect costs. For instance, the study in Bangladesh (Croft & 
Croft, 1998) found that by the time the TB patients had registered for treatment at an 
NGO, the mean financial loss per patient was US $ 245.-. Approximately half of this loss 
was due to loss of income, and most of the other half was spent for drugs.    
  
 In most low- and middle-income countries, more than 75% of the TB patients 
are in the economically active age group of 15 to 54 years (Murray, 1996, p. 212). Thus, 
loss of family income due to a case of TB is often severe. It is estimated that on average, 
TB causes three to four months of lost work time and lost earnings of 20 to 30% of the 
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annual household income. And for families of persons who die of TB, about 15 years of 
income are lost due to the premature death of the TB patient (Stop TB, 2000). Most of 
the indirect costs of having tuberculosis are difficult to assess and quantify. For instance, 
a study in South India found that 11% of 276 children of TB patients had discontinued 
school and 8% took up some form of employment as a result of the burden of their 
father's or mother's TB (Rajeswari et al., 1999). And another study in South India found 
that female TB patients reported a 50% reduction in household work, and two-thirds felt 
they were not able to attend adequately to the needs of their children (Ramachandran et 
al., 1997). Direct costs can also be substantial. For instance, in Thailand, out-of-pocket 
expenditure for the diagnosis and treatment of TB in the private sector accounts for over 
15% of annual income for households already below the poverty line (Kamolratanakul et 
al., 1999). And in Mumbai (Bombay) it was found that almost 10% of the income was 
used for travel expenses even though these patients had to come to the clinic twice a 
month only (Chakraborty et al., 1995). The study in South India (Rajeswari et al., 1999) 
gives the following overview in terms of the various costs: the proportion of various 
costs in relation to the annual family income was 13% for directs costs, 26% for indirect 
costs, 40% for total cost, and 14% for debts.  
 
In terms of macroeconomics, it is estimated that the burden of TB results in an 
economic toll of US $ 12 billion from incomes of the world's poorest communities every 
year (Stop TB, 2002). It follows that using money for TB control is a good investment 
for a government. A study in India from the mid-1990’s illustrates this. It found that 
projected incremental costs to the Indian government for successful DOTS 
implementation throughout India are of the order of US $ 200 million per year compared 
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to the tangible economic benefits of at least US $ 750 million per year (WHO, 1997). 
This is true for all low - and middle-income countries: for each dollar invested in DOTS, 
the expected return in increased economic output is more than 3.5 dollars (Stop TB, 
2002). Eliminating TB is a way of putting back billions of dollars into the national 
economies of poorer countries.  
 
All these figures demonstrate that the burden of disease due to tuberculosis is 
huge. This is a tragic paradox since effective and cheap therapy has been available for 
decades. This paradox indicates a dramatic failure to use medical advances for the wider 
benefit of humankind, as the quotes at the beginning of this chapter also suggest. 
 
 
1.2.3. The burden of illness 
 
In addition to the impact of TB indicated by its morbidity, mortality and DALY 
burden, and economic indicators, TB produces immense suffering that must be 
characterised in other ways, though it is strongly linked to the other indicators of the 
burden of TB. TB not only brings sickness and death but also causes emotional distress 
and relational strain within families and communities. TB has an awesome capacity to 
disrupt lives and families. Even within their families TB patients may experience being 
feared or ostracised, as studies revealed in India (Nair et al., 1997), Pakistan (Khan et al., 
2000; Liefooghe et al., 1995), Kenja (Liefooghe et al., 1997), and Mexico (Herrera et al., 
1971, cited in Rubel & Garro, 1992). In the study in Mexico, 52% of hospitalised but 
eventually discharged TB patients were no longer accepted in their families. And in the 
study in Pakistan the risks of not getting married and of divorce due to TB were seen to 
be greater for female than for male patients (Liefooghe et al., 1995).  
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Stigma is an important aspect of the social and emotional suffering from 
tuberculosis; chapter 4 explores the experience of stigma and its meaning. The following 
case study illustrates the heavy burden of illness of TB in a place where strong stigma is 
attached to tuberculosis. The case study is a shorter version of the original case study 
presented by Rangan and Uplekar (1999).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sharda, a mother of four, living in Western India, felt weak and tired and was 
troubled by cough. She visited the local private doctor who treated her with some 
cough mixtures, tonics and antibiotics for one and a half months. He later told her to 
get a check-up in the nearby town or at the local public health centre. However, over 
the next few months, Sharda had no further check-up and her physical condition 
deteriorated. Her mother-in-law then told her to go home to her own mother for 
treatment and rest. There, a neighbour was a health worker of the public health 
centre who told Sharda's mother that the sputum should be examined. This worried 
the family since usually only TB patients had their sputum examined. Giving sputum 
would result in having the whole neighbourhood talk about Sharda's health. 
Therefore, Sharda went to a reputed private doctor in a city. This doctor diagnosed 
TB and explained the need to take drugs for 6 to 8 months. The family refused to 
believe that Sharda had TB. Two other doctors were consulted before the diagnosis 
TB was accepted. It was clear that Sharda's TB had to be kept secrete from her in-
laws and husband. Otherwise, she would never be accepted back. When the private 
treatment no longer was possible due to lack of money and after a failed trial to get 
healed at a traditional healer Sharda started treatment in the public health centre and 
managed to complete treatment thanks to her brother's prodding.  
A letter was sent to Sharda's husband, and the husband, together with the elder 
children, came to Sharda's place. He wanted to take her home but his mother was 
sceptical and refused to accept her due to her TB, although now cured. Since the 
husband did not want his family to be ostracised because of having Sharda among 
them, he went home without her.  
A month later Sharda was informed that her husband had decided to get re-married. 
Devasted, Sharda lost all interest in life and two months later developed cough and 
fever. TB was diagnosed. However, Sharda refused treatment. 
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1.3. The control of tuberculosis in the world             
1.3.1. DOTS - the recommended control strategy          
 
The last major improvement in treatment of tuberculosis occurred in the late 1960’s/early 
1970’s with the introduction of rifampicin and pyrazinamide, which made highly 
efficacious and effective 6- to 9-month-long treatment possible (Fox et al., 1999) and 
paved the way for so-called short-course chemotherapy1. However, this cost-effective 
tool - one of the most cost-effective health interventions of all (De Jonghe et al., 1994; 
World Bank, 1993; Jamison & Mosley, 1991) - was not used at all or was not used 
effectively in many countries all over the 1970’s and 1980’s. An important step towards 
the end of an irresponsible neglect of tuberculosis and its control2 was made in 1991 
when Arata Kochi, then the Chief Medical Officer of the Tuberculosis Unit of the WHO 
(World Health Organisation) in Geneva, published an article. The title of this article - 
hailed as a classic public health paper (Sbarbaro, 2001) - was "The global tuberculosis 
situation and the new control strategy of the World Health Organization" (Kochi, 1991). 
In the same year, the World Health Assembly adopted the new control strategy (WHO, 
1991). However, the outline of this new control strategy was not very clear and another 
two years passed until the WHO took the unprecedented step of declaring tuberculosis a 
global emergency (WHO, 1993) and clearly propagated a treatment strategy (WHO, 1994).  
 
____________________ 
1 The first-line anti-TB drugs were introduced in the following years: streptomycin in 1944, thioacetazone 
in 1946, isoniazid in 1952 (but first synthesised in 1912! - Bloom & Murray, 1992; Meyer & Mally, 1912, 
cited in Rieder, 2002), pyrazinamide in 1952, ethambutol in 1961, and rifampicin in 1966 (Rieder, 2002).  
2 Three expressions of this neglect (reported in Klaudt, 1998) were: One, in 1986, the British government 
closed the TB unit of the British Medical Research Council (a major player in the development of short-
course chemotherapy). Two, in 1988, WHO had only one medical officer responsible for tuberculosis at its 
Geneva headquarters. Four decades earlier, WHO had had nearly fifty medical staff assigned to address TB 
in its European regional office alone. Three, in 1990, only 0.03% of foreign aid (16 million US $) went to 
TB control in the developing countries although TB was responsible for 26% of avoidable adult death in 
the so-called developing world (Murray et al., 1990).  
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The strategy was called DOTS for the first time in 1994 by the WHO (WHO, 2001, p. 
37). 
 
Based on decades of experience with various approaches to TB control that saw 
vertical approaches to TB control and waves of integration (Raviglione & Pio, 2002) 
DOTS has evolved and proven it can be implemented in all kinds of settings. It makes 
good use of the existing health services but at the same time specific key functions and 
central technical staff that also exercise supervisory function are an integrated part of a 
national TB programme that is based on DOTS. 
 
DOTS  3 has five key components: 
 
1.  Political commitment to sustained TB control activities 
2.  Case detection by sputum smear microscopy among symptomatic patients self-
reporting to health services ('passive case finding') 
   
3.  Standardised treatment regimen of six to eight months for at least all confirmed 
sputum smear positive cases, with directly observed therapy (DOT) for at least the 
initial two months of treatment (DOT should be for the whole length of treatment if 
rifampicin is being used for the whole length of treatment) 
 
4.  Free, reliable (i.e. regular and uninterrupted) supply of high-quality anti-TB drugs 
 
5.  A standardised recording and reporting system that allows the assessment of 
treatment results for each patient and for the TB control programme overall.  
   
_____________________ 
3 Until recently, DOTS stood for 'Directly Observed Treatment, Short-course'. However, in the year 2002 it 
was decided to see DOTS as a pure brand name, i.e. to no longer see it as an acronym for 'directly observed 
treatment, short-course'. When being seen as an acronym, DOTS gives undue emphasis to just one of the 
five elements of DOTS, namely to DOT, the only element of DOTS that is controversial (Lancet 
correspondence, 2001). 
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The strategy was developed based mainly on experiences of the IUATLD 
(International Union Against Tuberculosis and Lung Disease) in the late 1970s and early 
1980s (Enarson, 1991; Rouillon, 1991). The countries were Tanzania and then other 
African countries, and Nicaragua (WHO, 2001, p. 37). A key person was Dr. Karel 
Styblo (1921 - 1998), then the scientific director of the IUATLD. He used a managerial 
approach and introduced the so-called short-course chemotherapy in poor settings, 
thereby reducing treatment from up to 18 months to 6 to 8 months. Close supervision of 
the patient was emphasised. Later on, the term DOT was formed (DOT means a 
representative from the health care system watches the patient swallowing his or her 
medicines, be it in the health facility, in the patient's home or somewhere else, e.g. in the 
workplace). However, the concept of patient supervision comes from the 1950’s and 
early 1960s: in places as diverse as Hong Kong, Madras (today called Chennai) and 
London it was concluded that direct supervision of therapy was needed (Humphries, 
1995; Bayer & Wilkinson, 1995). The principle of DOT has also been known in Russia 
since the 1950s (Perelman, 2000; Rabuhin, 1960, cited in Heifets & Iseman, 2002). And 
in Cuba, tuberculosis treatment by DOT was started in 1970 (Gonzalez et al., 1994). In 
other words, the principle of DOT was developed decades before the DOTS strategy was 
developed. It is also noteworthy that a TB programme with all the elements of DOTS was 
implemented in the whole of Chile in 1984. This happened at least partly due to visits of 
Karel Styblo (Farga, 1999).  
 
In early 1997, WHO declared DOTS to be a "breakthrough in tuberculosis control 
that will make it possible to save millions of lives" (Kochi, 1997). This announcement 
caused concern among tuberculosis frontline workers and leading TB researchers (Brown 
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1997; Grange & Zumla, 1997). It was felt that the difficulties in expanding DOTS and the 
limits of DOTS in the light of new threats, e.g. HIV/AIDS and multidrug-resistant 
tuberculosis (MDR-TB4), were underestimated. A report published in 1999 illustrated that 
WHO had been too optimistic. The report found that 37 of 85 examined "DOTS 
countries" had treatment success rates of below 70% and that none of the 22 high-burden 
countries (the 22 countries that worldwide account for 80% of all new TB cases) 
achieved WHO targets for TB control (Netto et al., 1999). And a paper published in late 
1998 stated: "Without greater efforts to control tuberculosis, the annual incidence of the 
disease is expected to increase by 41% (95% confidence interval: 21 - 61%) between 
1998 and 2020." (Dye et al., 1998).  
 
It became clear that the WHO targets for the year 2000, namely to detect 70% of 
smear-positive cases and cure at least 85% of the detected cases, could not be reached. 
Achieving these targets for the year 2005, the new goal, remains a formidable challenge. 
Without considerable acceleration of progress, the targets, specifically a 70% case 
detection under DOTS, will be reached by 2013 only (WHO, 2002b). Still, progress has 
been made: in the end of the year 2001, 61% of the world's population lived in parts of 
countries providing DOTS; 155 countries were implementing DOTS, notifying 1.2 
million smear-positive cases (and 1.2 million smear-negative cases) under DOTS.  
 
_________________ 
4
 MDR-TB is defined as resistance to at least rifampicin and isoniazid, the two most powerful drugs. Its  
treatment often lasts 2 years, is very expensive and the medications often cause side effects. The recent 
development of the so-called DOTS-Plus strategy slowly makes treatment for some MDR-TB cases 
possible in low-resource settings.  
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However, these 1.2 million represent only 32% of the estimated global total (WHO, 
2003). With an additional 143,000 cases detected by DOTS programmes in 2001 (WHO, 
2003), the rate of progress in case finding in 2001 was not significantly faster. The 
average progress from 1994 to 2000 was a mean annual increment of 133,000 smear-
positive cases (WHO, 2002b). But globally, DOTS programmes must recruit an extra 
360,000 smear-positive cases each year to reach 70% case detection by the end of 2005 
(WHO, 2003). It was also found that in the year 2000, DOTS programmes successfully 
treated 82% of all registered new smear-positive cases. Only one of the 22 high-burden 
countries, namely Vietnam, reached targets of case detection and cure (WHO, 2003).  
 
 
1.3.2. Challenges in TB control and responses to them 
 
In early 1998, WHO organised a meeting of health experts in London (WHO, 
1998). This meeting identified six principle constraints to TB control, namely: 
 
1.   Financial shortages 
2.   Human resource problems  
3.   Organisational factors 
4.   Lack of a secure supply of quality anti-TB drugs 
5.   Public information gaps about the danger of TB 
6.   Lack of political will to develop and sustain effective TB programmes. 
 
Lack of political will was identified as the most fundamental constraint. However, 
in the past few years, this will has strengthened. The increased funding is one expression 
of this: external financing for TB control in low-income countries (including bank loans) 
totalled only US $ 16 M in 1990, but increased to US $ 190 M in the year 2000 
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(Raviglione & Pio, 2002). The WHO is the leading agency in a movement called 'Global 
Partnership to Stop TB' (often called the "Stop TB Partnership", “Stop TB Initiative" or 
“Stop TB”) that was launched in November 1998. The 'Global Partnership to Stop' is a 
global coalition of partners to accelerate social and political action to stop the spread of 
tuberculosis and to mobilise more resources for this. The goal is to expand, adapt and 
improve strategies to control and eliminate TB. The targets are:  
 
 
· By 2005: 70% of people with infectious TB will be diagnosed, and 85% cured 
 
· By 2010: The global burden of TB disease (deaths and prevalence) will be 
reduced by 50% (compared with 2000 levels) 
 
· By 2050: The global incidence of TB disease will be less than 1 per million 
population. 
 
Two important events organised by the Stop TB Initiative were the 'Ministerial 
Conference on Tuberculosis and Sustainable Development’, held in Amsterdam, March 
2000 (WHO, 2000), resulting in the "Amsterdam Declaration to Stop TB" (WHO 2000a), 
and the first so-called Stop TB Partners' Forum in Washington, October 2001 (WHO, 
2001b), resulting in the "Washington Commitment to Stop TB" (WHO, 2001c). Ministers 
of health and finance from 20 of the 22 high-burden countries were present in 
Amsterdam. The 'Amsterdam Declaration' highlighted the magnitude and seriousness of 
the global epidemic and outlined the ways to curb this epidemic. It called for accelerated 
expansion of control measures and for increased political commitment and financial 
resources to reach the targets for global TB control by 2005. In May 2000, a World 
Health Assembly resolution of the WHO restated this call.  
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The Stop TB Partners' Forum in Washington, hosted by the World Bank, reported 
on progress since the Amsterdam Conference and discussed ways to accelerate efforts to 
reach targets for TB control by 2005. The "Washington Commitment to Stop TB" 
renewed the goal that all people with TB have access to effective care. Care of patients 
with drug-resistant tuberculosis, enhancing collaboration between TB and HIV/AIDS 
programmes, and establishing close public-private sector collaboration were specifically 
mentioned. A commitment to co-ordinate effective across-border action, emphasising that 
the health sector alone cannot control TB, was also made. Specific goals for the end of 
the year 2001 and for the end of 2002 were made and the targets of the Stop TB Initiative 
upheld. Also, the 'Global Plan to Stop TB' (WHO, 2001) was launched. This plan can be 
seen as the framework of all the activities co-ordinated by the Stop TB Initiative. The 
plan lays out what needs to be done to control, and eventually eliminate, TB in the world. 
It describes the strategies and mechanisms to achieve this and what these 
accomplishments will cost. It estimates the five-year cost of TB control to be US$ 9.3 
billion (6.2 billion of this for DOTS expansion). The estimated funding gap between 
resources currently available or pledged and the amount required is roughly US$ 4.5 
billion. The recently established 'Global Fund to Fight AIDS, TB and Malaria' is expected 
to help close the funding gap. The new estimates in the latest WHO report indicate this. It 
is now estimated that for the period 2001 to 2005, the total funding gap for national TB 
control programmes is only 0.2 billion US dollars. There may be an additional shortfall of 
at least 0.9 billion US dollars due to deficiencies in staff and infrastructure (WHO, 2003). 
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Advocacy, resource mobilisation and co-ordination are basic functions of the 
'Global Partnership to Stop TB'. Six working groups are being co-ordinated. The working 
groups focus on:  
 
· DOTS expansion (http://www.stoptb.org/Working_Groups/DOTSExpansion/default.asp) 
· TB and HIV/AIDS (http://www.stoptb.org/Working_Groups/TBHIV/default.asp) 
· MDR-TB (http://www.stoptb.org/Working_Groups/DOTS.Plus.htm)  
· Development of new vaccines (http://www.stoptb.org/Working_Groups/TB.Vaccines.htm) 
· Development of new diagnostics (http://www.stoptb.org/Working_Groups/TB.Diagnostics.htm) 
· Development of new drugs (http://www.tballiance.org/home.cfm) 
 
 
And another initiative of the 'Global Partnership to Stop TB' is The Global TB 
Drug Facility (GDF), launched in March 2001 (http://www.stoptb.org/GDF). It is a 
global purchasing and distribution mechanism to expand access to, and availability of, 
high-quality TB drugs to facilitate global DOTS expansion.  
 
The various initiatives co-ordinated by Stop TB are a step forward and increase the 
likelihood that significant progress in TB control will occur in the years to come. Still, 
these developments do not necessarily mean that the identified constraints, especially the 
constraints regarding human resources and organisational aspects, are now being addressed 
comprehensively. Also, even if the search for new vaccines, diagnostic tool and drugs 
turns out to be successful , there remains a huge challenge, namely to see these new tools 
being made fully accessible for the poor and marginalised.  
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To see progress in the actual expansion of DOTS, the following main constraints 
that have recently been identified (WHO, 2002b) need to be addressed: 
  
· Lack of qualified staff and management skills 
· Shortage of laboratory equipment 
· Decentralisation of health services 
· Absence of collaboration between TB and HIV programmes 
· An unregulated private sector 
· Poor access to health services (partly due to war).    
 
 
 The problem of poor access is of great importance, and not just regarding TB 
control. It indicates that more fundamental issues also deserve a close look. A recent 
critical review (Jaramillo, 1999) identified four fundamental problems of DOTS: One, the 
cost for TB patients of diagnosis and treatment can be substantial even when the 
diagnostic procedures and drugs are free. Two, poor education on TB of TB patients and 
the stigma attached to TB hamper case finding and treatment. Three, preventive therapy 
(commonly 6 to 9 months of isoniazid) is not being provided in most low- and middle-
income countries. Four, long-term political commitment is unlikely since it becomes 
difficult to obtain political support over many years, especially when the incidence of TB 
starts to decrease. As the incidence goes down, concern about TB also decreases, causing 
the so-called U-shaped curve of concern (Reichman, 1991), i.e. support follows the 
incidence of TB. An even more fundamental critique in Jaramillo's review is that the 
understanding of traditional epidemiology regarding causality is reductionistic, neglecting 
social, economic and political issues. Jaramillo then presents as an illustration of a 
reductionistic understanding the view that the epidemic of multi-drug resistant 
tuberculosis is a consequence of (i) failure of health care providers to give adequate 
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treatment and (ii) failure of patients to adhere to treatment. Section 5 of chapter 1.3.3. 
discusses access to DOTS.  
  
 In many places, the most severe challenge to successful TB control is the 
HIV/AIDS pandemic. As of December 2002, 42 million people were living with 
HIV/AIDS (UNAIDS/WHO, 2002). Escalating tuberculosis case rates over the past 
decade in many sub-Saharan African countries and in parts of Southeast Asia are largely 
attributable to the HIV epidemic (Bleed et al., 2000). Since the mid-1980’s, annual case 
notification rates have risen up to fourfold in many African countries (WHO, 2001d). In 
the WHO African Region, an average of 38% of new TB cases are HIV-positive (Corbett 
et al., 2003). In 2000, nine percent of all new TB cases were attributable to HIV 
infection, but the proportion was much greater in the WHO African Region (31%) and 
some high-income countries (e.g. 26% in the United States). It is estimated that globally 
11 million adults were co-infected with TB and HIV in 2000 (Corbett et al., 2003).  
 
1.3.3. Limitations of DOTS 
1.   Diagnosis  
 
A limitation of DOTS is that diagnosis is based on sputum microscopy (reviewed 
in Jochem & Walley, 1999), a cumbersome procedure that has low sensitivity (see e.g. 
Levy et al., 1989). Its low sensitivity means that at least half of all TB cases cannot be 
detected by sputum microscopy, namely sputum smear-negative cases and 
extrapulmonary cases that make up an estimated 55% of all cases in the so-called 
developing countries (Murray et al., 1990). In countries with a strong presence of 
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HIV/AIDS, this percentage may be even higher. Still, WHO expects that in DOTS 
programmes 45-60% of all cases are smear-positive (WHO, 2002b). In the year 2000, 
only 42% of the TB cases notified by the 202 countries that reported to WHO and 44% of 
all estimated TB cases that occurred in the year 2000 in the 22 high-burden countries 
were smear-positive. In DOTS areas, the rate was higher, namely 52% (WHO, 2002b). It 
follows that for approximately half of all TB cases, diagnosis cannot be made with 
sputum microscopy, and it is not uncommon that only smear-positive patients receive free 
treatment. The importance of smear-negative cases is sometimes underestimated: while 
clearly less infectious than smear-positive cases (Rieder, 1999, p. 21) smear-negative 
cases also contribute to transmission of TB bacilli. For instance, a study in the USA 
suggested that in San Francisco, smear-negative but culture-positive cases were 
responsible for about 17% of TB transmission (Behr et al., 1999). And without treatment, 
a considerable proportion of smear-negative cases will turn smear-positive after some 
time (Fox, 1988). A study in Hong Kong found that 63% of 283 smear-negative patients 
judged to have active tuberculosis who were not given treatment turned culture-positive 
within 30 months (Hong Kong Chest Service/ Tuberculosis Research Centre, Madras/ 
British Medical Research Council, 1981). Sputum microscopy is cumbersome and giving 
sputum is perceived by some patients to be embarrassing (see chapter 4). Also, sputum 
microscopy may have a negative yield in spite of acute illness of the one who gave 
sputum. Thus, emphasising smear microscopy often has the undesired effects of 
alienating patients and discouraging private practitioners to collaborate with the public 
TB programme. The diagnostic process can be long; for instance, a study in Ho Chi Minh 
City, Vietnam found that 14% of the patients had not been finally diagnosed six to eight 
weeks after first attending a DOTS facility (Lönnroth et al., 2001). And a study in 
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Malawi found that among 499 TB symptomatics who were asked to give sputum 
samples, only 37% submitted the prescribed three specimens and collected the results of 
the examination (unpublished data from Squire and colleagues, cited in Jochem & 
Walley, 1999). For patients whose initial three sputum specimens are found to be 
negative, lengthy procedures are often prescribed, causing the diagnostic part of DOTS to 
act as a deterrent. The low sensitivity of sputum microscopy has the paradoxical effect 
that delayed health seeking may be better for the patient since at an early stage of disease, 
the likelihood to have smear-negative TB (and thus miss diagnosis) is higher (Lönnroth, 
2000, p. 78).   
 
2.  Treatment regimens 
 
This writer believes that there should be a stronger evidence base in terms of 
which regimens are most cost-effective and patient-friendly. For instance, two common 
regimens are: (i) using rifampicin for the initial two months only and then having a 
maintenance phase of six months of isoniazid and ethambutol; and (ii) a six-month 
regimen using rifampicin throughout the length of treatment. Some years ago there was 
some inconclusive debate about the equivalence of effect of these two regimens (Rieder 
et al., 2001; Mathew & Santha, 2000; Long & Scalcini, 2000; Long & Scalcini, 1999), 
though the arguments against the eight-month regimen were rather convincing. Only very 
recently has clear evidence emerged that (i) is inferior to (ii) (WHO, 2003a). Also, as 
discussed in chapter 6, it is not clear if using ethambutol as a fourth drug is really needed 
and if yes whether it should be used for two months only (as recommended in DOTS 
programmes) or for six months (as prescribed by many private practitioners). And while 
intermittent therapy has been used for decades, most modes of intermittent therapy (e.g. 
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intermittent therapy from the start of treatment) have not been tested in clinical trials, as 
admitted in a WHO workshop of October 1995 (WHO, 1996a, p. 6). In view of the 
considerable potential advantages of intermittent therapy their non-inferiority versus daily 
regimens should be tested rigorously and intermittent therapy promoted strongly if found 
to be equivalent to daily therapy.  
 
The standardised treatment regimens may also miss the need to consider 
prolonging treatment for certain patients. It is interesting to note that the new TB 
treatment guidelines of leading American anti-TB organisations now recommend to 
consider extension of treatment for patients with cavitation on the initial chest X-ray 
(ATS/CDC/IDSA, 2003, p. 609). Embracing such new recommendations is important not 
only for clinical reasons but also for convincing sceptical private practitioners that DOTS 
really is "best practice".  
 
There are also doubts if the so-called re-treatment regimen (for patients with 
previous anti-TB treatment for at least one month) is needed (Connolly et al., 1999; 
Wilkinson et al., 1998). One may also argue that for re-treatment patients it would be 
more cost-effective to get drug resistance results (though this is a lengthy procedure and 
not possible in many rural areas) than to automatically give them the re-treatment 
regimen. In other words, a stronger case should be made for making drug susceptibility 
testing available to a much larger number of TB patients.  
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3.  Implementation of DOT (directly observed therapy) 
 
An important task is to find ways to increase patient adherence to treatment, and 
DOT 5 is seen as the main approach. However, there are at least five potential problems 
with DOT: (i) a conceptual problem leading to a narrow focus; (ii) a lack of evidence of  
the effect of DOT; (iii) a lack of appreciation of the potential burden of receiving 
treatment under DOT. DOT may make continuation of treatment difficult; (iv) DOT may 
set into motion a selection process; and (v) DOT may act as a deterrent.  
 
One, there is a conceptual problem (as a recent review has pointed out - Ogden et 
al., 1999). Seeing DOT as the answer to increase compliance  6 implies that patient beliefs 
and behaviour are the main barriers to good compliance. Insensitive implementation of 
DOT may also suggest that controlling the patient is the key to success, rather than 
supporting and enabling the patient (Coker, 1999; Porter & Ogden, 1997). There is 
growing evidence that poor accessibility and quality of care and financial as well as 
social constraints of the patients are the main culprits of non-compliance [see (iv) of this 
discussion of DOT]. Focussing on DOT may thus lead to a neglect of other determinants 
of a successful TB programme and lead away from looking at the larger issues.  
__________________ 
5 DOT is implemented in various ways: (i) health facility-based DOT, meaning the patient comes to the 
health facility for each drug intake; (ii) someone from the health system (often community health workers) 
is responsible for observation of treatment which means that either the health worker goes to the patient's 
house or the patient goes to the health worker's house. (iii) a household member of the TB patient is given 
the task to act as treatment observer ('family DOT').   
6 The term compliance is more general and more often used than the term 'adherence'. In this thesis the term 
'adherence' is preferably used. The term 'compliance' is associated with obeying, submitting and deferring 
to instruction and indicates a power gap between the caregiver and the receiver. It also somehow implies 
that the caregiver delivers information clearly and that any failure to comply is thus the fault or problem of 
the patient. Acknowledging the importance of establishing a patient-provider relationship that is based on 
partnership, a move from 'compliance' to 'concordance' has been suggested (Royal Pharmaceutical Society 
of Great Britain, 1997, cited in Fox, 1997 and in Mullen, 1997). See also Trostle (1988) who critically 
looks at the term 'compliance' and postulates it should be re-conceptualised.  
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Two, there is no clear evidence of what the contribution of DOT per se is to 
improved programme outcome (Volmink & Garner, 2003). So far, the results of four 
controlled trials have been published. In the study in Pakistan (Walley et al., 2001) and in 
the first of the two studies in South Africa (Zwarenstein et al., 1998) DOT was not found 
to contribute to better programme outcome while in Thailand (Kamolratanakul et al., 
1999a), more patients under DOT (it was mainly family DOT) compared to patients 
under self-administered treatment completed treatment. The second study in South Africa 
showed a trend (the sample size was small) toward better treatment outcome with 
supervision performed by lay health workers (Zwarenstein et al., 2000). Even though 
these trials do not clearly show that DOT furthers treatment completion, it needs to be 
stressed that carefully implemented DOT makes sure that while the patient is under 
treatment the drugs are taken properly. Thus, trials examining the effect of DOT should 
not only look at completion of treatment but also at development of drug resistance. The 
primary outcome of interest should be development of drug resistance while on treatment. 
In other words, the main assumed benefit of DOT is avoiding the creation of drug 
resistance. There is some evidence from observational studies supporting this assumption 
(Trébucq et al., 1999; Chaulk et al., 1995). Unfortunately, none of the four randomised 
controlled trials looking at the effect of DOT on patients with active TB had as an 
outcome of interest emergence of drug resistance. 
 
Three, the burden of DOT can be heavy. Rigid DOT may actually make 
adherence to treatment more difficult. Health facility-based DOT implies that the patient 
has to come to the health facility daily (less often if treatment is intermittent). Clearly, 
this can be a heavy burden for a substantial proportion of patients. A study from 
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Pakistans illustrates this: all 36 respondents in a study in Pakistan complained of the 
fatigue and weakness induced by each visit to the health facility (Khan et al., 2000). Also, 
an important consideration is that social stigma may lead to non-compliance (mentioned 
in a review of Hudelson, 1996 and found in various studies, e.g. in a study in Vietnam: 
Johansson et al., 1999). Social stigma towards TB patients often makes DOT highly 
problematic since frequent walks or trips to the health centre or regular visits by the 
treatment observer to the patient's house may make concealment of the illness impossible. 
Such concern has been found in a qualitative study in Thailand (Ngamvithayapong et al., 
2001). And a study in Kerala, India revealed that 27% of TB patients being treated in a 
DOTS programme were not being treated under DOT. Twenty-eight percent (15/53) of 
them stated social stigma as the reason for not being under DOT (Balasubramanian et al., 
2000). 
 
Four, DOT may cause a selection process. Such selection process can be of two 
kinds. Under the pressure to reach certain targets, health care providers may be tempted 
to keep 'problematic patients' out of the DOTS programme. It may thus happen that 
patients that do not seem willing or able to comply with DOT (which are normally those 
in greatest need) are not accepted in a DOTS programme. Such an unfortunate selection 
process has been documented in India (Singh et al., 2002). Also, rigid DOT (especially 
daily health facility-based DOT) may set in motion another selection process: for the 
poorest and most vulnerable section of society it may make continuation of treatment 
impossible (Ogden et al., 1999; Hurtig et al., 1999). In focus group discussions in 
Vietnam, it was said that some patients have no choice but to discontinue treatment and 
return to work (Johansson et al., 1999). In a study in Pakistan the twelve interviewed 
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treatment defaulters all mentioned financial constraints as the major factor leading to 
default (Khan et al., 2000). Another interesting finding comes from a study of a DOTS 
programme in Malaysia, where 23 non-compliant patients were interviewed: more than 
half of the respondents (55%) stated the reason for non-compliance was inability to spend 
money for the transportation cost. And 17% stated more generally that they were unable 
to get transport. Family DOT was the second most often mentioned suggestion on how to 
improve the TB programme (O'Boyle et al., 2002).  
 
Five, DOT may act as deterrent. The more demanding a programme, the smaller 
its acceptability for the patient; DOT may thus deter patients from making use of DOTS 
(Heymann et al., 1998). Studies from Ho Chi Minh City in Vietnam indicate that the 
features of the public TB programme that are unattractive for the patients, e.g. DOT, are a 
reason why even an extremely well functioning DOTS programme (such as the one in 
Vietnam) is not accessed by all TB symptomatics (Lönnroth et al., 2001a; Lönnroth et 
al., 1998). A narrative from Manila illustrates this dynamic. A neighbour of mine came 
from a private doctor who had given her a prescription for TB treatment. Her reaction to 
my suggestion of having her sputum examined at the local health centre was: "I don't 
want to go there because when you get treatment there, then you have to go to the health 
centre every day." 
 
This critical look at DOT does not imply that DOT should be abandoned. Rather, 
it points to a key issue: how must DOT be implemented so that the patients perceive DOT 
as a supportive rather than punitive element? How can one make sure that DOT is 
characterised by the "development of intense personal bonds between patients and those 
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who care for them" (Sbarbaro, 1997) or "free, respectful and convenient treatment" 
(Khatri & Frieden, 2002a)? What determines if DOT is a means towards establishing 
clear communication and co-operation or towards making the patient the passive recipient 
of advice and treatment? It is clear that a TB control programme must create a service 
culture that motivates the patient to adhere to treatment (Wares & Clowes, 1997). But 
more operational research to clarify the role of DOT and the most appropriate forms of 
DOT is needed. A report from a South African study where the patients could choose 
what kind of supervision they wanted (Kironde & Meintjies, 2002) and a recent review 
article of Macq and colleagues (2003) present welcome explorations of the perceptions of 
DOT and the various forms of DOT. It is also important to explore the gap between 
'theory' and 'practice': similar to the study in Kerala (Balasubramanian et al., 2000) a 
recent study in Thailand found that the actual DOT practice often differs from the one 
initially assigned (Pungrassami et al., 2002; Pungrassami & Chongsuvivatwong, 2002). 
This raises the question of to what extent burdensome forms of DOT (burdensome for 
patients and/or health providers) are watered down and whether it might be better to 
promote less rigid forms of DOT that are then implemented more willingly and faithfully. 
In the discussions about DOT, less dogmatism would be welcome. For instance, brilliant 
but less than fully-balanced argumentation7 may incorrectly suggest that family DOT is 
not acceptable (Frieden & Sbarbaro, 2002). On the other hand, in my perception the 
Cochrane review on DOT for TB patients (Volmink & Garner, 2003) concluded 
prematurely that DOT and self-administered treatment have a similar effect on success of  
   
________________ 
7 The findings referred to from Thailand (Pungrassami et al., 2002) were misinterpreted. And the findings 
referred to from Nepal (Mathema et al., 2001) are from a study with potentially severe selection bias. 
 
Chapter 1: Background 
 28 
treatment. Also, reading the Cochrane review and then the papers of the quoted studies 
suggests that the reviewers did not give due weight to some findings of the reviewed 
studies that indicated there was a benefit of DOT.  
 
Operational research should also explore other ways of supervising drug intake. 
For instance, an interesting question is whether medication monitors can be used to 
reduce the number of patients who need labour-intensive DOT. The patients not under 
DOT would then have self-administered but monitored treatment. The patients whose 
medication monitors show that regular drug intake is not taking place can then be put 
under special care (i.e. DOT and enablers, as well as incentives for regular drug intake). 
A recent study from Haiti indicates that such medication monitors are feasible and cost-
effective (Moulding & Caymittes, 2003; Moulding & Caymittes, 2002).  
 
Whatever the focus of operational research regarding DOT is, it must not lead to 
placing the onus of treatment completion primarily on the patient and thereby diverting 
attention from the system or environment that disables the patient from completing 
treatment. Rather, it should incorporate the social, political, economic, and cultural 
dimensions of tuberculosis control. Farmer's assertion "throughout the world, those least 
likely to comply are those least able to comply" remains valid (Farmer, 1997). 
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4. The role of the health worker  
  
 The World Health Organization has identified the neglect of human resource 
development as one of the main constraints to rapid expansion of DOTS (WHO, 2002c). 
Being part of a DOTS programme is not an easy task for a health worker. Having good 
medical and managerial abilities is not enough. In the light of the emotional distress often 
being caused by TB, the stigma attached to tuberculosis, and the need of prolonged and 
regular but unpleasant drug intake, a health worker should have strong interpersonal 
skills, showing empathy and genuine care (Porter & Ogden, 2002; Grange, 1999; Grange 
& Festenstein, 1993). Being able to give patients support requires that the health care 
providers have enough own emotional strength. Health care providers may feel the need 
to shield themselves against emotional engagement or invasion (Van der Walt & Swartz, 
2002). A South African TB patient who was herself a trained nurse explained the 
impersonal approach of her treatment observer as follows: "Nurses prefer to avoid 
involvement with the patient. I don't think it is because of the germs. I think that they lack 
the emotional strength to provide the support that patients need. They are not prepared to 
acknowledge the person behind the folder. They prefer to deal with the disease rather 
than with the human being." (Van der Walt & Swartz, 2002). And a study in South Africa 
found that the crucial factors in terms of acceptability of a health facility are the emphatic 
dimensions (friendliness, good communication, encouraging, listening) (Westaway & 
Wolmarans, 1993). An illustration of the power of kindness was recently given through a 
case study in Ghana, where the kindness of the health provider at initiation to treatment 
brought the young female TB patient to tears. The patient completed DOTS treatment 
despite difficulties in attending the clinic (Lawn, 2000). Another example is a patient in 
Colombia with MDR-TB who was actually thankful to have tuberculosis; the positive 
experience of the presence of people that provide support and show genuine concern was 
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so powerful (Ernesto Jaramillo, personal communication, January 2003). It is 
fundamental that in the efforts to progress in the fight against the diseases of poverty, a 
central part be given to strengthening the health services and the health workers (Brugha 
& Walt, 2001). A recent report assessing the impact of 'Health Workers for Change' 
workshops in seven settings found that the findings from all seven settings indicated that 
overall health system development is essential for improved service provision including 
quality of care (Onyango-Ouma et al., 2001). The welcome emphasis on the diseases of 
poverty, namely HIV/AIDS, TB and malaria, brings the danger that strengthening the 
health services and the health providers is neglected (Verheul & Rowson, 2002). In the 
words of The Lancet: "Sustainable primary care must be the first ambition of any global 
fund for health." (Editorial in the Lancet, 2001). Strengthening primary care must include 
ways of enabling the health worker to be more patient-friendly, such as appropriate 
training in interpersonal skills and offering better remuneration. Also simple measures 
such as increased training and supervision of health providers can improve the outcome 
of a TB programme, as has been shown in places such as Malawi (Kelly, 2001) and 
Korea (Jin et al., 1993). 
 
5. Access to DOTS 
 
In spite of considerable progress in expanding DOTS over the last view years, 
only 28% of the estimated TB cases were treated in DOTS programmes at the end of 
2001 (WHO, 2003). Physical availability of DOTS does not mean that a DOTS 
programme is being accessed. A major reason for the low use of DOTS programmes is 
that a large proportion of people with TB symptoms seek care and get treatment in the 
private sector. The recent emphasis of WHO to bring DOTS to the private sector and 
establish public-private collaboration (WHO, 2001e)  is thus highly warranted. Another 
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reason for non-use of DOTS may be the economic and social vulnerability of large 
sections of the population. For instance, a study in Vietnam found  the main reasons for 
delay in help seeking were: (i) economic constraints, (ii) poor quality of health services, 
such as inadequate attitudes of the health care providers; and (iii) fear of social isolation 
(Johansson et al., 2000). Thus, reaching out to the private sector should be complemented 
with a growing awareness that DOTS needs to engage more with the strong political, 
social, economic and cultural dimensions of tuberculosis and its control (Gandy & 
Zumla, 2002; Ogden et al., 1999; Hurtig et al., 1999; Rangan & Uplekar, 1999; Farmer, 
1997). Gandy and Zumla (2002) dare state: "The DOTS strategy is approaching the limits 
of what can be achieved without more fundamental changes in public health policies as 
part of a wider programme to tackle poverty and social inequality." The large-scale forces 
that hinder rapid progress in reducing sickness and death must be exposed and addressed. 
The recent "Expanded DOTS Framework for Effective Tuberculosis Control" of the 
WHO (WHO, 2002d) seems to take this into account. Different sectors of society should 
be asked to become partners in the fight against TB. Health professionals are among 
those whose voices should be heard at all levels - Rudolf Virchow (1821 - 1902) argued 
that physicians must be the “natural attorneys of the poor” (cited in Farmer, 1999). 
Roughly one hundred years later, the Lancet discussed the social and public health 
dimension of epidemiology. This discussion affirmed that the study of social causes of 
disease is an important epidemiological goal and that speaking out for social betterment 
and human rights has its place (Rothman et al., 1998; Lancet Editorial, 1997).  
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1.4. Tuberculosis and its control in the Philippines  
 
 
 In 2001, the Philippines ranked 9th for the estimated incidence rate of all TB cases 
among the 22 high-burden countries and the estimated incidence rate was 297 per 
100,000 (WHO, 2003, p. 10). The percentage of multi-drug resistant TB among new 
cases of TB was estimated to be 3.2%, and it is estimated that only 0.4% of TB cases are 
harbouring HIV (WHO, 2003, p. 103).  
 
 Up to 1954, TB was the leading cause of death in the Philippines, and up to 1984 
TB was number two (Philippine Department of Health, 1988, p. 2). In 1998, tuberculosis 
was the sixth leading cause of mortality; the mortality rate was 38.3 per 100,000 
inhabitants, resulting in 28,041 reported TB deaths (Philippine Department of Health, 
2003). Estimates say that TB killed approximately 65,000 people in the Philippines in the 
year 2001 (Peabody et al., 2003) which translates into approximately 180 Filipinos dying 
of TB every day.  
 
 In 1997, a national prevalence survey regarding TB was performed (Tropical 
Disease Foundation 1997 and Tupasi et al., 1999). The main findings were: 
 
· Approximately 18% of the surveyed population older than 19 years were considered 
TB symptomatics and would have been qualified for case finding as defined in the 
national TB programme.  
 
· Only 57% of these symptomatic respondents took action: 32% self-medicated, 12% 
consulted a private practitioner, 7.5% a public health facility, 4.5% a (mostly private) 
hospital and 2% a traditional healer.  
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· The prevalence of active TB was 42/1000 population. The corresponding rate for 
culture-positive TB was 8.1/1000 and for smear-positive TB 3.1/1000.  
 
· The annual risk of infection was 2.3% (the annual rate of infection was 2.5% in the 
1981-1983 national tuberculosis prevalence survey; Philippine Department of Health, 
1984). Also when comparing other figures of the two prevalence surveys only a 
minimal decrease of tuberculosis since 1983 can be found. 
 
· Among respondents of urban poor areas of Metropolitan Manila and two other cities 
(a sub-sample of the surveyed population), the rate for culture-positive TB was 
12.4/1000 and for smear-positive TB 5.6/1000, and the annual rate of infection was 
6.5% (Tupasi et al., 2000). 
 
  The TB control programme (called NTP) was initiated in 1968, became nationwide 
in 1978 and was strengthened in 1986. The same year saw the introduction of short-
course chemotherapy. The devolution/decentralisation of the health services in the early 
1990’s complicated full implementation of the NTP. An external evaluation done in 1993 
revealed the following constraints: (i) an inadequate budget for drugs; (ii) poor quality of 
the diagnostic process; (iii) irregular programme supervision and monitoring; and (iv) 
poor patient adherence to treatment (Philippine Department of Health, 1993; Philippine 
Department of Health, 2001, p. 2).   
 
  The Philippines adopted the DOTS strategy in 1995, and since July 1996, DOTS 
has been increasingly implemented. By the end of 2001, 95% of the population had 
access to DOTS (WHO, 2003, p. 103). In 2001, 107,133 TB cases were notified, 59,341 
of them new smear-positive, representing 58% of the estimated total of new smear-
positive cases (WHO, 2003), p. 196). Access is limited in some remote areas and in areas 
of conflict/war. To increase the case detection rate, implementing DOTS in all 
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governmental hospitals, stronger social mobilisation and collaboration with the private 
sector is planned. Several efforts are already being implemented, and PhilCAT 
(Philippine Coalition Against Tuberculosis; a broad and very active umbrella 
organisation; Roa & Romulo, 2000) is spearheading most of these initiatives.   
 
  Treatment outcome in the 1999 cohort is encouraging: 87% of the enrolled new 
smear-positive TB patients had successful treatment (70% were 'cured' and 17% 
'completed treatment'). Only 6% defaulted; 3% transferred-out; 3% died; and 2% were 
treatment failures (data are from a presentation given by a staff of the Manila Department 
of Health, Center for Infectious Diseases). And in the 2000 cohort of new smear-positive 
patients, 88% had successful treatment (WHO, 2003, p. 103). However, it should be 
noted that it is possible that reported rates of successful treatment are too high, as was 
found in Malabon (Auer, 1998a). 
 
 Constraints are mainly seen in the following areas: (i) procurement and 
distribution of the anti-TB drugs; (ii) maintaining the quality of DOTS in view of a small 
number of the central TB staff and insufficient monitoring; (iii) uncertainty regarding 
commitment of local government units (WHO, 2002b, p. 104) and from a presentation 
given by a staff of the Manila Department of Health, Center for Infectious Diseases). 
Finances are also a constraint: the budget for the years 2001 to 2005 amounts to US $ 
109.3 million, and the funding gap was estimated to be 25.2 million. The main areas with 
a funding gap are diagnosis and activities to increase case detection and cure rates 
(WHO, 2002b, p. 104). For the year 2003, the NTP budget is US $ 9.1 million, and 36% 
of this amount is allotted for drugs. The funding gap for the year is expected to be US $ 
5.8 million (WHO, 2003, p. 104). 
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CHAPTER 2: GOAL AND OBJECTIVES 
 
2.1. Overall goal  
 
To contribute to more effective and more efficient control of tuberculosis in resource-limited 
settings.   
 
2.2. Objectives 
 
1. To assess TB illness experience in Manila from the perspective of  TB patients,  
   non-affected urban poor residents and health providers    
  
2. To establish the health seeking behaviour and perceived causes of tuberculosis of TB  
  patients in Malabon, Metro Manila 
 
3.   To assess how the private practitioners of Malabon diagnose and treat tuberculosis  
 
4.   To establish the views of the private practitioners of Malabon regarding public-private  
 collaboration in TB control 
 
5. To outline approaches for collaboration between the private practitioners and the public  
    TB programme in Malabon 
 
6.  To assess feasibility, acceptability, and effectiveness of fully intermittent TB therapy  
  (thrice-weekly) compared to daily TB therapy. 
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CHAPTER 3: STUDY AREAS AND DATA COLLECTION METHODS 
 
3.1. Study areas  
 
The studies took place in Metropolitan Manila ("Metro Manila"), a conglomerate 
of cities and municipalities that had approximately 11 million inhabitants in the year 2000 
(United Nations Population Division, 2000). Roughly one third of Metro Manila's 
population is living in poor areas (slums and squatter areas). 
  
Malabon (now called Malabon City; up to the year 2000 it was a municipality) 
had approximately 400,000 inhabitants in 1999. It is located in the north-west of Metro 
Manila and compared to the other cities of Metro Manila it is less highly developed and 
urbanised. Due to various demolitions of squatter areas the population size of Malabon 
has decreased in recent years. Malabon has 23 public health centres and approximately 50 
private practitioners that treat TB patients.  
 
Taguig is situated in the south-east of Metro Manila along the big lake Laguna de 
Bay. With an average annual population growth rate of 4.5% during the period 1995-2000 
it is the fastest growing area in Metro Manila (National Statistics Office, 2000). Taguig 
had 520,000 inhabitants in the year 2001, served by 20 public health centres. Most people 
live in urban areas, some in semi-urban areas.  
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3.2. Overview of data collection methods  
 
Chapters 4 and 5 present findings from a survey among TB patients of Malabon. 
These patients, interviewed in their houses, had received anti-TB treatment in the public 
health centres of Malabon. Chapter 4 includes findings from a survey among the public 
health care providers of Malabon, using a self-administered questionnaire and findings 
from focus group discussions (FGDs) carried out among non-affected local residents in 
three urban poor areas of Metro Manila, one belonging to Malabon, and two to Quezon 
City, the largest city of Metro Manila. Chapter 5 also made use of patient narratives. 
 
 Chapters 6 and 7 present the main findings from our survey among the private 
practitioners of Malabon who were interviewed in their clinics. Chapter 7 also includes 
findings from group discussions with the public health care providers of Malabon.  
 
 Chapter 8 presents the main findings from a randomised controlled trial in Taguig 
that compared daily with thrice-weekly therapy. The main source of data were the patient 
interviews; each patient was interviewed twice while on treatment and once shortly after 
the end of treatment. Other data used were health centre records and laboratory records. 
In addition, chapter 8 includes findings from group discussions with the public health 
care providers of Taguig.  
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TB illness experience from patient, community and provider perspectives in Manila, 
Philippines  
 
ABSTRACT      
 
Recognising the nature of the severe illness burden of tuberculosis and its implications for 
TB care are important steps to better TB control. We aimed to establish how TB patients 
experience their illness and its treatment, how non-affected urban poor residents perceive 
TB patients and why TB carries stigma. We also examined the patient-health care provider 
relationship. Our methods were: (i) interviews with 319 TB patients of public health 
centres of Malabon, Metropolitan Manila; (ii) three focus group discussions with non-
affected urban poor residents of Metropolitan Manila; and administration of questionnaires 
to health care providers of Malabon.  
 
Having TB commonly resulted in feelings of sadness, guilt, embarrassment, fear of dying, 
loss of self-esteem, and feeling ostracised. An index of stigma was established. In a 
multivariate analysis, six factors were found to be associated with high stigma score, e.g. 
having TB for at least the second time; having separated the eating utensils due to having 
TB; and not having been found by active case finding. 
 
Behavioural changes of the TB patients were: separating eating utensils; reducing or 
abstaining from sexual activities; sleeping separately; and reducing tobacco and alcohol 
consumption.  
 
Non-affected urban poor residents expressed ambivalence towards TB patients: fear of 
getting infected contrasted with feelings of concern and support. Non-affected people saw 
fear of infecting others as the major reason why TB patients feel embarrassed and 
withdraw from people. It was also found that the term ‘weak lungs’ is often being used as a 
euphemistic expression for TB.  
 
Health care providers tended to blame the patient and to give inappropriate health 
education messages.  
 
The illness burden is substantial. Misconceptions have the potential to increase the burden 
of TB. The findings suggest aspects of clinical care that need improvement, such as giving 
health information and interpersonal skills.  
 
 
Keywords:  pulmonary tuberculosis, illness experience, stigma, cultural epidemiology,  
  TB control, Philippines  
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INTRODUCTION 
 
 In terms of the burden of disease, the economic burden, and the burden of illness, 
tuberculosis (TB) is a top priority for international health. Approximately 16 million 
people have the disease at any time (Dye et al., 1999) and there were an estimated 8.5 
million new TB cases in 2001 (WHO, 2003). Almost two million people die of this disease 
every year (Dye et al., 1999).  
 
 The economic burden of TB is substantial. Indirect costs are especially important 
since more than 75% of those sick with TB belong to the economically productive age 
group 15 to 54 years (Murray, 1996). Studies suggest that on average three to four months 
of work time are lost (Stop TB, 2000). For the families of those who die from the disease, 
there is a loss of about 15 years of income resulting from the premature death (Stop TB, 
2000). The impact of TB on difficult-to-measure economic activities of many women must 
also be considered. For instance, in South India, female TB patients reported a 50% 
reduction in household work and two thirds reported that they were not able to adequately 
attend to the needs of their children (Ramachandran et al., 1997). Additional costs, both 
monetary and psychological, may result from stigma and discrimination against those with 
TB and members of their households. 
 
 In 2001, the Philippines ranked 9th for the estimated incidence rate of all TB cases 
among the 22 high-burden countries that worldwide account for 80% of all new TB cases, 
and the estimated incidence rate was 297 per 100,000. It was estimated that only 0.4% of 
the TB cases were co-infected with HIV (WHO, 2003). In 1998, tuberculosis was the sixth 
leading cause of mortality; the reported mortality rate was 38.3 per 100,000 inhabitants 
(Philippine Department of Health, 2003).  
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Apart from physical symptoms and death, TB brings emotional suffering as well as 
disrupted lives, families, and communities. Its treatment may adversely affect the patient's 
daily and social life.  
 
Social stigma is an important aspect of the illness experience identified with TB. 
Stigma was characterised by Goffman (1963) as the situation of the individual denied full 
social acceptance. Various forms of stigma exist in most cultures (Rubel & Garro, 1992), 
also in the Philippines (Nichter, 1994). Marginalised or weaker segments of a community 
may be especially vulnerable to stigma (Uplekar & Rangan, 1999). Findings from focus 
group discussions in Pune, India (Morankar et al., 2000) and Vietnam (Johansson et al., 
1999) suggest that stigma affects women more than men. This differential stigma may 
partly explain why in many countries, women experience more barriers than men in 
accessing health services (Uplekar et al., 2001).  
 
The severe and far-reaching illness burden of TB and the problematic interactions 
between health care providers and TB patients may well be major reasons why only 28% 
of global TB cases are currently identified and treated in DOTS programmes (WHO, 
2003). DOTS is the broadly promoted strategy to control TB which had been implemented 
by 155 countries in the year 2001 (WHO, 2003). New insights that shed light on the 
rationale for patient behaviour that is problematic or undesired from the point of view of a 
control programme are needed.  
 
 This study was performed to elucidate TB illness experience to make a contribution 
in clarifying ill-defined and hidden suffering, outlining policy for promoting appropriate 
help seeking, including the needed support for patients, and identifying barriers to 
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effective treatment. The paper examines the nature of the illness burden from three 
vantage points: the TB patient, the community (i.e. poor urban residents without TB), and 
health care providers. We examined the suffering coming from the personal distress of 
having TB and its social implications. The views of the community clarify the context of 
TB illness experience and social stigma. Consideration of the relationship between 
patients and providers shows how this relationship may also contribute to patients' 
distress. Our approach in this study is guided by the principles of cultural epidemiology. 
Cultural epidemiology provides an approach integrating frameworks and methods from 
epidemiology and anthropology to characterise illness experience from the perspective of 
affected people, meanings of illness and illness-related behaviour (Weiss, 2001). Figure 
4.1 outlines this conceptual framework. Focussing on illness experience indicates the 
importance of other complementary contexts accounting for the quality and effectiveness 
of health systems for TB control. These include consideration of political and socio-
economic constraints and limited resources for public health. Our study aimed at 
identifying key features of TB-related illness experience. These include patients' personal 
accounts of the illness and illness meanings (as suggested by consideration of the 
semantics for specifying TB), attention to the impact of social responses and illness-
related stigma, the experience of treatment for TB, and the nature of interactions between 
patients and providers.  
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Figure 4.1 
ILLNESS EXPERIENCE OF PEOPLE WITH TUBERCULOSIS  
 
 
 
A) The Actors 
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METHODOLOGY 
 
1.   Introduction and setting 
 Research in Metro Manila included semi-structured interviews with former TB 
patients treated in public health centres of Malabon, a municipality of Metro Manila, focus 
group discussions with no n-affected community members of three urban poor areas of 
Metro Manila, and administration of questionnaires to the health care providers of the 23 
public health centres of Malabon. Roughly one third of Malabon's 400,000 inhabitants 
belongs to the poor. Metro Manila had around 11 million inhabitants in the year 2000 
(United Nations Population Division, 2000).  
 
 Consent for the study was obtained from the municipal health office of Malabon 
and from the Department of Health in Manila. The patients were free to refuse an 
interview.  
 
2.   The patient interviews 
 
To characterise illness experiences, including the context of treatment, 319 patient 
interviews were administered. These 319 patients, all smear-positive, had received 
treatment in the public health centres of Malabon.  
 
The interviews inquired about the experience of symptoms of TB and focussed on 
key illness experience and treatment experience.  
 
The semi -structured interview was administered to these former patients in their 
homes at a point 1 to 16 months after the end of treatment. This instrument, consisting of 
131 questions, was written in the Filipino language (Tagalog), and it was developed 
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through a process of peer review and pre-testing (see Annex). Experience of the first 
author (CA) with four years of prior residence in impoverished urban areas of Metro 
Manila and fluency in Tagalog facilitated the development and administration of the 
research instrument. Culturally appropriate interactions with respondents, informed by 
extensive local experience of the principal investigator (CA) and the other interviewers, 
helped to ensure conscientious responses and valid data.  
 
Sixty-one questions were self-administered. The remaining questions were 
answered in an interview at a subsequent visit to the respondents. We decided upon this 
approach because answering the entire questionnaire in a single-session interview would 
have required about 50 minutes, and we were reluctant to come to people’s homes and 
request this much time. We also expected that some of the more personal questions would 
be answered more candidly if the respondent could answer these questions privately. 
Questions for self-report were closed and simple. Other questions that required more 
careful explanation were administered by an interviewer. Twelve questions were open-
ended. Interviewers administered the entire interview to patients who had difficulty 
reading or understanding the self-report questions (approximately seven patients), or who 
preferred having an interviewer for the whole questionnaire (approximately 50% of the 
sample).  
 
A total of 812 sputum smear-positive patients who were registered in the records 
of the 23 health centres of Malabon between 1 January 1996 and 31 July 1997 were 
identified. All had been treated in a non-DOTS programme in the governmental health 
centres. Finding these former patients, however, proved to be difficult; only 319 (39%) 
could be found and interviewed.  
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3.   Focus group discussions (FGDs)  
 
 
Three focus group discussions among non-affected lay people living in poor urban 
areas considered social and emotional effects of having TB and ideas about people with 
TB, including stigma. They also prompted discussion of the expression 'weak lungs' 
(mahina ang baga) which is widely used for TB. The FGDs were tape-recorded and 
transcribed for analysis.  
 
The FGDs were held in the participants’ communities in non-medical settings. In 
all three groups, the participants knew each other by their first names. All the participants 
knew the first author at least casually. Each discussion group consisted of nine 
participants, selected by convenience sampling. None of the participants had TB at the 
time of the FGD. However, some of the participants had had TB in the past. Two groups 
consisted of women and men of various ages. The third group was very homogeneous, 
consisting of young men with a history of drug abuse from various urban poor areas of 
Metro Manila who were in a Christian ‘rehabilitation programme’. Thus, in this focus 
group, the role of vices possibly received undue emphasis. Apart from this, we believe the 
statements of the FGDs are generally representative for the urban poor population of 
Metro Manila. 
 
4.   The health care provider questionnaires 
 
 
Various health care providers of the 23 health centres, namely 21 physicians, 25 
nurses, 23 midwives and 35 barangay health workers (health volunteers with a basic 
training) received and filled in self-administered questionnaires. These questionnaires 
contained questions concerning the TB patient and apart from the physicians' 
questionnaire, they also specifically addressed the interaction between the TB patient and 
the health care providers.  
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5.   Statistical analyses 
 
All data derived from the questionnaires were processed using Epi Info software 
package (version 6.04). For statistical analysis, Epi Info, STATA and SAS were used. 
Categorical data were compared using Pearson's Chi-square test (X 2). 
 
Our questionnaires had seven items suggesting stigma-related social distress. These 
items were feeling embarrassed about giving sputum, feeling embarrassed about having 
TB, feeling ostracised due to having TB, a loss of self-worth, guilt about having TB, 
feeling depressed about having TB, and fear of dying. We combined these items additively 
with equal weight to create an index of stigma, and validated this index with the 
Cronbach's alpha statistic (Cronbach, 1951), using the SAS statistical programme. This 
analysis indicated one item inconsistent with the others: dropping feeling embarrassed 
about giving sputum improved alpha from 0.721 to 0.735. This index of stigma was then 
correlated to various variables, and the non-parametric Kruskal-Wallis equality of 
populations rank test was used to compare the resulting means. For the variable age, 
Spearman's non-parametric correlation was used. The variables with p-values below 0.20 
(n = 15) were used for the linear regression. All the variables with p < 0.15 were included 
in a multivariate regression model (154 observations, stepwise backward regression, 
verifying the distribution of residuals was close to normal). STATA statistical software 
was used (Stata Corporation, 1999).  
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RESULTS 
 
After briefly describing the sample of TB patients, we focus on their personal 
illness experience and complement the findings with qualitative data from the FGDs. The 
section on community attitudes towards TB patients is based on findings from the FGDs. 
A section on TB illness semantics sheds further light on TB and its stigma. We also 
present the patients' views on the health centre personnel and end with data from 
questionnaires for the health care providers.  
 
A) Findings from the patient survey and the FGDs 
   
Sample characteristics of the TB patients 
 
We interviewed 319 patients. Most were male (70%). The mean age was 43.8 
years; 4% were younger than 20 years of age, and 5% were older than 70 years. Most 
(82%) were in the 15 to 59 year age group. Eighty-seven percent identified themselves as 
poor (31% chose 'rather poor', 49% 'poor' and 7% 'very poor'). About a quarter of the 
sample (27%) reported having previously had TB. Sixty-eight percent of the respondents 
reported that they had completed their treatment.  
 
Figure 4.2 presents the clinical symptoms of the respondents at the point when they 
became aware of their illness. The most common symptoms were cough (81%), fever 
(60%), haemoptysis (44%), and backpain (37%).    
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Figure 4.2: Recalled symptoms at illness onset (n = 319)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Illness experience: emotional impact 
 
 The patients were asked how finding out they had TB had affected their emotional 
state. The following feelings were 'definitely' or 'somehow' reported: sadness by 67% of 
the respondents, fear of dying by 49%, feeling guilty by 49%, feelings of embarrassment 
by 45%, loss of self-esteem by 41%, and feeling ostracised by 26%. The vast majority 
(86%) experienced at least one of these various forms of emotional distress. Figure 4.3 
presents details.        
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Figure 4.3:  Symptoms of TB-Related Emotional Distress after Learning Diagnosis  
                     (percentage; n = 319) 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 The following quotes from the FGDs illustrate the social dimension of the 
emotional distress:  
 
· "A TB patient feels very depressed. He is ill-tempered and irritable, especially if he 
feels being detested." (mother, approximately 45 years old) 
         
· "What must not be said is: 'Gosh, maybe we get infected through you!' Someone with 
TB is in a pitiful state and maybe after having heard you say this he will take poison 
to kill himself." (mother, approximately 50 years old) 
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 TB is a stigmatised disease. The following quotes from the FGDs illustrate that TB 
sufferers may have a 'spoiled' or 'marked' identity, causing them to feel mahiya (the 
Filipino mahiya means embarrassed, ashamed, shy):  
  
· "This state of feeling embarrassed goes on for months. For some months you don’t go 
out of your house. And if you do go out, then only for a short time. Unlike when you 
are normal, then you are outside very often. I experienced this when I was sick [with 
TB]; I was embarrassed. I only left our house when I had to do something important. 
Then you are back in your house and there you think about your difficult situation." 
(father, approximately 30 years old who had TB some years ago) 
    
· "A TB patient has self-pity. He thinks he is not entitled or worth to meet other 
people."  (mother, approximately 45 years old)  
   
 
 For one quarter of the respondents feelings of embarrassment occurred also during 
the diagnostic process: 25% said giving sputum was embarrassing (7% clearly, 13% 
somewhat, and 5% slightly embarrassing). The section 'community attitudes' discusses 
stigma from the perspective of the non-affected person.  
 
 In a bi-variate analysis, being male was found to be significantly associated with 
having a higher index of stigma (Kruskal-Wallis equality of populations rank test: p = 
0.03, X 2 = 4.6). Looking at the single items in the index of stigma, it was found that 
feeling ostracised and/or embarrassed was more common among men: 29% of the men 
reported feeling ostracised, compared with 18% of women (X 2 = 4.32, p = 0.04). And 
49% of the men reported feeling embarrassed, compared with 35% of women (X 2 = 5.57, 
p = 0.02). Among the single respondents, feeling embarrassed was not more common 
among men: 55% of these men felt embarrassed and 58% of these women felt 
embarrassed; p = 0.8). Young people were more likely to suffer from feelings of 
embarrassment than older people (X 2 = 10.66, with 4 degrees of freedom; p = 0.03). 
Chapter 4: TB illness experience: three perspectives 
 53 
 
 In a multiple regression analysis, the following six patient features were shown to 
be associated with a higher index of stigma: fearing that the TB illness might come back 
(fear of relapse) (p < 0.001); having TB for at least the second time (p = 0.002); believing 
TB was a dangerous illness (p = 0.004); not having been found by active case finding 
(active case finding was only done in urban poor areas) (p = 0.005); having separated their 
eating utensils due to their TB illness (p = 0.009); and having been a tobacco smoker 
before anti-TB treatment was started (p = 0.048). Also, increasing age was found to be 
marginally associated with lower index of stigma (p = 0.09). These seven factors 
explained 40% of the variance of the index of stigma (model R-squared).  
 
 Fears of falling sick again with TB persisted after completing treatment for 80% 
(for 50% this fear was 'definite', for 23% 'somewhat' and for 7% 'small'). One reason for 
this might be that only 26% felt 'fully healed' and 16% felt 'almost healed' at the time of 
interview (6% were not sure, 38% felt 'not really healed' and 14% felt clearly not healed). 
However, even among those who felt 'fully healed' or 'almost healed' at the time of the 
interview, 66% reported concern about relapse. 
  
Impact on lifestyle 
 
Respondents reported effects of TB on eating, sleeping, sexual activity, and what 
they called 'vices' (mainly smoking tobacco and regularly drinking alcohol). Behavioural 
changes in these four areas of life were recommended, mainly in order to reduce the risk 
of infecting others with TB, but also to increase the chance of full recovery. Table 4.1 
summarises behavioural changes in lifestyle.  
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Table 4.1: Behavioural changes while under treatment (n = 319) 
 
Treatment-related behavioural changes  Number of         % 
respondents       
Separate eating utensils: 
    For up to 1 month only 
    For more than 1 but less than 6 months 
    For 6-12 months     
    Up to the time of the interview 
    Time span unclear 
 
172            54% 
20 6% 
51            16%  
         61            19% 
38 12% 
  2              1% 
 
Slept separately:  
    For at least 6 months 
 
    73             23% 
        44            14% 
 
Reduced or renounced sexual activities: 
    For at least 6 months  
   
    57   (27% of 210*) 
        33   (16% of 210) 
 
 
* Only 210 of the respondents were ma rried.  
 
 
 
 
 The advice of health workers influenced many of these behavioural changes. Fifty-
one percent of the 172 respondents who separated their eating utensils from others in the 
household said that they were told to do so by health centre personnel (based on 
misconception that TB bacilli are spread through eating utensils). In the FGDs, the 
supposed role of eating utensils in spreading TB was mentioned at least twice in each 
group. Reflecting this widely held view, a 45-year-old woman explained: "If the one who 
has TB very often talks to you that’s okay. But if he eats and uses your eating utensils, 
then you need to boil them in water before using these eating utensils he used." 
 
 Twenty-seven percent of the 73 respondents who said they slept separately 
reported that they were told to do so by health centre personnel.  
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 Thirty-nine percent of the 57 married respondents who reduced or stopped sexual 
activities reported that they were told to do so by health centre personnel. In only one 
FGD was renouncing sexual activities mentioned, but not because of concern about 
contagion. The group considered exhausting activities, such as sexual intercourse, were 
not allowed for TB patients. A discussant in one FGD, however, said that TB bacilli could 
be transmitted through seminal fluid. Another FGD suggested another view, that TB is not 
transmitted by sexual intercourse. In the third FGD, sex was not mentioned. 
 
  
 Having TB can also bring about lifestyle changes that positively affect one's state 
of health such as reducing tobacco and alcohol consumption. Such behavioural changes 
can be expected to follow from a popular view, reported in patient interviews and the 
FGDs, that vices cause TB (see also Auer et al., 2000). Seventy-one percent of the 
smokers said they stopped smoking while under treatment, and at the time of the 
interview, 45% still had not resumed smoking. And 85% of those consuming alcohol no 
longer drank while on treatment. At the time of the interview, 41% still had not resumed 
consuming alcohol. In all three FGDs, participants referred to such vices at least four 
times. For instance, a father (approximately 35 years old) explained: "It’s in their lungs. 
Most of the old people, when they were still young, took alcoholic drinks on an empty 
stomach. This lowered their resistance. Then smoking came and too heavy consumption 
of alcoholic drinks."  
 
 Fifty-four percent of those who had smoked before TB was diagnosed suffered 
from feelings of guilt but only 43% of those who had not smoked before their diagnosis 
suffered from feelings of guilt (X 2 = 4.11, p = 0.04). There was no such association for 
alcohol consumption, however.  
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Experience of treatment  
 
 The interview inquired about the perceived effects of medication and side effects. 
It also considered the length of treatment and consequences of incomplete treatment. 
Respondents were also asked how long they considered themselves contagious once 
regular treatment started.  
  
 Generally, the respondents expressed confidence in the medication. More than 
one-third (35%) were 'very confident' about the curing effect of the treatment, 56% 
'confident', 6% 'rather confident', and 1% 'not confident'. Three respondents (1%) were 
uncertain.  
 
 Nine percent of the 319 respondents reported experience of considerable side 
effects, and 21% reported minor side effects. Approximately one-third of the respondents 
(35%) feared side effects (7% reported 'strong fear', 14% 'considerable fear', and 14% 
'some fear').  
 
 Most respondents (84%) acknowledged a need for treatment for a period of six 
months; 11% expressed some doubts, 3% strong doubts, and 2% were uncertain. And 97% 
stated that non-completion of treatment would have negative consequences.  
 
 
 Whereas length of treatment and consequences of non-completion were well 
known, there was widespread lack of knowledge about the duration of contagiousness 
once regular treatment started. Only 24% said, in accordance with biomedical knowledge, 
that they remained contagious up to one month. Most (56%) did not know how long they 
would remain contagious. Ten percent said they would be contagious for two to three 
months; and another 10% said it would be even longer; and 10% did not consider TB 
contagious at all.  
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Community attitudes: social impact and the stigma of tuberculosis 
 
 The FGDs with non-affected laypersons explored the social and stigma dimensions 
of the illness experience. FGD participants indicated that patients feel embarrassed about 
being contagious and that the contagious nature of TB causes others to avoid TB patients. 
The same discussants, however, recognised the need to support the TB patients. Self-
perceived stigma was seen to be more prevalent than enacted stigma.    
 
 The following quotes illustrate how feeling embarrassed or ashamed (mahiya) 
mainly arises from concern about being infectious:  
  
· "I think if I had TB, I would feel embarrassed to meet other people. Because they 
would be in a pitiful state if they get infected because I have TB. I probably would 
stay on my own, because I have TB. I would no longer meet others."  (male, 
approximately 20 years old) 
 
  
 Being contagious may mean that people avoid a TB patient. The following typical 
FGD quote illustrates this: "What the people think about someone with TB is: 'Oh, this 
one has a sickness. Let us not approach him!' This is how the people's thinking always is." 
(mother, approximately 50 years old). However, the basic attitude people have towards 
someone with TB is ambivalent; feelings of concern and compassion combat with the fear 
of getting infected. A 25-year-old man explained this as follows: "It depends who the TB 
patient is for you. Of course, if it is someone dear to you then it may really be your desire 
to serve him. (…) Even though you are afraid. But you need to serve him. Because he 
trusts in you. It is your responsibility."  
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In close relationships, 'acceptance' of the TB patient seems to be the rule. Still, it 
was stated in all three FGDs that TB patients are generally feared/avoided. It was also 
expressed (once in one FGD and three times in the other two FGDs) that TB patients are 
sometimes detested or feel detested (the Filipino word - pinandirian - can be translated as 
being detested, abhorred, loathed, disgusted):  
 
· “Some TB patients say that they merely have ‘weak lungs’, because they fear their 
friends no longer come to them. They fear being detested. That is why they lie so that 
the people don’t stay away from them.” (male, approximately 25 years old)  
   
· "I think we must give ‘special treatment‘ to TB patients. What should not happen is 
that when we see a TB patient then we seem to detest him. (…) I know of a case when 
a TB patient killed himself. He was detested.“  (father, approximately 35 years old) 
 
And in an informal one-to-one interview, a young lady from another urban poor 
area said: "Having TB is like having AIDS!" 
 
 One FGD discussed the question whether the TB patients are really ostracised or 
being avoided and detested or incorrectly perceive discrimination. Considering whether 
there was any legitimate basis for feeling ostracised, the discussants made the following 
points:  
 
· “No, because the TB patient gets healed.”  (mother, approximately 50 years old) 
   
· “No. It is in yourself only, you see. And if you are strongly embarrassed, then the 
people will inquire about you: “Why is he so embarrassed?”. So instead that the 
people don’t find out [your illness] they find it out all the more.” (female, 
approximately 20 years old).  
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In another FGD, too it was stated that it is only in the patient himself. Another 
participant reinforced this by saying: “It is only self-pity.“ On the other hand, all three 
FGDs mentioned that TB patients are being avoided. 
  
 
 The FGDs discussed whether or not someone who had had TB in the past has a 
reduced chance of getting married. It was found that having had TB does not reduce, or 
only minimally reduces the chances of getting married. Still, two reasons were given why 
young men might have a reduced chance. One, TB is a sickness strongly associated with 
vices which makes the man less attractive. Two, having had TB may cast doubts on the 
man’s capability to act as successful breadwinner. On the other hand, in one FGD it was 
said that the young man was less disadvantaged than the young lady because in the 
courting process it is the man who is active. 
 
 
Illness sema ntics: the expression ‘weak lungs’ (mahina ang baga)  
 
Words clearly indicate the nature of the social response and stigma. This section 
examines the impact of the name given to the illness tuberculosis. Most of our interviewed 
TB patients did not call their illness 'TB'. When asked whether their illness had been 'TB', 
'illness in the lungs' (sakit sa baga) or 'weak lungs' (mahina ang baga), only 23% stated 
'TB'. 'Illness in the lungs' was used by 37%, and 'weak lungs' by 34% (1.3% of the 
respondents said their illness was 'cough', and 2% were uncertain). 
 
 
 The findings of the FGDs suggest that the term 'weak lungs' has three kinds of 
meanings. First, the literal meaning: a person with 'weak lungs' is more prone to getting 
sick, especially to sicknesses of the respiratory tract. But 'weak lungs' is not or not yet a 
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disease. Someone with a negative chest X-ray may still have 'weak lungs'. Secondly, it 
refers to an illness less severe than TB: a minimal chest X-ray finding may be considered 
to be 'weak lungs'. Having 'weak lungs' is also seen to be a risk factor for developing TB, 
as this FGD quote illustrates: “From 'weak lungs' to TB is a step-to-step process. But some  
have directly TB.” (male, approximately 20 years old). However, there was one 
participant (male, approximately 25 years old) who said that 'weak lungs' was more severe 
than TB arguing that it can be a general, chronic condition. Thirdly, 'weak lungs' is 
frequently used as a euphemistic expression for TB. Doctors and TB patients use 'weak 
lungs' to avoid the embarrassing and/or frightening term TB:  
 
· “Some use the expression 'weak lungs'. They have TB, but they say they have 'weak 
lungs'.” (mother, approximately 50 years old)  
   
· “If your 'inner strength' is not so strong, then the doctors say you have 'weak lungs'. 
They will not tell you directly that you have TB. If the doctor is your friend he will not 
tell you directly. He may think: ‘O my poor friend, I know his character; he may be 
depressed. I'll just say: You have 'weak lungs'; just take these vitamins  1.” 
    (mother, approximately 50 years old) 
 
 
 In short, our findings from the patient interviews and the FGDs illustrate the partly 
severe undefined and hidden burden of TB and the social dynamics enforcing this burden.  
 
 
 
 
 
 
_____________________ 
1 Some doctors call isoniazid, and some even the whole anti-TB treatment, ‘vitamins for the lungs’ (bitamina 
sa baga) (see also Easton, 1998; Nichter, 1994). 
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B) Patient and health care provider perceptions 
 
 
A substantial component of illness experience results from the interaction between 
patients and the health system. We examined these interactions from both patient and 
provider perspectives.  
 
The patients were asked to grade their experiences with the personnel of the health 
centres in terms of three indicators of received quality of service. Most stated that the 
competence of the personnel, the personnel's explanation given to them and their kindness 
were of a good standard. A minority perceived their competence, their explanations, and/or 
their friendliness to be unsatisfactory (16%, 16%, and 11%, respectively). These 
perceptions did not differ among male and female patients, nor did they differ among 
different age groups. However, when comparing respondents who rated themselves to be 
relatively well off with those who felt they belonged to the poor or very poor, those better 
off were more sceptical: 22% of those who felt to be better off were not satisfied with the 
competence of the personnel while only 13% of those who rated themselves to be poor or 
very poor were not satisfied (X 2 = 4.03, p = 0.04). Those patients who had initially 
consulted a private doctor were not less satisfied with the health centre personnel 
compared to those who had initially consulted the health centre, a hospital or a traditional 
healer. Nor was there any evidence that those with a high educational level were more 
critical. However, those who did not feel fully healed (at the time of the interview) were 
more sceptical about the competence of the staff: 20% of those who did not feel fully 
healed were not satisfied with the competence of the health centre personnel while only 
7% of those who felt fully healed were not satisfied (X 2 = 6.8, p = 0.009). The 
corresponding rates were similar when those who had not completed treatment were 
compared with those who had completed treatment (26% vs. 12%; X 2  = 8.98, p = 0.003). 
Chapter 4: TB illness experience: three perspectives 
 62 
 
The health centre staff (69 physicians, nurses and midwives) and 35 barangay 
health volunteers were asked what caused patients to prematurely stop treatment. Patients 
getting fed up or lazy was the most common response. Especially among the barangay 
health volunteers, this was seen as an important reason (mentioned by 49%). Side effects 
was the second most common response (mentioned by 30%). Table 4.2 presents details.  
 
 
Table 4.2: Patients’ reasons for dropping out of treatment, according to health care providers  
 
 Patients’ reasons for dropping out of treatment, according to 
health care providers     
 
 
Reasons stated 
Physicians 
(n = 21) 
Nurses and midwives 
(n = 48) 
Barangay 
health workers
(n = 35) 
Total of all three 
groups of providers 
(n = 104)   
Patients get lazy or 
fed up         
 
19% 
 
27% 
 
49% 
 
33% 
 
Side effects    
 
43% 
 
35% 
 
14% 
 
30% 
 
Patients feel cured   
 
24% 
 
29% 
 
23% 
 
26% 
 
Treatment not 
available    
 
29% 
 
15% 
 
26% 
 
21% 
   
Patients lack 
knowledge   
 
19% 
 
8% 
 
3% 
 
9% 
 
Patients run out of 
money  
 
0% 
 
4% 
 
14% 
 
7% 
 
Patients are hard-
headed  
 
5% 
 
6% 
 
6% 
 
6% 
 
 
In another part of the questionnaire where the physicians, nurses and midwives 
were asked to grade features of case holding in terms of being a problem or not, patients 
not realising the importance of completing treatment was seen as the most prominent 
problem; it was mentioned by 76% (48/63).  
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Nine of the 35 barangay health volunteers (26%) stated it was hard to make follow-
up visits to the TB patients, half of them felt it was 'somehow hard', and 14% felt it was 
easy. Half of them (51%) explained that many of their TB patients were hot-headed, and 
37% perceived many of their TB patients to be ill-tempered. One fourth (23%) felt that 
their TB patients got angry easily. Other traits mentioned were over-sensitive, lazy and 
shy. Positive traits of TB patients were not mentioned. And only 29% of the barangay 
health volunteers felt that their TB patients' knowledge on TB was sufficient. Similarly, 
merely 37% stated that only few of their TB patients have inappropriate beliefs about TB.  
 
Information about TB given to patients commonly mentioned that it is a contagious 
disease. However, a substantial proportion of the health care providers (35% of the 
physicians, 64% of the nurses and midwives, and 59% of the barangay health volunteers) 
said they would tell their TB patients that they were still contagious for more than one 
month once treatment had started. Other common advice given by the nurses, midwives 
and barangay health volunteers was to tell their TB patients to stop or at least reduce 
smoking, to separate eating utensils and to eat nutritious food. Ninety-six percent of the 48 
nurses and midwives give these three kinds of health advice. And 81% (39/48) recommend 
stopping or at least reducing use of alcohol. Seventy-three percent (35/48) tell their TB 
patients to sleep separately. The only other advice mentioned by more than 30% (namely 
by 69%) was to encourage others in the patient's household to get a check-up.  
 
The barangay health volunteers gave similar advice. More than half of them 
encouraged the patients to eat nutritious food, stop vices (alcohol, smoking, illegal drugs), 
separate eating utensils, and reduce or stop sexual activity. 
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In short, a small proportion of patients was not content with the personnel in the 
health centres and the health care providers tended to blame patients. Also, some health 
advice was based on misconceptions.  
 
 
 
 
DISCUSSION 
 
This study examines aspects of the illness burden that complement more 
commonly cited aspects of disease burden. It considers the intangible costs of fear, 
diminished self-worth, depression, and social distress, as well as the role of the health care 
providers, factors that also affect help seeking and treatment adherence. We found that 
illness-related and treatment-related changes of behaviour have two main purposes. One, 
to avoid infecting others, and two to hasten recovery. The degree of infectiousness of TB 
is commonly overestimated and the ability of the drugs to make a TB patient non-
infectious is underestimated. This results in medically unjustifiable responses, such as a 
prolonged avoidance of the patients towards other people and of the people towards the 
patients, thereby maintaining stigma and contributing to the burden of illness.  
 
Stigma   
 
 
 We found that the TB patient's perception of being ostracised/avoided (self-
perceived stigma) is stronger than the actual ostracism (enacted stigma). The self-
perceived stigma (an individual's sense of 'spoiled' or 'marked' identity) may be stronger 
than the enacted stigma (the degree and ways how others devalue someone with TB and 
disqualify her or him from full social acceptance). Other studies in the Philippines have 
also shown that TB is a stigmatised disease (Nichter, 1994; Ortega et al., 1991; Sarmiento, 
1990; Philippine Department of Health, 1984). In a rural area, the informants stated that 
people thought having TB was something 'shameful' or 'a bad mark to the family' (Nichter, 
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1994). Nichter's study also showed that the term 'weak lungs' is mainly used to avoid the 
stigma-loaded term 'TB'. Similarly, another study in the Philippines found that only 13% 
of a sample of TB patients under treatment labelled their illness as 'TB' (Valeza et al., 
1992). Avoiding the term 'TB' or 'tuberculosis' is common: in Vietnam (Johansson et al., 
1996) and in Colombia (Jaramillo, 1998), the terms 'lung disease' and 'illness of the lungs' 
(enfermo de los pulmones), respectively are used.  
 
It is interesting that those found by active case finding had a lower index of stigma. 
In Malabon, active case finding basically consisted of microscopists going through urban 
poor areas and openly inviting people with cough for more than one or two weeks to give a 
sputum sample. It is thus not surprising that people that tend to feel stigmatised are not 
willing to positively respond to such an invitation that is given in the midst of their 
community. The DOTS approach does not recommend active case finding. But in the light 
of the low DOTS detection rates, there is reason to consider active case finding. Recently, 
Murray and Salomon (1998) argued for using active case finding. Our findings indicate 
that those TB patients most strongly affected by stigma may not be reached with active 
case finding that is not sensitive to the impact of stigma.  
 
We also found a strong association between stigma and separating eating utensils. 
The FGDs showed that the fear of spreading the disease is an important reason for feeling 
embarrassed, and thus, those suffering from stigma may want to do something practical to 
reduce their feeling of powerlessness and fear. However, the activity of separating eating 
utensils does not reduce the chance of spreading the disease. The cumbersome practice to 
separate eating utensils (and in many cases also to boil them in water) has the potential to 
aggravate stigma and the feelings of alienation and guilt, and narratives of TB patients we 
have confirm this. It is also illustrated by the comment of a private doctor who said: 
“Filipinos are sensitive when it comes to separating eating utensils.” We believe it is not 
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advisable to recommend a stigma-enhancing and ineffective activity; inaccurate and 
imprecise knowledge, specifically the wrong assumption that burdensome practices need 
to be done for a prolonged time, may also lead to denial and fatalism. This may result in 
not doing the few measures that are medically justified to avoid the spread of TB and to 
hasten recovery.  
 
Care must be taken to distinguish between medically justified and necessary 
behavioural changes that are to be promoted (e.g. "don't cough openly during the early 
weeks of treatment") and unnecessary behavioural changes that come from an 
inappropriate and stigma-driven understanding (e.g. "don't mix with people while on 
treatment"). In this, it is healthy to acknowledge the tension between wanting to avoid 
behavioural changes that increase stigma (e.g. sleeping separately) and the obligation to 
avoid the risk of spreading TB. What complicates the matter is that treatment does not 
have the same effect on all patients. For instance, for most patients it is correct to state that 
after two to four weeks of regular treatment, his or her disease is no longer contagious. But 
in the light of the fact that multidrug-resistant TB (MDR-TB) is not uncommon (a recent 
study in another part of Metro Manila found that 7% of TB patients treated in public health 
centres had MDR-TB; report forthcoming. See also chapter 8), it might not be advisable to 
tell the patients that after some weeks of treatment contagion no longer is an issue. This is 
a difficult trade-off: is it justified to tell TB patients to be concerned for up to one year 
about spreading their disease when for at least 90% their concern is no longer justified 
after some weeks of treatment? Since the risk of MDR-TB is much higher in previously 
treated patients a sensible compromise may be to tell all previously treated patients to be 
conscious about the danger of spreading their disease for a prolonged time.  
 
We found that previously treated TB patients suffer more under stigma. The added 
stigma among previously treated TB patients may be a reason why in some studies (e.g. 
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Santha et al., 2002; Zwarenstein et al., 1998) previously treated TB patients were found to 
be under a high risk of not completing treatment. It is interesting to note that in the study 
of Zwarenstein and colleagues (1998), clinic-based DOT seemed to discourage re-
treatment patients from completing treatment while in another study in South Africa clinic-
based DOT worked quite well for re-treatment patients (Kironde & Meintjies 2002). In our 
study, the patients were not under directly observed therapy (DOT). Several studies have 
indicated that implementing DOT in areas where social stigma is pronounced can be 
problematic (Singh et al., 2002; Ngamvithayapong et al., 2001; Balasubramanian et al., 
2000). A recent review concluded that stigma is a reason for non-completion of treatment 
(Thomas, 2002). Clearly, there is a lack of understanding about the role of stigma and its 
potential for complicating TB care, e.g. adherence to treatment. The role and relationship 
of the four factors (i) stigma, (ii) appropriate knowledge and health education, (iii) 
infectivity, and (iv) mode of treatment supervision need to be further explored.  
 
Validity of the findings 
 
  In view of the size and diversity of Metro Manila, there are of course limitations of 
how widely we may generalise findings. Several additional points in that regard should be 
considered.  
 
  Only 39% of the 812 known smear-positive TB patients could be found and 
interviewed. Many patients moved back to the province. Others could not be found due to 
inadequate addresses in the health centre records. The bias was probably less of a factor 
than the low percentage (39%) indicates, because many of the patients came from rural 
areas, and they were likely to have been in Malabon only for their treatment. 
Consequently, we interviewed more than 39% of the affected persons residing in Malabon.  
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  Refusal to be interviewed constitutes only a minimal potential bias since only ten 
former patients declined to be interviewed. 
   
  Recall bias may be a limitation of the study, inasmuch as patients were interviewed 
retrospectively (1 to 16 months after the end of treatment). Social desirability bias also 
needs to be considered. Thus, in spite of having related to the interviewees in an informal 
and culturally appropriate way, the proportion of patients reporting distressful emotions is 
probably an underestimate. In addition, we found only 29% stated to have perceived their 
illness as ‘very serious’ or ‘serious’; this seems to be an underestimation in the light of the 
finding that 49% reported fear of dying. It should be kept in mind that reported indicators 
of stigma seem to be significantly lower for disease-affected respondents compared to the 
non-affected, as a study in Africa among patients of onchocercal skin disease showed 
(Vlassoff et al., 2000). This point also needs to be considered regarding the FGDs: the 
participants were non-affected urban poor residents, not TB patients. 
 
 
Implications for TB control 
 
 The substantial emotional and social burden of TB makes it especially important 
that health care providers give accurate, relevant and appropriate information in an 
empathic, empowering and encouraging way. The social and emotional implications of 
health advice must carefully be considered. Several areas of specific concern arise from 
the results. 
 
 First, health education among the health care providers and the general 
population should address misconceptions to fasten the case finding process, support case 
holding, and reduce stigma. For instance, the misperception that using eating utensils of a 
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TB patient is a way of getting TB is prevalent among the public, the public health care 
providers, and among private practitioners of Malabon (report forthcoming). It is 
important that the health care providers refrain from unnecessary and burdensome health 
education messages. On the other hand, the importance of completing treatment must be 
emphasised. Other medical advice given to minimise the spread of TB, such as avoiding 
open coughing, sleeping separate from others and not having sex are justified while the 
TB patient is still infectious. However, we found that only one fourth of the interviewed 
patients knew that being contagious persists up to one month only once proper treatment 
has started and that many health care providers overestimated the length of being 
contagious. In the light of stigma, it is important to correctly inform the patient that this 
burdensome state of being contagious does not last long (however, as discussed, in 
settings with high rates of MDR-TB this is not true). It should also be considered that 
sleeping separately may not be possible in crowded living conditions and may increase the 
self-perceived stigma. Avoiding sex while on treatment may aggravate the intangible 
burden (i.e. it can create emotional and relational stress). 
 
Secondly, correct terms to specify tuberculosis should be used, even though 
Filipino culture may encourage euphemisms. Telling TB patients that they merely have 
’weak lungs’ is misleading and may contribute – especially in the long term – to the 
spread of TB. Using the term 'weak lungs' may also promote self-medication and default 
from treatment by undermining appreciation of the serious nature of the illness. And the 
fact that 'weak lungs' can refer to TB as well as to acute respiratory infection further 
complicates treatment.  
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 Thirdly, the health care providers should specifically address the patients‘ fear of 
dying and of experiencing a relapse. It should be explained that when being fully adherent 
to treatment, the chance of recovery is very high and the likelihood of relapse very small. 
The term 'weak lungs' may contribute to fear. Inasmuch as the term 'weak lungs' is also 
used for respiratory illnesses (Nichter, 1994), former TB patients who develop an acute 
respiratory infection may interpret this as a sign that TB ('weak lungs') is recurring.  
 
 Fourthly, the health care providers also need to be aware that gender plays a role. 
In our study, men seemed to be more prone than women to suffer from feeling 
embarrassed and ostracised, suggesting a need for special sensitivity towards men, 
especially since in the Philippines, most health centre personnel are female. Findings from 
studies in other countries suggest that women, especially unmarried women, are more 
affected by social stigma than men (Khan et al., 2000; Rangan & Uplekar, 1999; 
Hudelson, 1999; Liefooghe et al., 1995). Our finding that among the single respondents, 
women were slightly more likely to feel embarrassed than men also highlights the 
vulnerability of unmarried women.  
 
Finally, patient support within the family and if possible also the community 
should be strengthened to reduce the adverse emotional and social impact of TB. An 
encouraging finding comes from a rural area of India where the support for the patient in 
the case holding process consisted not only of a family member as ‘treatment partner’ but 
also of a former TB patient and of the immediate neighbourhood of the TB patient. It was 
observed that TB largely lost its stigma over time (Schüth, 1998). This suggests that with 
innovative approaches, stigma can be reduced. 
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Health seeking and perceived causes of tuberculosis among patients in Manila, 
Philippines 
 
SUMMARY 
 
Inefficient case finding is an important stumbling block to successful control of 
tuberculosis (TB). Multiple health seeking may account for delayed case finding. Health 
seeking behaviour, health seeking delay, perceived causes, and perceived quality of care 
related to TB were studied in interviews with 319 sputum smear-positive TB patients. The 
patients were treated in 22 governmental health centres of Malabon, a municipality of Metro 
Manila, Philippines. Only 29% of the respondents had gone first to a health centre after 
onset of TB-related symptoms, and more than half (53%) had initially consulted a private 
doctor. A chest X-ray was obtained for nearly everyone (97%). Two-thirds of the patients 
(66%) had received a prescription for drugs, and 29% had purchased and taken anti-TB 
drugs for at least three weeks before they came to a governmental health centre. Concerning 
community interactions, 36% said they knew at least one person who had been treated for 
TB without success. The health seeking delay after symptom onset was relatively short – 
64% of the respondents said they went to a health facility within one month. Case studies 
illustrate the rationale for health seeking and explain delayed initiation of appropriate 
treatment for many patients. Findings underscore the need for and indicate approaches to 
health communication for improved control of TB. Our findings from interview narratives 
also suggest that improved interpersonal skills of health centre staff and co-ordination 
between the private doctors and the health centres may substantially improve services for 
TB patients.  
 
 
Keywords:  pulmonary tuberculosis, health seeking, health providers, perceived causes of 
TB, Philippines  
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INTRODUCTION 
 
Control strategies for TB involve two components: case finding and case holding. 
Currently, active case finding, i.e. attempts to screen populations at large or to target 
specific populations, is much less widely used than passive case finding (i.e. only those 
who come to the health facilities are screened and diagnosed) (Murray, 1994, pp. 603-4). 
Effective control requires case finding at an early stage of illness, both for the welfare of the 
patient and to minimise spread of the disease and development of drug resistance. Also, the 
case finding process should entail no more than minimal financial costs for the patient. Most 
TB patients are poor, and any money they may be required to spend for diagnosis and case 
finding may ultimately compromise case holding, that is, their ability to remain in treatment. 
  
Many people with symptoms of tuberculosis first approach a private doctor 
(Pathania et al., 1997; Valeza et al., 1991). A process of multiple and varied help seeking 
that may be called ‘shopping’ for diagnosis and treatment thereby begins. Typically, poor 
patients end up in public health services, mainly because they cannot pay for prolonged care 
in the private sector (Nair et al., 1997). Moving from one provider to another often delays 
the diagnosis and the start of treatment, and thus increases the likelihood of developing 
multi-drug resistant TB, and it often involves considerable costs to patients. Several reasons 
may lead to this ‘shopping’: (i) the felt need of the patients to explore alternative providers, 
especially when symptoms persist or re-appear; (ii) lack of trust in the public health 
services; (iii) sub-optimal health services, and (iv) financial constraints that require patients 
to shift from more expensive providers they see initially to others they can afford.  
 
A body of literature documents how effective health seeking and case finding are 
influenced by the health system, community, family, and other personal issues (Pathania et 
al., 1997; Rubel & Garro, 1992). Personal issues include the ways people experience their 
symptoms and illness, perceived causes and experiences with the health care system. A 
survey among TB patients of public health centres of Malabon, a municipality in Metro 
Manila, Philippines, examined these factors, considering how they may contribute to 
multiple health seeking and delayed treatment. The respondents’ experiences and 
perceptions about TB, their health seeking behaviour, health seeking delay and possible 
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determinants of this delay were established. Two case studies illustrate how these factors 
operate. 
 
In 1997, the rate of TB cases registered in the health centres of Malabon was 325 per 
100,000 inhabitants. There was a functional TB program operating but the DOTS strategy 
(Directly Observed Treatment, Short-course; the widely promoted strategy to control TB, 
now being used in more than 100 countries) (WHO, 1998a) had not yet been implemented. 
Twenty-three governmental health centres operate in Malabon, all of them offering TB 
services. At the time of the study, three of these health centres had laboratory facilities for 
sputum examination, and there were six teams of health workers engaged in active case 
finding and sputum microscopy in the low-income areas of Malabon.  
 
METHODOLOGY 
 
Patients were surveyed in Malabon, an urban municipality of Metro Manila with 
approximately 360,000 inhabitants in 1996. A total of 812 sputum smear-positive (sm+) 
patients who were registered in the records of 22 of the 23 health centres between 1 January 
1996 and 31 July 1997 were identified. One health centre did not have sm+ patients during 
the study period. Finding these former patients, however, proved to be difficult; only 319 
(39%) could be found and interviewed.  
 
A semi-structured interview, which included questionnaire items for self-report, was 
administered to former patients in their home at a point 1 to 16 months after the end of 
treatment. This interview-questionnaire of 131 questions, written in the Filipino language 
(known locally as Tagalog), was developed through a process of peer review and pre-
testing (see Annex). Experience of the first author (CA), who had already spent four years 
residing in impoverished urban areas of Metro Manila and was fluent in Tagalog, facilitated 
the development and administration of the research instrument. Culturally appropriate 
interactions with respondents, informed by extensive local experience of the principal 
investigator (CA) and the other interviewers, helped to ensure honest responses and valid 
data.  
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Sixty-one questions were self-administered. The remaining questions were answered 
in an interview at a subsequent visit to the respondents. We decided upon this approach 
because answering the entire questionnaire in an interview would have required about 50 
minutes, and we were reluctant to come to people’s homes and request this much time for an 
interview. We also expected that some of the more personal questions would be answered 
more honestly if the respondent could complete the questionnaire in the absence of the 
interviewer. Questions for self-report were closed and simple (e.g. marital status, number of 
people in the patient’s household), and they were self-administered. Other questions that 
required more careful explanation were administered by an interviewer. Twelve questions 
were open-ended. Interviewers administered the entire interview to patients who had 
difficulty reading (approximately five patients) or understanding the self-report questions, or 
who preferred having an interviewer (approximately 50% of the sample).  
 
The interview included questions regarding the patient (e.g. marital status, education, 
socio-economic status). It also inquired about the emotional impact of having TB, about 
perceived quality of care received in the health centres and details about case finding and 
case holding. Perceived causes of tuberculosis were also explored. Consequently, the 
patients were asked to explain in general why someone may get TB (‘health beliefs’), and 
they were also asked how they acquired TB in their own particular case (‘explanatory 
models of one’s own illness episode’). For the general case, they were asked to classify 
thirteen presented potential causes into ‘definite causes’, ‘probable causes’ or ‘not causes’ 
of TB. These potential causes were selected from a review of the literature and through 
ethnographically sensitive interaction with urban poor residents and TB patients over an 
extended time. Regarding causes of TB patients’ own illness, only eight potential causes 
were presented to the respondents and the possible answers were ‘yes or ‘no’. Some causes 
that were included among response options for the question about why someone may get TB 
– such as drying sweat on the back, sleeplessness, and exposure to dust or chemicals – were 
not presented in this item regarding patients’ own illness.  
 
 All data derived from the questionnaires were processed using Epi Info software 
package (version 6.04, USD Inc., Stone Mountain, GA, USA).   
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RESULTS 
 
The sample 
Among the respondents 70% were male, and 80% were between 20 to 60 years of 
age; 87% considered themselves to be poor. About a quarter of the sample (27%) reported 
having previously had TB, and so for them, the interview was not dealing with their first 
personal experience with TB.  
 
What people know or perceive about TB when they are not yet affected is an 
important determinant of their health seeking. TB was found to be a well-known disease. 
Nearly everyone (84%) knew somebody who had had TB, and a quarter of the sample 
(27%) had a close friend or relative with the disease. A few more (28%) reported that when 
they first came for treatment, there was someone else with TB in their household. More than 
half (52%) knew someone who had died of it, and many knew people who had been in 
treatment, either successfully (57%) or unsuccessfully (36%). 
 
Table 5.1 indicates respondents’ ideas about the perceived dangerousness and risk 
of acquiring TB before becoming ill with TB. Approximately 20% of the respondents had 
considered TB to be only slightly dangerous or a harmless disease and 15% did not consider 
themselves vulnerable to TB.  
 
Table 5.1:  Perceived dangerousness of TB and perceived risk of acquiring TB (n = 319)       
Dangerousness of TB    Number  Percentage 
Really dangerous   177     55% 
Quite dangerous     75     24% 
Slightly dangerous     18       6% 
Not dangerous     44     14% 
Don’t know       5       2% 
   
Perceived risk of acquiring TB     Number  Percentage 
Could get TB easily  144     45% 
May get TB   114     36% 
Probably would not get TB     30       9% 
Definitely would not get TB     19       6% 
Don’t know    12       4% 
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Seventeen percent stated not to have known or to have been unsure whether their 
condition could be treated effectively (be it with drugs of Western medicine or in other 
ways).  
 
Perceived causes 
Perceived causes help to explain the meaning of a problem, whether it is considered 
a medical problem or a particular disease, and the implications based on cultural, familial, 
and personal background. Perceived causes may influence health seeking behaviour and 
treatment delay. Figure 5.1 presents the perceived causes of TB in general. The responses 
are summarised in order of the frequency of reports as definite or possible. Sweat drying on 
one’s back, followed by smoking, microbe, and drinking alcohol were the most frequently 
reported definite or possible cause of TB in general. A higher proportion of men than 
women considered ‘often smoking’ to be a definite or probable cause for someone getting 
TB (94% of the men vs 86% of the women; C2 = 5.5, p = 0.02). Sex differences among 
respondents reporting ‘often drinking alcohol’ were similar; 94% of the men and 84% of the 
women considered this to be a definite or probable cause for getting TB (C2 = 7.3, p = 
0.007). On the other hand, fewer men than women reported fatigue or overwork to be a 
definite or probable cause for acquiring TB (80% of the men vs 91% of the women; C2 = 
5.3, p = 0.02).                               
 
Figure 5.1: Perceived causes of TB in general (n = 319) 
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 A subgroup of 216 patients was asked about the spread of TB, and notably, 12% did 
not recognise it to be contagious: 7% said it was not, and 5% said it was ‘rather not’ 
contagious. 
 
 Figure 5.2 summarises perceived causes reported by patients to explain how they 
themselves acquired TB. Sixty-two percent of the respondents gave more than one answer. 
Many emphasised a moral aspect of vulnerability: vices and hard work were mentioned 
much more frequently than mechanistic causes, such as person-to-person transmission.  
 
Figure 5.2: Perceived causes of patients’ TB (n = 319)  
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Self-blame appeared to play a role among men. They were more likely than women 
to report ‘vices’ as the perceived cause of their own TB (64% vs 12%; C2 = 72.7, p < 
0.0001). On the other hand, men were less likely than women to identify hard work as the 
cause for their own TB (44% vs 57%; C2 = 4.6, p = 0.03), as they did for explaining the 
causes of TB generally.  
 
Health seeking 
About two-thirds of patients (69%) had been told by someone to have a medical 
check-up for their symptoms. This advice came from a spouse (18%) or a relative or 
someone else in their household for 59% of the sample. Table 5.2 indicates that in many 
cases (53%) a private doctor was the first health care provider approached for treatment. 
Less than one-third of the respondents first approached a health centre. Only nine 
respondents (3%) reported consulting a traditional healer (albularyo) first, although three 
additional respondents mentioned they saw a traditional healer at a later point. 
 
Table 5.2:  Health facility first approached for help (n = 319) 
First health facility approached    Number   Percentage 
Private doctor    170        53% 
Health centre (HC)       91        29% 
Hospital       40   13% 
Traditional healer (albularyo)         9     3% 
Diagnostic centre        4     1% 
Non-governmental organisation         3     1% 
 
In addition, one respondent went first to a company doctor and one 
respondent did not answer this question. 
 
 
Almost two-thirds of the respondents (63%) stated that before they were sick with 
TB, they had never been to the health centre (HC). Forty-five percent of those patients who 
had used the HC before falling sick with TB went to the HC first after initial symptoms of 
TB, compared with only 19% of those who had not yet used the HC when they fell sick with 
TB (C2 = 24.6, p < 0.0001). 
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 According to guidelines for TB control in the Philippines, the HCs should not 
routinely request X-rays. However, 97.5% of the respondents —all of them with a record of 
being smear-positive—stated they had a chest X-ray; only eight patients did not have the 
unnecessary X-ray. Since none of the HCs has X-ray equipment, this means that all but eight 
patients went to at least two health care providers for diagnostic procedures.   
 
 The following case study indicates that impolite health centre personnel may be an 
important reason for consulting private doctors. It also indicates that for many patients and 
health care providers, chest X-rays may be preferable to sputum examinations.  
 
Case study 1: Health worker’s attitudes and diagnostic priorities 
 
Bong (a pseudonym), a single man from a squatter area who had had TB twice in the past 
seven years, developed symptoms  suggesting TB. One morning he coughed up blood-
streaked sputum, and later that same morning he presented the sputum sample to the nearby 
health centre to have it examined. They didn’t accept it, however, and told him to come back 
the following day. This he did, bringing his blood-streaked sputum sample from the previous 
day and another early morning sputum sample of the current day. The health worker received 
him rudely, asking, "Why do you bring a sputum sample?" After Bong explained, the health 
worker accepted only one of the samples, and with obvious disgust she smeared some of it 
on a slide, holding the slide far away from her. Bong was discouraged. When he returned to 
the health centre, he was told that his sputum sample was negative. He was not told to give a 
second sputum sample, but was advised to get a chest X-ray.  
 
 
 
 Consulting a private doctor was more likely to result in a diagnosis on the spot. The 
diagnosis was made at the clinic for 94% of the 170 patients who first went to a private 
doctor, but only for 84% of those who first went to the HC (C2 = 6.0, p = 0.01). Among 
those initially not diagnosed at the HC, the diagnosis was made by a private doctor or at a 
hospital.  
 
 The cost of treatment was not considered appropriately for many patients. Two-
thirds of the patients (66%) received a prescription for drugs; 21% of these 209 persons 
receiving prescriptions said they had not been told by their private doctor or at the hospital 
that anti-TB medication was available free of charge in the HCs. In our total sample, 57% (n 
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= 182) reported purchasing anti-TB drugs before they came to the HC, and 29% had been 
taking them for at least three weeks before they came to the HC. These 182 patients were 
nevertheless smear-positive when they underwent sputum microscopy at the HC. Table 5.3 
provides additional details.  
 
Table 5.3: Duration of TB treatment before coming to the health centre (n = 319) 
Weeks of prior treatment        Number and percentage of patients 
  Number        Percentage        Cumulative %  
More than 4 months     6                    2%                    2% 
3 - 4 months   13                    4%                    6% 
Approximately 2 months   18                    6%                  12% 
3 - 4 weeks   56                  18%                  29% 
1 - 2 weeks   61                  19%                  48% 
Less than one week   28                    9%                  57% 
None    137                  43%                100% 
 
 
Delayed health seeking 
The delay from first awareness of symptoms to beginning treatment is a matter of 
considerable public health interest. Table 5.4 summarises the lag time from reported 
symptom onset to first health seeking at a health care facility. The median lag time was one 
month, and the inter-quartile range was half a month to two months. Twenty percent of the 
302 respondents had had symptoms for at least three months before they approached a health 
facility. 
 
Table 5.4:  Lag time from onset of symptoms to first health seeking (n = 302*)   
Lag time (health seeking delay)          Number and percentage of patients  
 Number    Percentage (of 302)   Cumulative %      
  
More than 6 months      25                  8%                         8% 
5 to 6 months      16                  5%                       14% 
3 to 4 months      20                  7%                       20% 
1 to 2 months      35                12%                       32% 
Between half a month and one month      90                30%                       62% 
Up to half a month     116                38%                     100%  
  
* Seventeen respondents are not included (eleven respondents did not have symptoms and for   
   six respondents the degree of delay was not clear) 
Chapter 5: Health seeking of TB patients in Manila 
 84 
 
The emotional impact of TB on health seeking delay was considered. Reactions such 
as sadness, fear of dying, guilt, embarrassment, and loss of self-esteem were not associated 
with increased health seeking delay. Among those who felt ostracised because of their TB, 
however, 41% had had a lag time longer than four weeks, compared with only 29% for those 
who did not say they felt ostracised (C2 = 3.9, p = 0.05).  
 
 Among other possible determinants of health seeking delay, we examined perceived 
dangerousness of TB and perceived susceptibility when not yet sick with TB, and knowing 
at least one person who was treated unsuccessfully for TB. None of these three factors were 
associated with health seeking delay. We also examined the perceived causes of TB and 
none of them were associated with health seeking delay, neither perceived causes for TB in 
general, nor perceived causes of patients’ own illness.  
 
 Among eight additional factors that were considered (age, sex, marital status, self-
perceived impoverishment, having or not having been at the HC before getting sick with TB, 
degree of education, employment status, and having or not having TB for the first time), only 
marital status was significantly associated with health seeking delay. Among those without a 
marital partner only 24% had a lag time longer than four weeks, compared with 36% for 
those with a marital partner (C2 = 4.3, p = 0.04). 
 
 The patients were asked what they felt contributed to the delay. The two most 
frequent responses were that the symptoms were considered harmless and the cost of 
medical care too high (Table 5.5). 
  
Table 5.5:  Frequency of reasons reported for delayed health seeking (n = 228*) 
Reasons for delay   Persons reporting Percentage (of 228)
Illness considered harmless       135         59% 
Lack of money         51        22% 
Symptomatic person was working         16          7% 
Self-treatment considered sufficient           9          4% 
Other reasons          29        13% 
 
* Those patients with a short delay were not asked. There were 228 patients who were  
   asked and gave an answer. A patient could mention more than one reason. 
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 Difficulty staying in treatment appears to results from dissatisfaction with care and 
the search for acceptable alternatives. The experience of the following patient indicates how 
the perceived inferior quality of care may motivate patients to seek other providers.  
 
Case Study 2: ‘Shopping’ for health care by a dissatisfied health centre patient 
 
Juan (a pseudonym) is 48 years old, married, and ill with a new case of TB. When he was 
troubled by chest symptoms he purchased antipyretics and amoxicillin without consulting 
a health care provider. After approximately three weeks of unremitting symptoms he went 
to a HC where his sputum was examined. Although the HC records showed he had a 
positive sputum smear, Juan said no one told him the results of his sputum examination. 
The HC, which had run out of anti-TB drugs when Juan came for help, asked Juan to get 
an X-ray. Juan bought drugs for two months, but it is not known what kind of anti-TB 
drugs he bought. Then he went to a private doctor for an X-ray, which was positive for 
TB. Juan was given a prescription and bought the prescribed drugs. Although he could go 
back to work one month after having started to take these drugs, he could no longer afford 
to purchase these drugs after three months. 
Juan mentioned he was discouraged at the HC because often there was no physician 
present, and he was told to come back the next day. He also felt the HC staff had not given 
him sufficient information or an adequate explanation of his condition. At the time of 
interview Juan felt his TB was clearly not yet healed. 
 
 
 
DISCUSSION     
 
One fifth of the patients had symptoms for at least three months before they approached a 
health facility. The median lag time from symptom onset to starting treatment was only four 
weeks, but this figure is somewhat misleading because a certain proportion of the 
respondents was found through active case finding. Because records are unreliable, the 
precise number of these patients is unknown, and although the median lag time 
underestimates the problem, the magnitude of this underestimate is unclear. Treatment delays 
in our study are similar to those of a previous study in the Philippines (Valeza et al., 1991), 
which found 32% of 180 urban respondents had a delay of at least two months (compared to 
30% in this study), and 16% had a delay of at least six months (compared to 12% in this 
study). 
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 Our study did not show a relationship between any perceived causes of TB and 
delayed health seeking, and the role of several other anticipated predictors of delayed health 
seeking remained unsubstantiated. These included the idea that TB is not dangerous, not 
feeling personally at risk, and lack of awareness of person-to-person transmission. The 
absence of such relationships is consistent with studies suggesting that fear does not 
necessarily motivate health seeking (Leventhal, 1965, cited in Toledo et al., 1979). The 
tendency to minimise the severity and dangerousness of TB may also reflect a coping 
mechanism, rather than long-standing ideas about the disease or a lack of information. 
Consequently, health educational efforts should not overstate or over-dramatise the issue, as 
this could reinforce stigma and denial, thereby further delaying help seeking.  
 
 Our data showing 29% of respondents went first to the HC, compared with 53% who 
went first to a private doctor, is consistent with other studies in the Philippines. A study by 
Valeza and colleagues (1991) in several other regions of the country found that 52% of 571 
TB patients had also approached a private doctor first. Several factors may explain the use 
of services other than public health centres first: People expect private providers to be more 
effective, more easily accessible, more sympathetic and more likely to respect privacy than 
governmental health care providers (Pathania et al., 1997). They appear to maintain this 
view despite contradictory evidence, as was found in India where research showed a large 
number of private providers offer poor services for TB patients (Uplekar & Shepard, 1991; 
Uplekar & Rangan, 1996). It is not just that private practitioners are perceived as better. 
There is also a lack of awareness that HCs even provide services for TB, or an overall low 
regard based on the poor reputation of HCs.  
 
 Our findings support these explanations and raise additional questions: almost half of 
the patients who had used the HC for something else before falling sick with TB went to the 
HC first when they sought help for symptoms of TB, compared with only one-fifth of those 
who had not used the HC before their TB illness. Prior use encouraged, rather than 
discouraged, further use. Could this be taken as evidence that HCs are better liked than their 
reputation suggests? A study examining that question in India found that people generally 
ascribed a poor attitude to HC staff. However, when Indian TB patients who had used both 
the private and the public sector providers were asked to compare the two, they said the 
behaviour of the public doctors was better (Uplekar & Rangan, 1996, p. 24).  
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 It seems the way most health providers, public and private, relate to their patients 
needs to be improved. The study by Uplekar and Rangan showed health education was a low 
priority for providers and received little more than scant attention. Patients received only “a 
series of across-the-desk instructions, which the patient could rarely comprehend.” (Uplekar 
& Rangan, 1996, p. 54). In South America as well, research in Cali, Colombia, revealed that 
the communication skills of most health workers were also poor (Jaramillo, 1998).  
 
 Recognition of the importance of the quality of the initial patient counselling needs to 
become a higher priority. Anecdotal evidence indicates that there are health providers 
whose TB patients all complete treatment (Sumartojo, 1993). An empathic and respectful 
style of listening and interacting with patients is essential. This enables patients to speak 
frankly, which in turn helps the health care provider to appreciate the problems that confront 
their patients. Giving priority to such values in the clinical interaction engenders mutual 
respect that contributes to development of an effective therapeutic alliance, especially 
important to support the six-month-long course of treatment for TB. Patients and clinicians 
who consider each other partners with a shared goal, to cure TB, are more likely to foster a 
clinical relationship conducive to effective treatment. Although it is easy to find examples of 
troubled doctor-patient relationships, identifying solutions is more challenging (Rubel & 
Garro, 1992; Zwarenstein, 1999). Nevertheless, there are success stories (see e.g. Steyn et 
al., 1997), and it is important to learn from them.  
 
 Another reason why private doctors are so attractive may be that for chest-related 
symptoms patients want an X-ray, and many private doctors rely heavily on chest X-rays. 
For example, data from Korea show that 75% of 224 cases diagnosed with tuberculosis in 
facilities other than health centres relied exclusively on X-ray findings (Mori et al., 1992).  
 
 The cost of case finding to patients is often considerable. A study in rural Africa 
found that approximately half the monetary costs and majority of the time lost from work and 
other social costs are incurred before diagnosis (Saunderson, 1995). A study in Thailand 
found the pre-diagnostic out-of-pocket expenditures to be similar or higher than the post-
diagnostic out-of-pocket expenditures (Kamolratanakul et al., 1999). Ways to reduce these 
costs are needed. It is crucial that the case finding process entails only minimal expenses for 
the patient so that she or he can bear the cost of treatment that follows. Minimal case finding 
expenses not only reduce financial barriers to treatment; they also facilitate a positive 
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attitude towards the health provider. Other benefits of efficient case finding include reduced 
transmission of the TB bacilli, less likely development of drug resistance, less physical and 
mental suffering; and reduced likelihood of incomplete recovery.  
 
 Most TB patients buy the prescribed anti-TB drugs when they come from the private 
doctor. Buying anti-TB medication, rather than receiving it free at the HC, not only 
aggravates the financial hardships of the poor, it often results in incomplete and/or irregular 
intake of drugs (Nichter, 1994). Better public-private collaboration and innovative 
approaches to improving interactions between the public and private health providers need 
to be developed (Brugha & Zwi, 1999). Policy should be implemented that requires private 
doctors to refer patients who lack the financial means to complete treatment on their own. A 
reliable supply of high-quality anti-TB drugs in the health centres is of course essential for 
such a policy to be effective. 
 
  Several factors may have compromised the validity of our data. Since patients were 
interviewed 1 to 16 months after the end of treatment, recall bias may have been a factor. 
Only 39% of the 812 known sm+ TB patients could be found and interviewed. Many patients 
moved back to the province, and inadequate addresses for others in the health centre records 
made it impossible to find them. Consequently, there may have been a selection bias. This 
was probably less of a factor than the low percentage indicates, because many of the patients 
came from rural areas, and they were likely to have been in Malabon only for their 
treatment. Consequently, we reached a larger proportion of the affected persons residing in 
Malabon. Only ten former patients declined to be interviewed; thus, refusal to be 
interviewed constitutes only a minimal potential bias.  
 
  Our findings clarify important aspects of treatment delay for TB in the Philippines 
and relevant issues in the doctor-patient relationship require attention for improved TB 
control. With the implementation of DOTS and consideration of alternative strategies for 
implementing control measures, it is hoped that these insights may be useful and that they 
may form policy in the Philippines and comparable regions. 
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CONCLUSION 
 
The urgent need to foster co-ordination and collaboration between the private and 
the public health providers is clear. In addition, several findings of this study suggest that 
improved health communication is an important supporting element in case finding, both 
general information about TB, perhaps making better use of television and radio, and 
tactful individual health communication in health facilities.  
 
 This study found that the family plays an important role in health seeking. This is as 
expected in the Philippines where the family remains an important source of support. 
Health communication to promote health and prevent illness should be conveyed to more 
than one person in the family. Our finding that 28% of respondents reported someone else 
with TB in their household when they themselves came for a medical check-up 
underscores the importance of “family-based” health communication. Encouraging the 
public to always be accompanied by a family member when seeking health care and 
enabling community health workers to adequately convey health communication messages 
to the families in their houses are two approaches to strengthen family-based health 
communication. Two kinds of educational materials may act as enabler: Culturally 
sensitive materials that the health worker can give to the patients and materials for the 
health workers themselves. The latter was produced in the Philippines: so-called cue cards 
were developed for the health providers dealing with TB patients. These cue cards 
contained the key words of the ten essential messages that need to be conveyed to TB 
patients (Valeza et al., 1990).  
 
 Overuse and inappropriate use of X-rays, and failure to examine sputa in 
accordance with current policy indicate the need to update skills and practice of private 
practitioners and HC staff.  
 
 Clearly, health communications alone are insufficient for adequate control of TB. 
They cannot reduce lag time to treatment unless health services are available, affordable, 
and acceptable. There is no substitute for competent, efficient and patient-oriented 
personnel who effectively engage patients in a productive treatment alliance, and of course, 
medicines must be readily available. Efforts to promote the DOTS strategy must account 
for the human aspect of clinical interactions. The technical and organisational aspects of 
TB control should not detract from appreciation of the human aspects of treatment and 
control strategies.  
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Diagnosis and management of tuberculosis by private practitioners in Manila, 
Philippines             
 
ABSTRACT        
  
Setting: Private for-profit health care providers are prominent in the health system of the 
Philippines.     
Objectives: To examine the practices of the private practitioners in Malabon, Metropolitan 
Manila, Philippines, concerning diagnosis and treatment of TB.     
Design: Forty-five private practitioners of Malabon who treat adult TB patients were 
interviewed.     
Results: For diagnosis, most private practitioners relied on the clinical presentation and 
result of an X-ray. Only 13% of the respondents routinely also ask for sputum examination. 
Ninety-sex percent used X-ray as a tool to monitor treatment.  
 
Sixty percent of the respondents prescribed a regimen consisting of isoniazid, rifampicin, 
pyrazinamide, and ethambutol. Except for rifampicin, over-dosage was common. For re-
treatment cases, none prescribed the WHO-recommended re-treatment regimen. 
 
The private practitioners perceived the main reasons for patient non-adherence to be the 
patients' lack of finances to buy drugs and patients' perceived well-being after a certain 
period of treatment. Patients' lack of money was seen as the main obstacle to compliance. 
The only case holding mechanism mentioned was occasional visits of the TB patients to the 
clinic.    
Conclusion: Private practices for diagnosis and treatment of TB typically deviate from 
guidelines. The quality of care among private practitioners needs improvement. Innovative 
strategies are required.  
 
 
 
 
Keywords:  private practitioners, tuberculosis, diagnosis, treatment, Philippines  
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INTRODUCTION 
 
Private for-profit health providers play an important role in most countries of the 
world, especially in Asian countries (Brugha & Zwi, 1999a). In India, 50 to 80% of the 
tuberculosis (TB) patients first seek professional help from a private health provider 
(Pathania et al., 1997). And in urban Pakistan 80% of the patients being treated in the public 
TB programme had first sought help from private practitioners (Marsh et al., 1996).  
 
Shortcomings in the diagnosis and/or treatment of TB by private providers have been 
reported in various countries. Such shortcomings include failure to use sputum microscopy, 
inappropriate treatment regimens, failure to properly educate patients and a lack of case 
holding mechanisms. 
 
In the Philippines, 50% of the total health expenditures consists of out-of-pocket 
expenditures (WHO, 2000b). A nationwide tuberculosis survey in the Philippines found that 
in response to symptoms of TB, most sought no professional help: 43% of the respondents 
took no action, 32% self-medicated, 12% consulted a private practitioner, 8% a public health 
centre, 4% a hospital, and 2% a traditional healer (Tupasi et al., 2000a). Recent research in 
Malabon, Metropolitan Manila, Philippines showed that 53% of the TB patients treated in 
public health centres had gone to a private practitioner as their first health seeking action, and 
66% of the patients had received a prescription for drugs before getting treated at the public 
health centres (Auer et al., 2000). A survey across the Philippines among family physicians 
revealed misunderstandings in the area of transmission and inadequate prescriptions, 
especially for re-treatment cases (Manalo et al., 1998).   
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It is important to establish the deficiencies of the practitioners’ knowledge and 
practices so that these deficiencies can be addressed and the principles of the DOTS strategy 
made known. Also, assisting the private practitioners to adhere to the principles of DOTS not 
only benefits their patients but also enhances collaboration between the private and public 
sectors.  
 
 Our study aimed to determine diagnostic and treatment practices for TB, including 
case holding mechanisms, among private practitioners in Malabon, Metro Manila with 
reference to accepted standards of TB care.   
 
METHODS 
 
We surveyed 45 private for-profit practitioners who treat TB in Malabon, Metro 
Manila. Malabon had approximately 400,000 inhabitants in 1999. The public health sector 
consists of 23 health centres providing TB care. Although the DOTS strategy was 
implemented in May 1999, not all elements of the DOTS strategy were functioning 
satisfactorily by the end of 2000.  
 
Our survey aimed to interview all private practitioners with adult TB patients. Private 
practitioners were identified by actively searching for private clinics and by asking health 
centre staff to identify private practitioners in the catchment areas of their health centres. 
Most private practitioners (41) were interviewed in 1999; four were interviewed in early 
2000.  
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The interview questionnaire, was pre-tested and reviewed with several doctors. There 
was an almost even mix of closed and open-ended questions. The interview lasted 
approximately fifty minutes, on average, and was performed in the doctors’ clinics in the 
absence of patients and clinic staff.  
 
 
RESULTS 
 
 
The private practitioners  
None of the 45 identified private practitioners refused to be interviewed. Four 
additional private practitioners that also had adult TB patients, identified subsequently, were 
not interviewed. It is estimated that at least 90% of Malabon’s adult TB patients of 1999 that 
approached a private practitioner went to these 45 private practitioners. Of these 45 private 
practitioners (25 male and 20 female), 22 (49%) were less than 41 years old, 9 (20%) were 
between 41 and 50 years old, and 14 (31%) were between 51 and 81 years old.  
 
These 45 private practitioners estimated they saw a total of 3,530 adult TB patients in 
the previous year. Based on this estimate, the rate of TB patients who consult private 
practitioners in Malabon is approximately 880 per 100,000 inhabitants. According to the 
private practitioners' estimates, only 1.6% of their TB patients had extra-pulmonary TB.  
 
For most private practitioners (61%), less than 10% of their total number of patients 
were adult TB patients. A quarter (25%) of the private practitioners stated that 10 to 15% of 
their total number of patients were adult TB patients. And 14% stated that at least 20% of 
their total number of patients were adult TB patients. Eighty percent of the respondents 
characterised the economic status of at least 80% of their TB patients as poor.  
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Diagnostic process 
Contrary to DOTS principles, almost all respondents (93%) relied on the clinical 
presentation and result of an X-ray to decide whether or not to start anti-TB treatme nt. Only 
six respondents (13%) said they routinely also asked for sputum examination (microscopy). 
Nineteen (42%) said that in some cases they would also ask for a sputum examination in 
addition to an X-ray. Two respondents reported they used X-ray only ‘when considered 
necessary’. One of them mainly relied on the clinical presentation and the other one on 
sputum microscopy. Figure 6.1 presents the answers of the respondents when specifically 
asked about the role of various diagnostic tools.  
 
 Figure 6.1: Diagnostic tools used by private practitioners to diagnose TB (n = 45) 
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Of those respondents who did not always use X-ray (n = 11; 24%), only one reported 
‘often’ using sputum examination, and three reported to ‘sometimes’ use sputum 
exami nation. The remaining 7 (16%) rely on the signs and symptoms and on the question of 
whether the patient had been in contact with someone with open TB. In addition, one of the 7 
also ‘always’ considers the response of the TB suspect to antibiotic treatment.  
 
Most respondents thought chest X-ray was a tool with high specificity, i.e. the 
reliability of X-ray findings was believed to be high. The question, asked to only 39 of the 45 
private practitioners, was if a chest X-ray that is considered “positive for TB” by one 
radiologist is also considered “positive for TB” by another, independent radiologist. Fifty-six 
percent (22/39) believed interpersonal discrepancy in X-ray interpretation happened in only 1 
to 5% of the cases; 26% expected an interpersonal discrepancy in 10% of the cases, and 15% 
in 15 to 20% of the cases. The remaining respondent expected an interpersonal discrepancy 
in 25% of the cases.  
 
Thirty-eight percent of the respondents (17/45) had own X-ray equipment. Their 
responses about diagnosing TB patients were not different from the responses of those 
without own X-ray equipment.  
 
 
Monitoring treatment  
Use of X-ray was also popular as a tool to follow-up or monitor treatment: all except 
two respondents used X-ray to monitor response to treatment. Most (60%) asked for only one 
follow-up X-ray (normally at the end of treatment) and 27% asked twice for follow-up X-ray 
(normally after two or three months and at the end of treatment). Nine percent asked once, 
twice or three times for a follow-up X-ray during treatment.  
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Only 20% of the private practitioners reported using follow-up sputum examinations 
for some or all of their TB patients, even though two-thirds stated that follow-up sputum 
examinations for monitoring treatment are ‘important’ (53%) or ‘essential’ (13%). 
 
Treatment 
 
 
The private practitioners were asked what they normally prescribed to a patient with 
far-advanced tuberculosis, weighing 45 kg. Table 6.1 presents their responses. Twenty-seven 
respondents (60%) prescribed a quadruple regi men, consisting of isoniazid (H), rifampicin 
(R), pyrazinamide (Z), and ethambutol (E), but only 15 (33%) prescribed this quadruple 
regimen for six months. Of these 15, only 4 (9%) prescribed 2HRZE  / 4HR (meaning: H, R, 
Z, and E for the first two months of treatment, and then H and R for another four months). 
Eight (18%) prescribed 2HRZE  / 4HRE, and the remaining three (7%) prescribed Z for more 
than two months. Eleven (24%) prescribed triple therapy consisting of HRZ, but only 6 
(13%) of them prescribed 2HRZ / 4 HR, the regimen endorsed up to the middle of the 1990’s 
by the Philippine National Tuberculosis Control Programme (NTP). Based on WHO 
recommendations, the main regimens used in the NTP are: (i) 2HRZE  / 4HR for smear-
positive patients and smear-negative patients who do not have minimal TB, as judged by a 
chest X-ray; and (ii) 3HRZES 1 / 1HRZE / 5HRE for previously treated patients.  
 
 
 
 
 
 
                                                           
1 S = streptomycin 
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Tables 6.2 and 6.3 present the duration of treatment and the dosage, respectively. While 
58% (26/45) of the respondents reported prescribing R and also H for six months and 64% 
(29/45) prescribe Z for two months, only 11% (5/45) prescribe E for two months. As to dosing 
for a patient weighing 45 kg, 91% (41/45) prescribed the recommended 450mg for R (480mg in 
one case), 16% (7/45) the recommended 300mg for H (320mg in one case), 11% (5/45) the 
recommended 1000mg for Z, and 29% (13/45) the recommended 800mg for E.  
 
An operational formulation of acceptable treatment accepted a somewhat longer course of 
treatment than WHO-recommended regimens. (This is in accordance with the latest TB 
treatment guidelines of leading American anti-TB organisations that now recommend to consider 
extension of treatment for patients with cavitation on the initial chest X-ray - ATS/CDC/IDSA, 
2003, p. 609.) If we define an acceptable regimen as either HRZE for 6 to 9 months with PZA 
for not more than 3 months and with acceptable dosages (Rifampicin 450 or 600mg, isoniazid of 
not more than 400mg, PZA of not more than 1500mg and Ethambutol of less than 1200mg), or 
HRZ / HR for 6 to 9 months with PZA for not more than 3 months and acceptable dosages, then 
half of the respondents (47%) prescribed acceptable regimens. 
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TABLE 6.1:  
Private practitioners prescribing various treatment regimens for far-advanced TB (n = 45) 
  
 
Number of months prescribed for each drug 
  
Respondents 
   prescribing this regimen 
 
            N               % 
 Regimen Isoniazid Rifampicin PZA Ethambutol  Streptomycin  
 
1.  According to WHO/NTP guidelines 
 
    
 
1.1.  
  
6 
  
6 
  
2 
 
2 
 
- 
         
          4                9 
 
2. Acceptable deviation from guidelines 
           
        17              38 
 
2.1. 
  
6 
  
6 
  
2 
 
6 
 
- 
         
          8              18 
 
2.2. 
  
6 
 
6 
 
3 
 
3 
 
- 
         
          1                2 
 
2.3. 
  
6-9 
 
6 
 
2 
 
6 
 
- 
         
          1                2 
 
2.4. 
  
6-9 
 
6-9 
 
2 
 
6-9 
 
- 
         
          1                2 
 
2.5. 
  
6 
 
6 
 
2 
 
- 
 
- 
         
          6              13 
 
  3. Problematic deviation from guidelines (treatment longer than recommended)  
 
        13              29 
 
3.1. 
  
6 
 
6 
 
4 
 
6 
 
- 
         
          1                2 
 
3.2. 
  
6 
 
6 
 
6 
 
2 
 
- 
         
          1                2 
 
3.3. 
  
6-12 
 
6-12 
 
2 
 
6-12 
 
- 
         
          1                2 
 
3.4. 
  
6-12 
 
6-12 
 
6-12 
 
6-12 
 
- 
         
          1                2 
 
3.5. 
  
8 
 
8 
 
6 
 
3 
 
- 
         
          1                2 
 
3.6. 
  
9 
 
9 
 
9 
 
9 
 
- 
          
          1                2 
 
3.7. 
  
12 
 
12 
 
2 
 
 6-12 
 
- 
         
          1                2 
 
3.8. 
  
12 
 
12 
 
2 
 
12 
 
- 
         
          1                2 
 
3.9. 
  
12 
 
12 
 
2-4 
 
 2-12 
 
- 
         
          1                2 
 
3.10. 
  
18 
 
18 
 
6 
 
18 
 
- 
         
          1                2 
 
3.11. 
  
 6-12 
 
 6-12 
 
6-12 
 
- 
 
- 
         
          2                4 
 
3.12. 
  
 6-12 
 
 6-12 
 
- 
 
- 
 
6-12 
         
          1                2 
 
4. Problematic deviation from guidelines (treatment shorter than recommended) 
 
          7              16 
 
4.1. 
  
4 
 
4 
 
4 
 
4 
 
- 
         
          1                2 
 
4.2. 
  
3-6 
 
3-6 
 
2 
 
3-6 
 
- 
         
          1                2 
 
4.3. 
  
 < 6 
 
< 6 
 
< 6 
 
- 
 
- 
         
          3                7 
 
4.4. 
  
3-6 
 
3-6 
 
- 
 
- 
 
- 
         
          2                4 
 
5. Other problematic deviation from guidelines 
         
          4                 9 
 
5.1. 
 
6 
 
6 
 
6 
 
- 
 
1 
         
          1                 2 
 
5.2. 
 
6 
 
6 
 
2 
 
6 
 
3 
         
          1                 2 
 
5.3. 
 
6 
 
6 
 
6 
 
6 
 
2 
         
          1                 2 
 
5.4.1 
 
6-12 
 
6-12 
 
2-3 
 
3-6 
 
- 
         
          1                 2 
 1 Apart from isoniazid, rifampicin, PZA and ethambutol, this regimen included a fifth drug for the initial  
 two to three months of treatment. This fifth drug was specified as a “third generation drug”. 
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TABLE 6.2:  Prescribed duration of treatment for each of the four main drugs for  
 far-advanced TB (n = 45) 
 
Specified duration Isoniazid & Rifampicin1 Pyrazinamide    Ethambutol 
                 (used by all respondents)        (used by 42 respondents)    (used by 30 respondents) 
__________________________________________________________________________ 
1-12 months:  -  -  3   
 
2 months:  - 29 2  5 2 
 
2-4 months:  -  5  - 
 
3-4 months:  -  -  4 
 
4 months:  1  -   - 
 
3-6 months:  4   1   - 
 
6 months: 25 2, 3  5 10  
 
6-9 months:  5    -   - 
 
6-12 months:  4  2  7 
 
12 months:  3 4   -  1  
 
18 months:  1  -   -
_________________________________________________________________________ 
1 Forty-three used these two drugs for the same duration. One used 6 months of H and 6-9 months of R,  
  and one used 12 months of H and 6 months of H.  
   
2 Duration recommended by WHO.  
 
3 25 used 6 months of H and 6 months of R. In addition, one used 6 months of H and 6-9 of R. 
 
4 Three used 12 months of H and 12 months of R. In addition, one used 12 months of H and 6 months of R.  
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TABLE 6.3: Prescribed dosage for each of the four main drugs for patients weighing  
           45 kg with far-advanced TB (n = 45) 
      
Kind of 
drug  
  
 Rifampicin (used  
 by all respondents)  
  
 Isoniazid 
 (used by all respondents) 
  
 Pyrazinamide (used   
  by 42 respondents) 
  
Ethambutol (used  
by 30 respondents) 
 
 Dosage 
 
 
240 mg         1 1 
450 mg       40 2 
480 mg         1 
600 mg         3 
 
 
 
 
160 or 200 mg       2 
300 mg                  6 2        
320 mg                  1  
300-400 mg           3 
400 mg                30 
500 or 600 mg       3 
 
 
none                 3 
200 mg             1 
500 mg             1 
1000 mg           5 2 
1500 mg         33 
2000 mg           2 
 
 
 
none                  15 
400 or 500 mg     9 
600 mg                1 
800 mg              13 2 
1000 mg              6 
1200 mg              1 
 
1 Number of respondents who mentioned this dosage. 
 
2 Dosage recommended by WHO. 
 
 
 
 
 
The private practitioners were also asked about their re-treatment regimen, that is 
what they prescribe for a patient who previously had anti-TB treatment for at least 2 months. 
Twenty-seven respondents (60%) stated they prescribed the same regimen for new cases and 
for re-treatment cases. Fifteen (33%) prescribed a weaker regimen (less drugs and/or shorter 
duration of treatment), and only one respondent prescribed a stronger regimen. Two 
respondents said they referred such patients to a specialist or for drug susceptibility testing. 
None prescribed the recommended regimen.  
 
For treating patients with multidrug-resistant TB, none of the private practitioners 
mentioned an adequate regimen.  
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Prescribing vitamins was common: 32 (71%) 'always' prescribed vitamins, and 12 
(27%) 'sometimes' prescribed vitamins, and one private practitioners did not prescribe 
vitamins. Only three private practitioners prescribed tonics.  
 
Twenty-five (56%) of the 45 respondents had their own drug supply or their own 
pharmacy from which they assumedly supplied drugs to their TB patients.  
 
Patient education 
 
Only 40% of the private practitioners told their TB patients clearly that they had 
tuberculosis ('TB' or 'tuberculosis' were the used terms), and 27% used 'TB'/'tuberculosis' 
and/or a euphemism, such as 'weak lungs' (mahina ang baga in Filipino) 'illness in the lungs' 
(sakit sa baga), and 'spot in the lungs' (espot sa baga or tama sa baga). One third (33%) used 
only euphemistic expressions.  
 
 Health educational priorities for the private practitioners included: (i) providing 
information about treatment and/or the importance of compliance (reported by 62%); (ii) 
recommending ways to prevent infecting others (62%, including eight respondents who 
advised patients to use separate eating utensils); (iii) promoting intake of nutritious food  
(40%); (iv) recommending to stop risk behaviours, mainly smoking and drinking alcohol 
(27%); and (v) explaining the importance of adequate rest (20%).  
 
 More than two thirds (71%) reported they had no health education materials; 18% 
said they usually have, and 11% said they sometimes have such materials (mostly leaflets). 
Most said they would definitely (84%) or possibly (11%) like to have such materials. 
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 Effective health education to patients requires accurate knowledge among health care 
providers, but this was a problem. Misconceptions among the providers about infectivity 
were common: almost two thirds of the respondents (62%) said that using the eating utensils 
of a sputum smear-positive TB patient is a risk for getting infected. And 36% said there was 
a risk that someone gets infected from fomites in bedsheets, cloths of a smear-positive 
patient.  
 
Case holding mechanisms  
 
 Apart from occasional visits of the TB patient to the clinic no case holding 
mechanisms were mentioned. Most private practitioners (58%) stated to ask for a clinic visit 
monthly, 13% for a clinic visit more frequently than once a month, and 29% for a clinic visit 
less frequently than once a month. 
 
  When the private practitioners were asked if their TB patients complied with this 
request, approximately half of them (47%) estimated that 75% to 100% of their TB patients 
complied. One fourth (27%) estimated that 40% to 70% of their TB patients follow this 
request. And 20% estimated that 10% to 35% of their TB patients follow this request (three 
private practitioners did not respond to this question).  
 
   The respondents were asked what they would do when a TB patient did not appear 
for the next appointment. Almost two-thirds (62%) indicated no follow-up for defaulters. 
Table 6.4 presents the reported defaulter actions.  
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TABLE 6.4:  Follow-up specified by private practitioners when a TB patient misses  
      a scheduled clinic visit (n = 45) 
    
Action done by the private practitioner      Number        Percentage 
                     
Thought about this problem but has not yet found a 
mechanism or system to do something  
 
20                    44% 
    
Calling those TB patients who have a telephone  
 
10                    22%    
None (arguing that it is up to the patient to come back)   
 
  8                    18%    
Reminding TB patients through relatives or neighbours 
the private practitioners happen to meet  
 
  6                    13%  
  
Visiting those TB patients living near the clinic  
(by clinic staff or by the private practitioner)  
 
  2                      4% 
    
Reminding the patient when happening to meet him/her 
(e.g. in church)   
 
  1                    (2%) 
   
    Note: Of the 45 respondents, three gave two answers and one was a non-respondent.  
 
 
 
Perceived patient adherence to treatment 
 
 
 The private practitioners were asked what they believed was the percentage of their 
patients who regularly took treatment up to completion of treatment. Sixteen percent of the 
respondents were very optimistic: they estimated 90 to 95% of their TB patients correctly 
and regularly took their medication up to completion of treatment. And 29% estimated 75 to 
85% of their TB patients were adherent. Thirty-eight percent estimated between 30 and 70% 
of their TB patients were adherent, and 4% estimated only 2 to 5% of their TB patients were 
adherent. The remaining 13% felt they could not respond because of insufficient caseload.  
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The two main reasons by which they explained patient non-adherence were lack of 
finances to continue to buy drugs (mentioned by 91% of the respondents) and feeling 
improved enough that further treatment seemed unnecessary to patients (76%). About half of 
the respondents (49%) mentioned patients lacked awareness of the importance of adherence 
to treatment. Patients getting lazy or fed up, and patients experiencing adverse reactions were 
each mentioned by 36% of the respondents. 
 
DISCUSSION 
 
 
Validity of the findings 
 
 We did not attempt to verify the answers of the private practitioners with 
observations or by consulting patients. Consequently, some of the findings probably reflect 
the knowledge of the private practitioners more accurately than their practices. Various 
studies have found a gap between the private practitioners' knowledge of what to prescribe 
and their actual practice while treating patients, for instance in treatment of tuberculosis in 
Karachi (Thaver et al., 1998). And research in India revealed discrepancies between reported 
diagnostic and treatment practices of the private practitioners and what their patients actually 
followed (Uplekar et al., 1998). Any problems identified through self-report are likely to be 
an underestimate of problems in practice.   
 
The interviewer of the private practitioners (the first author) was not an official part 
of the public TB programme, but the introduction of the questionnaire made it clear that the 
interviewer had links to the public TB programme. Thus, the answers of the respondents may 
have been incorrectly too much in accordance with the TB guidelines of the Department of 
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Health. A good example is sputum microscopy. Since most private practitioners know that 
sputum examinations are the main diagnostic procedure in the public TB programme, there 
probably was a tendency to overstate the use of sputum microscopy. Such discrepancy was 
documented in a study in India (Uplekar et al., 1998). In short, social desirability bias and 
reluctance to admit outdated practices may have resulted in findings too much in line with 
Department of Health and WHO recommendations.  
 
Recall bias together with social desirability bias and over-diagnosis of TB may 
explain the rate of 880 per 100,000 inhabitants, as estimated by the respondents. This rate is 
extremely high, and it does not include the TB patients treated in the public sector. It is 
estimated that in the Philippines the 1998 incidence rate was 307 per 100,000 (WHO, 
2000c). Even if we assume that Malabon is especially heavily affected by the TB epidemic, it 
is clear that our respondents overestimated the number of TB patients in their practice.  
 
Deficiencies in the diagnostic process and in monitoring of treatment  
 
Over-reliance of chest X-ray for diagnosis and monitoring treatment with 
corresponding under-use of sputum examination was common.   
 
There are several reasons why X-ray is preferred over sputum examination: (i) easier 
process and faster result when opting for X-ray; (ii) sputum microscopy - if not undergone in 
a public TB programme - generally entails higher expenditures for the patients than X-ray. 
(iii) Due to the low sensitivity of sputum microscopy, the value of sputum microscopy is 
questioned. (iv) Poor reputation of sputum microscopy, also because giving sputum is 
strongly associated with having TB (Rangan & Uplekar, 1999). (v) Over-estimation of the 
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reliability of chest X-ray. (vi) A substantial proportion of private practitioners has their own 
X-ray facility (38% in this setting).  
 
The three reasons mentioned first (and in areas where stigma is a major problem also 
the forth reason) are valid concerns. However, a higher awareness of the limitations of X-ray 
and a clearer appreciation of the advantages of sputum microscopy may well create a higher 
demand for sputum microscopy among private practitioners. Improving the knowledge of the 
private practitioners regarding X-ray radiology and sputum examination may thus bring 
changes. Probably more important is to provide easy access to high-quality sputum 
examination, for instance by simple referral procedures for the private practitioners' TB 
symptomatics to public facilities performing sputum examinations. But this exposes private 
patients to the public system which both patients and private providers may resist.  
 
 
Few respondents used follow-up sputum examinations for monitoring of treatment. 
Requesting patients to undergo X-ray while on treatment was much more popular. Follow-up 
chest X-rays are generally not recommended (WHO, 1997a; Mangura & Reichman, 1999). 
However, it can be useful for bacteriologically negative cases (Gordin et al., 1989), and for 
such cases it is generally recommended, also in the Philippines (Task Force on Tuberculosis, 
2000). The main problem is that at three months of treatment, an unimproved X-ray finding 
is not uncommon (Gordin et al., 1989) and is not a matter of concern. But it may result in 
inappropriate changes in treatment (e.g. prolonged treatment) and cause unnecessary anguish 
in the patient.  
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Issues in treatment 
 
Although most private practitioners (60%) knew the recommended quadruple drug 
combination, they were not prescribing it correctly. For new cases there was a tendency to 
over-prescribe. And TB patients with previous treatment of TB were almost always treated 
inappropriately (not long enough and not with a fivefold regimen). The following paragraphs 
look at these issues in more detail. We also examine the evidence-base of the WHO-
recommended regimens since successfully winning the private practitioners over for the 
DOTS strategy somehow implies that the regimens used by the DOTS strategy are based on 
available evidence.  
 
We found that in terms of dosing and duration of usage of each drug, most private 
practitioners did not follow the recommendations. Using ethambutol for six months was 
common and some experts recommend this for areas where resistance to isoniazid (such as 
the Philippines) is common. It is also promoted by many drug companies. A randomised 
controlled trial comparing 2HRZE/4HR with 2HRZE/4HRE among TB patients with strains 
resistant to isoniazid would be helpful.  
 
The role of ethambutol is not only unclear regarding its use during the maintenance 
phase of treatment; there is also no convincing evidence that it is needed during the first two 
months of treatment. A recent meta-analysis did not find differences in treatment outcome 
between three and four drugs, except for adverse reactions (more frequent with four drugs) 
and compliance rates (higher with four drugs; some studies used streptomycin instead of 
ethambutol) (Task Force on Tuberculosis, 2000). We found only three studies comparing 
three with four drugs in which data on isoniazid resistance were available. Two studies did 
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not find that treatment response to three or four drugs correlated with initial isoniazid 
resistance (however, the sample sizes were small) (Yu et al., 1996; Yu et al, undated). In the 
third study, twice-weekly therapy was compared, and the dosages were rather low. Adding 
six months of ethambutol was found to improve the treatment response (Tuberculosis 
Research Centre, 1997). Large trials addressing the question of whether adding ethambutol to 
a triple regimen is advantageous should be performed.  
 
It must be considered that adding ethambutol has several disadvantages: One, using 
ethambutol increases the financial and logistic burden for TB programmes and is a financial 
burden for private patients. Two, ethambutol is associated with severe ocular side effects. 
Three, the use of ethambutol may result in decreased treatment adherence either directly due 
to increased number of tablets to be taken or indirectly due to side effects. Four, addressing 
the deficiencies of the private practitioners should be done by presenting evidence-based 
treatment recommendations. The public programmes and WHO lose credibility when a 
recommended regimen has no solid evidence base.  
 
 On the other hand, there is clear evidence that using pyrazinamide for more than two 
months is not useful (Singapore Tuberculosis Service/British Medical Research Council, 
1979; Singapore Tuberculosis Service/British Medical Research Council, 1981). For TB with 
drug resistance, a longer course of pyrazinamide might provide some benefit though we do 
not know of studies supporting this view. In the Philippines, the prescription sheet of a 
quadruple fixed dose combination recommends an intensive phase of treatment for three 
months. The drawbacks of added toxicity, of more likely non-compliance due to a high 
number of tablets that need to be swallowed for a longer time and of an increased financial 
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burden need to be balanced with the unlikely benefit of using pyrazinamide for more than 
two months.  
 
The inadequate prescription habits of the private practitioners for re-treatment cases 
are of concern. The regimens mentioned by the respondents may leave a rather high 
percentage of previously treated TB patients uncured and aggravate drug resistance. Some 
research, however, questions whether this may be as serious as it seems, inasmuch as some 
research suggests re-treatment patients may be treated with the regular regimen used for new 
patients (Wilkinson et al., 1998; Connolly et al., 1999). Especially for re-treatment cases 
with pan-susceptible TB bacilli, the re-treatment regimen is most likely not needed. On the 
other hand, for patients with multi-drug resistant TB (MDR-TB), the re-treatment regimen is 
inadequate (Kimerling et al., 1999; Farmer, 1999a). Only the availability of a test that would 
determine the resistance pattern within a few days would be the way out of the unfortunate 
reality that for many patients the re-treatment is either unnecessarily high-powered or lacks 
potency. Still, for re-treatment cases, the conventional drug susceptibility test should be 
performed if possible. Treatment can then be adjusted once the resistance pattern is known. 
This requires rethinking policy and then assuring such policy may be implemented in the 
public TB programmes and among private practitioners.  
 
 
 Another practice that imposes risk for development of drug resistance is the almost 
complete absence of case holding mechanisms. This absence of case holding mechanisms - a 
common feature of private TB care (WHO, 2001e) - is a threat to the health of the patients 
and a public health threat.  
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Ways to assist the private practitioners to improve care 
 
The findings of this survey call for remedial actions. What can easily be implemented 
and logically follows from our findings is to provide the private practitioners with 
appropriate health education materials. They appear willing to use such materials. However, 
health education materials alone normally do not increase adherence to treatment (Haynes et 
al., 2002).   
 
To change the private practitioners' practices, simple dissemination of information, 
e.g. through seminars, is not expected to be effective (Oxman et al., 1995). More promising 
are multifaceted approaches, combining e.g. practice visits, using local opinion leaders 
(Thomson O'Brien et al., 2002), and patient-mediated interventions to reduce the pressure on 
the private practitioners that comes from the patient demands (Kamat, 2001; Schwartz et al., 
1989). Assisting the private practitioners to optimise their prescription practices should be 
relatively easy, especially if participation of the influential pharmaceutical companies and a 
commitment to evidence-based medicine can be brought about. The big challenge is to see 
effective case holding mechanisms established for TB patients treated in the private sector. 
Operational research that explores the role of incentives and disincentives, including 
legislation and regulation is needed. The option of re-certification (i.e. renewal of the license 
to practice depends on fulfilling certain standards) should be discussed. Measures to promote 
case holding should be evaluated and refined continuously. Processes that enable and 
encourage private practitioners to meet as peers in order to find effective case holding 
mechanisms suitable to them and their patients need to be found. However, efforts among the 
private sector alone will be of limited value. Communication as well as collaboration 
between the private and public health sector is crucial in the search for effective TB control. 
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CONCLUSION 
 
This study showed that there is room for improvement in the diagnosis of TB among 
private practitioners of Malabon. Although the private practitioners need more accurate 
knowledge, the main challenge is to find patient-friendly mechanisms that will enable the 
private practitioners to diagnose TB correctly and efficiently.  
 
With respect to proper treatment, most private practitioners know the correct 
quadruple drug combination but they do not know how to prescribe them in accordance with 
recommended policy. There is a tendency to over-medicate new patients, and TB patients 
with previous treatment of TB are almost always under-medicated. Findings indicate needs 
for improved diagnostic and treatment practices of private practitioners in Metro Manila. 
These results are also consistent with findings from other studies that highlight the 
importance of public-private collaboration among global and national priorities for TB 
control.  
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Public-private collaboration for TB control in Manila, Philippines: views from both 
sectors 
 
SUMMARY    
In the Philippines, many TB patients are treated by private practitioners. Questions about the 
private practitioner's quality of care and efficiency of service as well as limitations of the 
public sector suggest needs for improved collaboration between public and private sectors.    
This study examines the private practitioners' felt needs for additional knowledge on clinical 
management of tuberculosis and their views on the public TB programme and collaboration 
with the public health sector. It also examines the views of the public health centre 
personnel about the private practitioners, their own TB programme, and public-private 
collaboration.    
Forty-five private practitioners were interviewed. Group discussions with personnel of the 
public health centres inquired about collaboration with private practitioners.    
The private practitioners' most frequently mentioned needs for updated clinical knowledge 
were about appropriate use of sputum microscopy, how to tell patients that household 
contacts need a check-up, and motivating the patients to adhere to treatment. There was 
considerable interest to receive and follow the national TB guidelines.    
The main perceived problems they identified with the public TB programme were 
insufficient drug supply, poor quality of the TB drugs, and lack of health education. Two 
suggestions on how to establish public -private collaboration (mandatory referral of poor TB 
patients to the public TB programme and allowing private practitioners to use the 
governmental TB drugs) were generally welcome, but they expressed reservation 
concerning feasibility of the latter suggestion. The personnel of the public health centres 
were positive about mandatory referral of poor TB patients to the public TB programme but 
sceptical about allowing private practitioners to use the governmental TB drugs.    
Our findings suggest steps to facilitate public-private collaboration and the need for specific 
human resources. The public programme needs to be strengthened and collaboration 
prioritised. 
 
 
Keywords:  tuberculosis, DOTS, private practitioners, public-private collaboration,  
  Philippines 
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INTRODUCTION 
 
Private for-profit health providers play an important role in most countries of the 
world (Brugha & Zwi, 1999, p. 168). For the 22 countries that account for 80% of all new 
tuberculosis (TB) cases in the world, the out-of-pocket expenditures expressed as percentage 
of the total health expenditures range from 23% (Russia) to 91% (Cambodia) (Uplekar et al., 
2001). In most other countries as well, people with tuberculosis from all levels of socio-
economic status make use of the private health care sector (Uplekar, 1999). It is estimated 
that in India, 50 to 80% of the TB patients first seek professional help from a private health 
provider (Pathania et al., 1997). And a survey in Ho Chi Minh City, Vietnam found that 
about half of the patients being treated in the public TB programme had initially chosen a 
private health provider and that there was no significant association between socio-economic 
status and use of private providers (Lönnroth et al., 2001). On the other hand, other studies 
in Asia found that the level of utilisation of private providers increases with socio-economic 
status (Yesudian, 1994; Aljunid & Norhassim, 1992; Ministry of Health Malaysia, 1988).  
 
 Recent research in Malabon, Metro Manila, Philippines revealed that 53% of the TB 
patients treated in public health centres had gone to a private practitioner as their first health 
seeking action and 66% of the patients had received a prescription for drugs (Auer et al., 
2000). The patient survey in Malabon also found that there was no association between self-
perceived degree of poverty of patients and either the public or private status of their 
commonly approached health provider or whether they received a prescription for TB drugs 
during help seeking. Nor could an association be found between self-perceived degree of 
poverty and having or not having bought TB drugs for at least two weeks (unpublished 
survey data).  
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In general, the following makes the private providers attractive in comparison to the 
public health sector: (i) easier accessibility (sometimes geographically and often in terms of 
clinic hours); (ii) shorter waiting periods; (iii) a more stable doctor-patient relationship; (iv) 
more considerate staff attitudes; (v) a greater degree of confidentiality; and (vi) more 
reliable availability of staff and drugs (Brugha & Zwi, 1999a, p. 171; Swan & Zwi, 1997; 
Aljunid, 1995). Also, making use of private practitioners may not be much more expensive 
than making use of public facilities; even when using public health facilities, there are often 
considerable costs that are mainly hidden. Common hidden costs are wasted trips to public 
facilities due to irregular drug supplies, donations at the public facility, and opportunity 
costs due to long hours of travelling to and waiting in public facilities, especially when DOT 
(directly observed therapy) is health facility based.  
 
The common notion is that the private sector provides better services than the public 
sector (Lönnroth et al., 1998). However, evidence suggests that the services offered in the 
private sector are often poor (Swan & Zwi, 1997; Aljunid, 1995). A review at WHO found 
undue emphasis on chest X-ray for diagnosis, neglect of sputum examinations (for diagnosis 
and monitoring of treatment), inappropriate drug prescriptions and little or no recording of 
case data were common problems in the private sector (WHO, 2001e, p. 24). Studies in 
Malaysia (Hooi, 1994) and in South India (Rajeswari et al., 2002) showed patients who first 
visited private providers had longer health system delays (i.e. delay in the health seeking 
process that is due to the provider) than those who first went to government health facilities. 
Another study in India found that TB patients preferred the behaviour of public over private 
doctors in clinical consultations (Uplekar & Rangan, 1996, p. 24). 
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Failure to establish public-private collaboration may result in vario us problems.  
First, it may prolong the health-seeking phase. This often worsens the clinical condition and 
increases the likelihood of developing drug resistance. It also furthers transmission of the 
TB bacilli and aggravates the negative emotional and social consequences of having TB. In 
addition, it aggravates the financial repercussions of having TB and burdens the health 
services. Second, inadequate treatment is more likely to happen from inappropriate 
prescriptions, the patients' financial incapacity to buy the drugs as prescribed, and a weak or 
non-existing case holding mechanism. Third, establishing a diagnosis by the public sector 
(which relies heavily on sputum microscopy) is less sensitive if TB patients have already 
consumed anti-TB drugs. Negative sputum smears believed to be due to previous intake of 
anti-TB drugs have been identified as a problem by public health providers in Malabon, 
Metro Manila (Auer, 1998a). Fourth, patients may be less willing to accept the medications 
given in the public health services since the patients were accustomed to the anti-TB drugs 
prescribed by their private practitioners that differed from those at the public health centre. 
Fifth, since private practitioners generally do not report on their TB patients, any assessment 
of the epidemiological situation of tuberculosis in a country, e.g. the national TB case 
detection rate, remains inaccurate. 
 
  
The last few years have seen a growing international interest in collaboration 
between the private and the public health sector. The important role of the private sector and 
the need to include the private sector in disease control strategies are increasingly being 
acknowledged. A recent WHO consultation in Geneva discussed strategies for public private 
sector collaboration and highlighted the need to develop and assess such collaborative 
approaches (WHO, 2001e). And the latest WHO document on DOTS even states that 
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involving private health care providers is imperative (WHO, 2002d). Also in the Philippines, 
there has been a call to establish collaboration between the private and public sector in 
tuberculosis control (Tupasi et al., 2000, Tupasi et al., 2000a; WHO, 2001f, p. 69). In 1999, 
the gross national product per capita in the Philippines was US $ 1020.-, life expectancy 69 
years, and infant mortality rate 31 per 1000 life births 1, and 27% of the population lived with 
an income of below 1 US $ a day (UNICEF, 2002). The population size was 76.5 million in 
May 2000 (National Statistics Office, 2002). In 2001, the country ranked 9th in the world for 
the estimated incidence rate of all TB cases. The annual estimated incidence rate for the year 
2001 was 297 per 100,000 and the percentage of multi-drug resistant TB among new cases 
of TB was estimated to be 3.2%. By the end of 2000, 90% of the population had access to 
DOTS, the internationally promoted strategy to control TB which had been implemented by 
155 countries in the year 2001. One year later, DOTS coverage reached 95% of the 
population (WHO, 2003). For many years already, the private sector has been strong in the 
Philippines. For instance, a Ministry of Health report of 1981 stated that 59% of the 
physicians was entirely engaged in private practice and that among the remaining 41%, 
nearly all did some private practice part-time (Roemer, 1991, p. 301).  
 
 
 
 
 
 
____________________ 
1 However, according to the Philippine government, infant mortality rate was only 17.3 per 1000 life births 
(figure for 1998). <http://www.doh.gov.ph/data_stat/html/infant_10.htm>, accessed on Sept. 11, 2002. 
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Various questions should be considered to facilitate establishing effective 
collaboration. One set of questions is addressed to private practitioners, such as the common 
deficiencies among private practitioners and how these deficiencies can be addressed. 
Important questions regarding the public TB programme are what the public sector can offer 
to facilitate collaboration and how the public programme can increase its capacity in 
anticipation of the increased workload as a result of successful collaboration with the private 
sector. Other key questions are what local mechanisms that can facilitate collaboration are 
already in place and what are the complex influences which determine patient behaviour? 
 
We aimed to examine the perceived need for pub lic-private collaboration, the 
attitudes towards collaboration, existing collaborative efforts (if any), and problems to 
expect. Thus, we surveyed forty-five private for-profit practitioners of Malabon to examine 
knowledge and practices regarding diagnosis  and treatment of TB (report forthcoming), as 
well as their perceived needs regarding further information on TB and its control. Their 
views on collaboration with the public health sector and on suggestions how such 
collaboration could look like were also established. Here we present the findings relevant to 
collaboration between the private and public sector. Also presented are findings regarding 
public-private collaboration from group discussions with health personnel of public health 
centres of Malabon.  
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METHODS 
 
1.   The setting 
 
The study was performed in Malabon, a municipality of Metro Manila with 
approximately 400,000 inhabitants in 1999. Roughly one third of Malabon's population 
belongs to the urban poor. The public health sector consists of 23 health centres (and a 
hospital where TB patients are not typically treated); it adopted DOTS in May 1999, but not 
all elements of the DOTS strategy were functioning satisfactorily by the end of 2000. In 
addition to TB care in the public sector, a large number of licensed private practitioners also 
treat patients with TB. None of their clinics are located in urban poor areas. There is one 
NGO that has a TB treatment programme. It operates through a local church in an urban 
poor area. Traditional healers are common in Malabon, but rarely consulted for tuberculosis 
(Auer et al., 2000).  
 
2.   The survey among the private practitioners  
  
Our survey aimed to interview all private practitioners that have adult TB patients. 
These private practitioners were identified by actively searching for private clinics and by 
asking health centre staff to identify private practitioners in the catchment areas of their 
health centres. Most private practitioners (41) were interviewed in 1999; four were 
interviewed in early 2000.  
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The interview questionnaire, containing 100 items, was pre-tested and reviewed with 
several physicians. There was an almost even mix of closed questions and open-ended 
questions. The interview lasted approximately fifty minutes on average, and it was 
performed in the doctors’ clinics without the presence of patients and clinic staff. The 
interview elicited information about clinical practice with respect to diagnosis, treatment, 
case holding, case notes, and TB surveillance. The interview asked about ideas concerning 
infectiousness of TB and provider-perceived needs and ways of updating knowledge about 
TB. The survey also inquired about perceived quality of the public TB programme, its 
strengths and weaknesses, and suggestions for collaboration with the public TB programme.  
 
3.   Group discussions with health personnel of the public health centres of Malabon  
 
Seven health centres broadly representative of the whole sample of 23 health centres, 
were selected by convenience sampling. The number of participants at each ranged from two 
to five. Most of the 28 participants were physicians, nurses, or midwives; and three were 
community health volunteers (locally known as barangay health workers).  
 
The facilitator of the group discussions (CA) who was known to the health centre 
staff from extensive prior participatory research among them, made use of an interview 
guide to systematically cover the points of the research agenda. The main topics of 
discussion were the relative strengths and weaknesses of the private practitioners and the 
public health centres. Consideration of specific suggestions for public-private collaboration 
concluded the discussion. Detailed notes from the discussions were maintained by the 
facilitator.   
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4.   Ethical approval 
 
 The study received clearance from a review body of the Department of Health Manila. 
This review body is part of the office of 'Essential National Health Research'. The municipal 
health office of Malabon welcomed the study. Also, a committee of the Swiss Tropical 
Institute that reviews study proposals regarding ethical issues approved the study.  
 
 
 
RESULTS 
 
A)  Survey of private practitioners 
 
 This section first presents priorities of the respondents regarding their need for 
updated knowledge of TB and its control. We then examine their views about the public TB 
services, and their attitude towards collaboration with the public TB programme.  
 
Felt need for more knowledge 
 
The respondents were asked to comment on twelve common elements of TB control 
and any need for more information about them (Table 7.1). The top items mentioned were 
(i) appropriate use of sputum microscopy; (ii) how to tell patient that household contacts 
need a check-up; and (iii) motivating the patient to adhere to treatment. 
 
We presented the same 12 elements of TB control and asked the private practitioners 
to comment on the need for improved practices of Metro Manila's private practitioners in 
general in reference to these 12 elements of TB control. Interestingly, two items regarding 
diagnosis that were perceived to be top items (first and fourth) in terms of own need for 
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more information, namely 'Appropriate use of sputum microscopy' and 'Accurate reading of 
X-ray films' then ranked only seventh and eighth, respectively.  
 
Table 7.1: Perceived information needs of private practitioners of Malabon (n = 45)  
 
Ranking of the twelve items presented to 
the private practitioners (in descending 
order of felt need to get information)    
 M o r e   i n f o r m a t i o n   n e e d e d? 
        Yes              Possibly           No 
Appropriate use of sputum microscopy  58%   20%     20%    
How to tell patient that household contacts 
need a check-up (tracing household contacts)  
 
56%   
 
 18% 
 
22%   
Motivating the patient to adhere to treatment  56%   29%   13%    
How to deal with side effects    53%    27%   16%   
Accurate reading of X-ray films    53%    27%   16%   
Patient health education about TB  53%    31%   13%   
Monitoring patient during treatment  53%    24%  20%   
Length of treatment period  53%    22%  22%   
Informing relatives of patient about TB  47%    24%   22%   
Correct dosing of drugs   42%   16%   40%   
Standard treatment  36%   31%   31%   
Appropriate use of X-ray  33%   27%   36%    
Note: Not all respondents answered to all items (thus, some percentages may not add up to 100%) . 
 
 
 
 
When asked how they update skills for clinical management of TB, the following 
points were mentioned by at least 44% of the respondents: various meetings (seminars, 
conventions, scientific meetings), professional literature (periodicals and journals), 
educational leaflets and brochures, and inputs from the medical representatives of 
pharmaceutical companies. When asked how they would like to receive more information, 
they typically acknowledged of all of them except medical representatives of pharmaceutical 
companies. Only three respondents (7%) valued such advice. 
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The following three findings indicate that most respondents were not properly 
updated on TB control. First, only eleven respondents (24%) more or less accurately knew 
what the acronym DOTS stands for. Second, only one doctor knew what the acronym 
PhilCAT stands for (PhilCAT: Philippine Coalition Against Tuberculosis; a broad and very 
active umbrella organization; Roa & Romulo, 2000). Third, only five respondents could 
explain what intermittent therapy is.  
 
Although DOTS was not yet well-known, respondents expressed interest in receiving 
and following the TB guidelines (based on DOTS) of the Department of Health: 62% 
expressed much willingness to follow these guidelines, and 33% expressed some 
willingness. There was also a widespread interest to attend continuing medical education 
meetings sponsored by the Department of Health: 51% were "very much interested", and 
44% "quite interested". One chose not to respond and one responded with no interest to 
attend. A third (32%) wanted such meetings once a year, 39% wanted it twice a year and 
30% thrice a year. 
 
 
Case notes and reporting by private practitioners 
 
 Nearly half of the respondents (47%) were clearly discontented and 29% somewhat 
discontented with the available tool they were using for case notes. Most of the practitioners 
expressed their interest in having a recording tool similar to the treatment card of the public 
health centres. Only one respondent said he gave his TB patients a 'treatment card' for 
recording drug intake. Most respondents (78%) expressed clear interest and 16% some 
interest in using a treatment card for their patients.  
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 Even though 82% of the private practitioners knew that TB is a notifiable disease, 
none of them had a reporting system.  
 
 Forty percent indicated a clear willingness to receive reporting forms and send these 
reports regularly to the near-by public health centre or to the Municipal Health Office, 53% 
indicated some willingness, and 7% no willingness.  
 
Perceived quality of the public TB programme 
 
 
The private practitioners identified the following problems with the public TB 
programme: (i) insufficient treatment supply (mentioned by 67%); (ii) lack of health 
education (22%); (iii) poor quality of the TB drugs (18%); (iv) insufficient follow-up and 
monitoring of patients under treatment (11%): and (v) insufficient funding of the programme 
(9%).  
 
They also discussed problems among the personnel of the public health centres, 
whom they thought lacked motivation and dedication (mentioned by 24%); failed to educate 
patients (20%); and were open for corruption (7%). When specifically asked about 
weaknesses of the public TB programme, the main concerns were insufficient drug supply 
and poor health education, followed by a lack of commitment and motivation of the 
personnel, lack of funding and poor quality of the drugs and/or treatment. When specifically 
asked regarding the quality of the TB drugs used in the health centres, only 30% of the 
respondents stated that the TB drugs in the health centres were as effective as the TB drugs 
of multinational companies. Figure 7.1 presents detail.  
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Figure 7.1:  Private practitioners’ perceptions of inferiority of TB drugs in the  
 public health centres (n = 45) 
 
 
    Private practitioners’ response to the question of whether the TB drugs used in the  
    health centres are as efficacious as the TB drugs of multinational companies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attitude towards public-private collaboration 
 
The private practitioners were asked to comment on two approaches to collaboration 
between them and the public TB programme. They were asked to consider the idea of making 
referral of poor patients to the public health centres compulsory. The most commonly stated 
advantage was availability of free treatment, mentioned by 76% of the respondents. Other 
advantages were infrequently acknowledged: 16% mentioned it would curb the spread of TB; 
11% mentioned it would facilitate patient health education; and 7% mentioned it would make 
compliance/completion of treatment more likely. The main perceived problems of this idea 
"Hard to say"
35%
No response
2%
Doubtful if the health 
centre drugs are 
equally efficacious
7%
Efficacy of the health 
centre drugs is inferior
27%
Efficacy is the same
29%
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were that treatment is not always available at the health centres, a concern mentioned by 36% 
and that the quality of drugs and/or treatment may be poor (20%). Table 7.2 presents more 
perceived problems.  
 
Table 7.2: Problems expected by private practitioners of Malabon from compulsory  
 referral of poor patients to the public health centres (n = 45) 
   
Perceived main problem when referral of poor patients to 
the public health centres is compulsory  
 
   Frequency of response 
   Number      Percentage  
Treatment is not always available at health centre   16                 36% 
Quality of drugs/treatment may be poor     9                 20% 
Some patients may not like to be referred to the health centre     7                 16% 
Some private doctors may dislike losing patients and income     4                   9% 
The health centres may not have the capacity for more patients     4                   9% 
Follow-up of patients is inadequate at the health centres     3                   7% 
Smear-negative patients may not be accepted at health centre     3                   7%  
Patients may not receive enough information about  
good treatment  
 
   
   2                   4% 
Some patients don’t trust the TB drugs of the health centres     2                   4% 
Note: Multiple responses were possible. 
 
 
 
 
 To make the question more immediate, the respondents were asked what would be 
disadvantageous for them if this idea was implemented. Three-fourth (74%) stated 
implementing this idea would not be disadvantageous for them. Only three (7%) said their 
income would go down. Other unwelcome consequences were mentioned by only one 
respondent each: (i) the income from the private practitioner's drugstore would go down; (ii) 
miscommunications with the patients would occur; and (iii) private practitioners would be 
unable to monitor patients' treatment and treatment outcome. When the respondents were 
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more specifically asked what would be the financial repercussions for them, there were four 
kinds of answers. One, 27% of the respondents said there would be no effect. Secondly, 27% 
of the respondents said their income would go down or would go down minimally but they 
would not mind the financial loss. Thirdly, 14% of the respondents said their income would 
go down only minimally. Fourthly, 32% of the respondents said their income would go 
down.  
 
 When asked if it would be a good idea to give the private practitioners a certain 
amount of money for each referred TB patient, 20% answered positively. Forty-one percent 
felt this was not needed or not realistic. And 39% were negative towards it.  
  
 The respondents were also asked whether they had referred some of their patients to 
the public health centres during the twelve months before the interview. Most (83%) said 
they had referred TB patients; 11% of the respondents had referred between 30 and 100; 
31% between seven and twenty; and 33% between one and five patients.    
 
 Forty-four respondents were asked if they normally mention to the patients that there 
are free anti-TB drugs available at the health centres; all respondents said they did. Fifty-five 
percent of them, however, mentioned this to their poor TB patients only, and 45% claimed 
to mention this to all their TB patients. 
 
 The second idea presented to them was that the private practitioners could avail of 
TB drugs from the health centres for their patients if they had a case holding mechanism and 
sent reports to Malabon's health office. Nearly three-fourth (73%) endorsed the idea (29% 
felt this was a "very good idea" and 44% felt this was "quite a good idea"). A minority 
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(18%) felt it was not a good idea, and 9% were not certain. While many approved of this 
idea, doubts about its feasibility were common: 5% felt this idea could be "very easily", and 
29% felt it could be "quite easily" put into practice. A fifth (20%) said it was hard to 
comment on this, and 27% felt it was not easy but possible. For 20% it was definitely not 
easy. 
 
 We wanted to know if there were already existing relationships with personnel from 
the public health centres. The question was if private practitioners met at least one health 
centre staff once every three months. One third (33%) affirmed this. Seven of these 15 
respondents said they met health centre staff more frequently or more than only one person 
from the health centres. 
 
B) Group discussions with personnel from the public health centres  
 
 The findings from the group discussions present perceived strengths and weaknesses 
of both public and private providers and the views of the participants regarding the two 
suggested approaches to public-private collaboration in TB control. 
 
Perceptions about private practit ioners  
 
 The participants identified both strengths and weaknesses. Among the strengths, they 
discussed: (i) the consultation and diagnostic process proceed fast; (ii) their clinics are nice, 
have complete facilities and are open in the evenings and on week-ends; (iii) the physicians 
themselves deal with the patients (unlike in the health centres were often, the nurses and/or 
midwives deal with the patients); (iv) the drugs are from transnational companies; (v) they 
choose the best treatment; and (vi) some of the private practitioners are specialists. 
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 They also considered a number of weaknesses: (i) the diagnostic process is too fast, 
leading to a neglect of sputum examination; (ii) when the X-ray does not show clear signs of 
TB, there is a temptation to declare the patient has minimal TB so that there is treatment and 
thus income; (iii) weak treatment monitoring (e.g. no DOT); (iv) weak recording; (v) some 
are not up-to-date regarding TB and its control; e.g. DOT not known to them; (vi) some are 
strongly money-oriented and lack concern for the patients; and (vii) low awareness regarding 
the TB programme in the health centres.  
  
 When the participants were asked what they believed the private practitioners think 
about the health centres, only one positive statement was made, namely that the private 
practitioners refer patients to the health centres and therefore seem to have some trust in the 
health centres. Other expressed perceptions were negative: the private practitioners: (i) have 
low regard for the health centres; (ii) underestimate the capacity of the health centres; (iii) 
think the health centre physicians lack knowledge and training and that the health centre 
lacks equipment; (iv) consider the processes of the health centres to be slow; and (v) do not 
trust the drugs of the health centres. 
 
 The participants saw themselves and their health centres in a better light. They 
consider the health centre personnel to be well trained, updated and capable and also felt 
their diagnostic processes (mainly sputum examinations) were quite fast now. They also 
mentioned that treatment is available "these days", that health education and DOT is being 
done, and that the TB services are free of charge. They also felt that their approach to the 
patients is personal; most patients would be known to the staff. Still, they mentioned some 
weaknesses, namely a lack of manpower and unreliable supply of slides and drugs, as well as 
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some slowness in certain processes; e.g. the drugs may not yet be ready when the sputum 
examination result is known. Finally, they acknowledged that some health centres tend to be 
crowded.  
 
Attitude towards two proposals for public-private collaboration 
 
 The participants were asked to comment on two suggestions for enhancing 
collaboration: compulsory referral of poor patients and access to TB drugs for private 
practitioners in return for clear measures to improve case holding and reporting. They 
generally felt compulsory referral was a good idea, but saw the following problems on the 
side of the private practitioners: the private practitioners; (i) may not be able to find out if a 
patient really is poor; (ii) do not ask for sputum examinations; (iii) may lack knowledge 
regarding the public TB programme; and (iv) may not be willing to refer patients, i.e. to 'lose' 
patients. The participants also mentioned the need to have a proper process for this referral 
scheme and that their health centres may sometimes lack the needed TB drugs.  
 
 The participants were more sceptical about the second idea presented to them, i.e. 
that the private practitioners could avail of TB drugs from the health centres for their patients 
if they had a case holding mechanism and sent reports to Malabon's health office. In only one 
health centre was there a positive comment, namely that this would mean a reduced burden 
for the health centres. In another health centre a comment was that for this to happen it 
would be important to have standard treatment in the health centres and in the private clinics. 
Interestingly, one participant recalled that some years back (when there were lots of TB 
drugs available), such a scheme had actually been in place for an NGO working in two 
places of Malabon.  
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 They saw the following problems on the side of the private practitioners: the private 
practitioners may feel like employees of the public programme; may sell the TB drugs; 
would still ask for a consultation fee; and have weak case holding mechanisms, e.g. no direct 
observation. From the health centre side they saw two problems: first, the health centre 
physicians may feel offended because this scheme suggests that the health centre physicians 
can't be trusted to take care of the TB patients. And second, there would be confusion about 
case records and reporting.  
 
 
 
DISCUSSION 
 
 
Limitations of the study 
 
The interviewer of the private practitioners (the first author) was not an official part 
of the public TB programme, but the introduction of the questionnaire made it clear that the 
interviewer had links to the public TB programme. Thus, the answers of the private 
practitioners may have been incorrectly too positive about the public TB programme and 
about collaboration with the public TB programme. Such social desirability bias is very 
likely to occur when respondents are directly being interviewed one-to-one.   
 
No formal efforts were made to counteract this bias. However, an informal way of 
verification of the findings was that all the interviewed private practitioners were visited 
several times after the interview. These visits strengthened the impression that 
approximately half of the respondents were genuinely interested in public-private 
collaboration.  
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Another limitation is that no attempts were made to verify answers of the private 
practitioners. For instance, it was not checked with the corresponding public health centres if 
a private practitioner really referred people with symptoms of TB to them.   
 
Prospects for public-private collaboration in Malabon 
 
 
The following encountered perceptions and characteristics of the private practitioners 
were found to be potential stumbling blocks in establishing public-private collaboration:  
 
· Perceived lack of availability of anti-TB drugs in the health centres  
· Lack of trust in the efficacy of the anti-TB drugs of the health centres 
· The treatment regimens used in the public health centres are questioned  
· Partly a lack of trust in the commitment of the health centre staff 
· Loss of income feared if referral to health centres is frequent 
· No record keeping  
· Poor or non-existing case holding mechanisms among private practitioners.  
 
Another complication was the lack of unity in the Medical Society of 
Malabon/Navotas, which is factionalised in two distinct groups. 
 
Nevertheless, some degree of public-private collaboration is already on-going: most 
private practitioners refer TB patients to the public centres and there is some experience of a 
past scheme where the public TB programme provided TB drugs to an NGO. And our 
survey found that at least half of the respondents were open to public-private collaboration. 
A recent telephone survey across the Philippines found an even higher proportion of private 
practitioners being willing to collaborate with the public TB programme. However, most of 
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them wanted to be financially rewarded for this (Portero & Rubio, 2003). In Malabon, we 
found:  
 
· Most private practitioners expressed a need to receive further information about TB 
and its control and a desire to get updated on the public TB programme 
 
· Many also indicated a willingness to report to the public health sector 
 
· They also expressed their willingness to follow the guidelines of the public TB 
programme, i.e. to follow a standard diagnostic and treatment procedure 
 
· There was awareness that the financial demands of private TB treatment are a real 
threat to treatment adherence 
 
· Half of the private practitioners stated that frequent referral of their TB patients to the 
health centres would either not affect their income or it would not bother them 
 
· Most liked the idea of having access to the public TB drugs, and one third believed 
such a scheme could be developed easily or quite easily 
 
 
 
Moving towards public-private collaboration: next steps 
 
 
 Our findings suggest the following avenues should be pursued to achieve better 
public-private collaboration: 
 
a) A referral system 
 
Most private practitioners in Malabon already refer TB patients, commonly those 
who are obviously poor. An official referral letter and a commitment of the public 
programme to let the private practitioner know the outcome of treatment of the referred 
patients would make this referral mechanism more acceptable. Similar efforts to provide 
feedback to the private practitioners on each patient referred proved important in a public-
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private collaboration TB project in Hyderabad, India (Murthy et al., 2001). Other options 
need to be explored, such as: (i) mechanisms that facilitate a regular visit of the referred 
patient to the private practitioner, e.g. every two months; (ii) incentives for referring 
patients, e.g. receiving TB health education materials from the public health sector when TB 
patients are referred; and (iii) strengthening the awareness of the private practitioners 
regarding the dangers of incomplete treatment and the costs of full private TB treatment. A 
daily six-month-regimen costs at least Peso 4000.-. This corresponds roughly to the monthly 
cash-on-hand income of low-income earners. Ethical standards of care in some places, like 
Nairobi, require private practitioners to make their patients sign an agreement that states the 
patient has chosen private care knowing about the free public TB programme (WHO, 2001e, 
p. 56).  
 
Experience of New York City demonstrates that success is possible: strengthening 
the public TB programmes and actively informing and educating the private practitioners 
resulted in a four-fold increase in referrals from the private sector (Fujiwara et al., 1996, 
cited in Uplekar et al., 2001a). On the other hand, in a public-private collaborative TB 
project in Kathmandu, Nepal, where the public sector had very limited capacity to engage 
with the private sector, very few patients were referred from the private to the public sector 
(Hurtig et al., 2002). 
 
While it is not in the short-term financial interest of private practitioners to refer 
patients, it may well be in their long-term interest. Private practitioners in two places in 
India participating in a public-private collaboration TB project expressed their belief that if 
they work with the public TB programme and offer free services to patients, these patients 
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and their families may stay with their practice for treatment of other health problems 
(Uplekar et al., 2001a). Similarly, properly informing their patients about the cost of TB 
treatment and the free services of the public TB programme may provide a strong and 
welcome sign of genuine concern and thus make the private practitioner more popular. But it 
may also enhance stigma, and practitioners need to be careful to explain the rationale for 
referral, so that referral is not perceived as an indication of a low, undesirable status of TB.  
 
b) Helping the private practitioners improve their practices  
 
The expressed desire for more information and the willingness to follow the 
governmental TB guidelines should motivate the public sector to provide seminars to 
improve clinical expertise of private practitioners. Disseminating evidence-based 
information to private practitioners is the first step (Mills et al., 2002). However, it must be 
kept in mind that seminars alone are seldom effective (Thomson O'Brien et al., 2002a). 
Academic detailing has been suggested as a more promising approach (Thomson O'Brien et 
al., 2002b). This approach, however, is highly labour-intensive. For instance, in Karachi, an 
intervention to improve the performance of private practitioners included academic detailing 
that required two physicians to visit the private practitioners eight times (Thaver & 
Harpham, 1997). Academic detailing should be accompanied by other measures, such as 
mobilising local opinion leaders (Thomson O'Brien et al., 2002) and patient-mediated 
interventions. 
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c) Tools to enhance public-private collaboration  
 
Various tools and forms routinely used in the public sector for recording, reporting 
and health education should be adapted for private clinics. For instance, adapted reporting 
forms should be given to the private practitioners and the private practitioners should be 
contacted regularly (best by phone or in person) by personnel from the public health system 
to gather the needed data. Evidence suggests that only actively telephoning private 
practitioners works (Aljunid, 1995).  
 
 
d) Making free drugs available to the private practitioners  
 
A careful assessment of the experience of an earlier strategy for a public TB 
programme to provide TB drugs to an NGO may provide valuable lessons. Based on this, 
discussions between the public health sector and the private practitioners should be held on 
how to establish a mechanism that makes public TB drugs available to the private 
practitioners who fulfil certain conditions. Of course, careful co-ordination with the central 
office of the national TB programme to ask for the needed supply of drugs and for full 
authorisation is fundamental for this.  
 
Recently a public-private collaborative project has started in Delhi, giving private 
practitioners access to free public TB drugs. These private practitioners have informed the 
community through prominent boards in their clinics that they can get free TB medication 
(Uplekar et al., 2001a). 
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Other steps to strengthen public-private collaboration  
 
A well-running public TB programme is a prerequisite for public-private 
collaboration. Special attention is needed to ensure prompt diagnosis and a reliable drug 
supply, and to develop a patient-friendly implementation of supervision of treatment. 
Continuous training and empowerment of the health centre personnel with reference to 
recently published principles (WHO, 2002c) to ensure technical capability and interpersonal 
skills are crucial. Where needed and possible, health centres should be renovated and their 
equipment upgraded. Human capacity needs to be set free to work on establishing public-
private collaboration. Public physicians should be released from clinical responsibilities to 
ensure the smooth running of the DOTS programme and to liaise with the private sector. It is 
crucial that the public sector has the capacity and resources to engage with the private 
sector, as experience with a public-private collaboration TB project in Kathmandu showed 
(Hurtig et al., 2002).  
 
The public TB programme should offer evening seminars for the private practitioners 
to respond to the expressed needs and willingness of the private practitioners and issues of 
diagnosis and treatment that need improvement. It is crucial that these seminars be of high 
quality. Of great help would be if a well-known chest physician could be won over to 
become a part in this public -private collaboration endeavour. A key ingredient in the 
successful public-private collaboration TB project in Hyderabad (Murthy et al., 2001) is the  
_____________________ 
 
2 In May 2000, a dinner-seminar for the public and the private practitioners was organised by the Swiss 
Tropical Institute in co-ordination with the health office of Malabon to give an update on TB control and to 
give a first stimulus regarding public-private collaboration. A well-known chest physician was the key 
speaker. The attendance of the meeting was fair. Some months later, the health office of Malabon organised 
a dinner-seminar for the private practitioners to present the publ ic TB programme and discuss public-private 
collaboration. Attendance was satisfactory. However, the quality of the meeting was not high. At a second 
meeting, performed approximately eight months later, only three private practitioners were present and the 
quality of the meeting was poor.    
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fact that the hospital physician who visits the private practitioners is a well-known and well-
respected chest physician (KJR Murthy, personal communication, February 2000). The 
seminars could also serve as a first forum to discuss practical issues regarding collaboration. 
To facilitate the taking of the steps toward collaboration, the creation of a local committee 
that is composed of representatives of the public and the private sector may be helpful. Such 
a committee should have the local knowledge and insights to develop practical approaches 
to collaboration. It would also have an important role to play to guide on-going 
implementation and evaluation of public-private collaboration initiatives. This committee 
could also decide whether measures to understand the local situation better are needed.  
 
Another option that should be considered is to have an NGO serve as intermediary 
between the public TB programme and the private practitioners. This approach has been 
implemented in Kathmandu, Nepal (Hurtig et al., 2002) and Chennai, India (Balambal, 
2001).  
 
It is also important to address the expressed concerns of private practitioners and the 
public health care providers. This should be done in collaboration with the central office of 
the national TB programme. These concerns encompass issues such as: (i) the lack of trust 
in the public TB drugs; (ii) the lack of trust in the DOTS regimens; (iii) the over-reliance on 
chest X-rays. Of great help is that through the efforts of PhilCAT, national comprehensive 
guidelines for TB control are now available in the Philippines. PhilCAT has also recently 
drafted a document regarding a unified strategy of TB control for government agencies and 
the private sector (Task Force on Tuberculosis, 2000). The challenge remains of effectively 
disseminating these materials through some of the mechanisms suggested above.  
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Seminars and academic detailing will hopefully create a strong demand from the 
private practitioners to have their patients with symptoms of TB undergo sputum 
examinations. Mechanisms for free sputum examinations performed by the public sector for 
private patients need to be considered and developed in collaboration with the central office 
of the national TB programme.  
 
To improve public knowledge of TB and evoke appropriate responses, health 
education activities targeting the general population, especially the low-income groups, are 
needed. Mass media campaigns have been effective (Jaramillo, 2001; Grilli et al., 2002). In 
an advanced stage of public-private collaboration, the health educational activities should 
proceed through active and innovative collaboration with private practitioners.  
 
 
CONCLUSION 
 
 Our study identified obstacles to public-private collaboration but also indicated the 
potential value of public-private collaboration. More information about the private 
practitioners is needed, especially perceived incentives and disincentives for the private 
practitioners with respect to public -private collaboration. Local communities, like Malabon, 
will benefit from a stakeholder analysis. On the other hand, it is no longer appropriate to 
wait for more information; the time has come to proceed with public-private collaboration. 
Suggested measures should be continuously evaluated and revised as indicated.  
   
The support of NGOs, research institutions, and funding agencies to support public-
private collaboration must be actively cultivated.  
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Feasibility, acceptability and effectiveness of fully thrice-weekly intermittent TB 
therapy compared to daily TB therapy in public health centres in Manila, Philippines 
 
ABSTRACT          
 
Introduction: Intermittent therapy ma kes supervision of treatment more feasible for patients 
and providers, and it reduces the costs for drugs by up to 50%. Intermittent therapy regimens 
are recommended, but the evidence base is not very strong.  
 
Objectives: To compare the feasibility, acceptability, and effectiveness of thrice-weekly and 
of daily therapy in a public health care setting.  
 
Methods: Randomised controlled trial; thrice-weekly therapy was randomly assigned to 10 
of the 20 health centres of a municipality in Manila. All TB patients of the other 10 health 
centres received daily therapy. Patients were interviewed three times. Drug susceptibility 
tests were performed.  
 
Results: 806 patients (451 under thrice-weekly and 355 under daily therapy) were 
interviewed shortly after treatment start. 18.5% were re-treatment cases. Multidrug-resistant 
TB was found among 2% of the new and 26% of the previously treated patients.  
Under thrice-weekly therapy, DOT in the health centres was more common than when 
treatment was daily (32% vs. 21%). Thrice-weekly therapy was more popular among 
patients and health personnel and resulted in savings of about 40% of the cost of drugs.  
 
There were also some disadvantages of thrice-weekly therapy compared to daily therapy: 
difficulty swallowing the pills as well as nausea were reported more frequently (16% vs. 
11% and 30% vs. 21%, respectively). And sputum conversion rate assessed after two 
months of treatment was lower (74% vs. 81%; p = 0.03). Treatment outcome was simi lar, 
but treatment failure and default due to side effects was more common among those treated 
thrice weekly (p = 0.08 and p = 0.04, respectively). In a multivariate model, adverse 
treatment outcome (failure, relapse) was not associated with mode of treatment. 
 
Conclusion: In the light of the potential benefits of intermittent therapy, its equivalence to 
daily therapy should be established firmly and if confirmed, fully thrice-weekly therapy 
should be used more widely.    
 
Keywords:  tuberculosis, intermittent regimens, acceptability, effectiveness, randomised  
  controlled trial  
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INTRODUCTION 
 
  Tuberculosis continues to be one of the most devastating diseases in the world. It is 
estimated that 8.5 million new TB cases occurred in the year 2001 (WHO, 2003) and that 
1.8 million people died of TB in the year 2000 (Corbett et al., 2003) As these two figures 
indicate, effective treatment of tuberculosis remains a major problem even though powerful 
drugs have been available for half a century now.  
 
Short-course chemotherapy: the backbone of tuberculosis control 
 
  The last major improvement in the treatment of tuberculosis occurred in the late 
1960’s/early 1970’s with the introduction of rifampicin and pyrazinamide, which made 
highly efficacious and effective 6- to 9-month-long treatment possible (Fox et al., 1999) and 
paved the way for so-called short-course chemotherapy. However, this cost-effective tool - 
one of the most cost-effective health interventions of all (Murray et al., 1991; World Bank, 
1993) - has not been used widely. With the recent implementation of the DOTS strategy 
progress has been made (DOTS: the broadly promoted strategy to control TB which had 
been implemented by 155 countries in the year 2001; WHO, 2003). Still, a rapid 
acceleration of progress in the expansion of DOTS is needed to reach the WHO-targets of a 
global case detection rate of 70% and a successful treatment rate of at least 85% by the year 
2005 (WHO 2001f, p. 5). More human and financial resources need to be mobilised (Floyd 
et al., 2002). And a more cost-effective, patient- and health provider-friendly 
implementation of DOTS must be explored and pursued rigorously; the available 
interventions must be delivered better (Remme et al., 2002). Since no new diagnostic tools 
or anti-TB drugs can be expected in the years to come, there is a need to sharpen the existing 
tools. 
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Intermittent therapy  
 
  Using intermittent therapy (drugs are taken only twice or three times a week with 
generally increased dosages) may be such a way of enhancing the effectiveness of DOTS. It 
has the potential to make supervision of treatment (DOT - directly observed therapy) more 
feasible for patients and for health providers. Indeed, a review from 1980 (Sbarbaro, 1980) 
even stated that daily directly observed therapy was not viable and that intermittent therapy 
was an effective approach for overcoming non-adherence to treatment. Another advantage of 
intermittent therapy is that it reduces the costs for drugs by up to 50% (see table 2 in Van 
Gorkom et al., 2001). There is also evidence that severe side effects occur less often 
(Tuberculosis Research Centre, 1997; Hong Kong Chest Service/Tuberculosis Research 
Centre, Madras/British Medical Research Council, 1989; Hong Kong Chest Service/British 
Medical Research Council, 1981; Hong Kong Chest Service/British Medical Research 
Council, 1976; Tempel et al., 1950). 
 
  While daily treatment is common, various treatment schemes with intermittent 
therapy were and are being used. Intermittent regimens after an initial intensive phase of 
daily therapy were already studied in the early 1950s (Fox, 1971). For instance, a report on 
an intermittent regimen with streptomycin and isoniazid was published in 1954 (Mackey-
Dick, 1954, cited in Sbarbaro, 1980). In some areas, intermittent therapy is used after two 
(or three) months of daily treatment, for instance in Sulawesi, Indonesia (Becx-Bleumink et 
al., 1999) and Peru (Suarez et al., 2002). In other places, twice-weekly therapy is used after 
an initial phase of several weeks of daily therapy, for instance in the USA (Cohn et al., 
1990; Sterling et al., 1999) and in South Africa (Davies et al., 1999). Twice-weekly therapy 
from day one of treatment has also been used (Caminero et al., 1996). Fully thrice-weekly 
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therapy from day one of treatment is being used in India (Khatri & Frieden, 2002) and in 
Myanmar (National Tuberculosis Programme Myanmar, 2000) in all DOTS areas. And in 
large parts of China, treatment every other day (i.e. 3.5 times per week) from day one of 
treatment is being used (China Tuberculosis Control Collaboration, 1996). Intermittent 
regimens are recommended, e.g. by the British Thoracic Society (British Thoracic Society, 
1998), the American Thoracic Society (ATS/CDC/IDSA, 2003) and the World Health 
Organization (WHO, 1997a). The latter endorsed intermittent therapy in 1974 (WHO, 1974) 
but does not encourage the use of twice-weekly therapy, mainly due to the fact that a missed 
dose represents a big fraction (50%) of the total number of weekly treatment doses (WHO, 
1997a, p. 26). With the occurrence of rifapentine, once-weekly regimens during the 
maintenance phase are being tested now (Benator et al., 2002; Tam et al., 2002).  
 
Rationale for the study 
   
  Observational studies have shown intermittent therapy to be effective (Khatri & 
Frieden 2002; Connolly et al., 1999; El Sadr et al., 1998; Cao et al., 1998; Yan et al., 1996; 
Chaisson et al., 1996; Neher et al., 1996; China Tuberculosis Control Collaboration 1996; 
Alwood et al., 1994; Hong Kong Chest Service/British Medical Research Council, 1991. 
See also WHO, 1997b for an overview). However, a few studies had less good results, e.g. 
one from Malawi (Harries et al., 2001) and two from India (Tuberculosis Research Centre, 
1997, Datta et al., 1993). A recent Cochrane review (Mwandumba & Squire, 2002) 
concluded that larger randomised trials are warranted. The review found only one 
randomised trial that properly compared intermittent therapy (it was thrice-weekly therapy 
from day one of treatment) with daily therapy (Hong Kong Chest Service/British Medical 
Research Council 1981. This study in Hong Kong indicated a possibility of an increased 
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relapse rate with intermittent therapy. There are also some concerns that with intermittent 
therapy their might be a higher likelihood of development of drug resistance while on 
treatment (Mitchison & Dickinson, 1971). However, to our knowledge this potential danger 
has not been documented, and in a study in mice bacterial resistance to isoniazid appeared to 
develop at a slower rate in the mice treated intermittently (Bloch, 1961, cited in Sbarbaro, 
1980). And a recent review only mentioned once-weekly but not twice-weekly or thrice-
weekly treatment as a risk factor for the development of drug resistance (Mitchison, 1998). 
Considering the established and potential advantages of intermittent therapy, non-inferiority 
of intermittent therapy compared to daily therapy should be tested thoroughly and if 
confirmed, intermittent therapy should be used widely. In 1998, WHO identified a 
"profound neglect of research relevant to tuberculosis control activities". Cost-effectiveness 
analyses and alternative ways of delivering the DOTS strategy were found to be among the 
priority areas of research (WHO, 1998b). And in 2002, the Special Programme for Research 
and Training in Tropical Diseases (TDR) of UNDP/World Bank/WHO stated that the first 
TB research priority is health policy and systems research to promote a wider use of DOTS, 
and to make better use of existing tools (TDR, 2002). In view of the enormity of the 
tuberculosis problem and due to the fact that every year, millions of TB patients are being 
treated, clarifying which regimens are most appropriate and efficient must be a high priority.  
 
METHODS  
 
Setting 
 
 The study took place in Taguig. Taguig is an urban and partly semi-urban 
municipality of Metropolitan Manila, Philippines; it had 520,000 inhabitants in the year 
2001, served by twenty public health centres whose catchment area populations ranged from 
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6,500 to 96,000. Most of the twenty health centres have an own physician; some health 
centres share a physician with another health centre. All health centres have at least one 
nurse and one midwife. Sputum microscopy is being done in four health centres, and quality 
assurance measures are in place. With the exception of one health centre, the patients can 
submit their sputum specimens in their local health centre. 
 
  DOTS was introduced in Taguig in late 1996. DOTS was generally implemented 
well in Taguig and Taguig was recommended by the Philippine Department of Health as an 
area where research can be performed. A physician and a nurse act as the 'TB co-ordinators'. 
They both also serve as local staff in a health centre.  
 
Randomisation and patients  
 
  Randomisation took place at the level of health centres (cluster randomisation; 
randomisation at the level of the patients would not have been feasible). Stratified random 
sampling was performed: among the ten health centres with the highest number of TB 
patients in the year 1999 and in the first half of 2000, five were randomly allocated to thrice-
weekly therapy. The same was done for the remaining ten health centres. Starting November 
13, 2000 all newly enrolled TB patients of the public sector in Taguig were either given 
daily therapy or thrice-weekly therapy, depending on whether their health centre was 
allocated daily therapy or thrice-weekly therapy. However, in all the 20 health centres, 
failure cases were given daily therapy. The trial lasted until the end of December 2002.  
 
  All patients whose initial sputum examination (at least one of the three specimens) 
was positive for acid-fast bacilli (AFB) on sputum microscopy or whose sputum sample 
showed growth for Mycobacteria on culture were included in the study (patients in whose 
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sputum only one acid-fast bacillus or one colony on culture was found were included in the 
study). Failure cases were excluded from analysis. No other exclusion criteria were applied.    
 
  Before being initiated to treatment, the patients were asked by the health centre staff 
regarding previous treatment. However, the patient interviews revealed that many patients 
classified as 'new patients' had actually had previous anti-TB treatment for at least one 
month. The health centres of such patients were then informed and advised to shift the 
patient to the re-treatment regimen.  
 
  Follow-up sputum examinations were done two, four and five months after initiation 
to treatment for new patients and three, five, and seven months after initiation to treatment 
for patients under re-treatment (according to the national guidelines). The samples of the 
first follow-up sputum examination and of the last follow-up sputum examination of patients 
included in the study underwent culturing. In addition, the samples of other follow-up 
sputum examinations that were AFB-positive also underwent culturing.   
 
Diagnostic procedures 
 
  Patients with symptoms of tuberculosis had to submit three sputum examinations: 
two on-the-spot samples and one early-morning sample. Staining was with Ziehl Neelsen. If 
only one sample was found positive, the patient usually had to submit another three sputum 
samples. AFB-positive samples and AFB-negative samples of patients who had at least one 
cavity on their chest X-ray were stored in cool temperatures (in styropore boxes with pieces 
of ice). Several times a week, the sputum samples (but not more than two per patient) were 
brought for culturing to the 'TB Research Laboratory' of the Philippine General Hospital, 
located in nearby Manila City. There, AFB microscopy was done by the concentrated 
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technique and each sample underwent decontamination process by the 4% NaOH procedure 
(Petroff's Method) and was inoculated to a solid medium (Löwenstein Jensen) and to a 
liquid medium (7H9 broth). Reading of cultures for growth was done every week until the 
eighth week of incubation and even extended up to twelve weeks when necessary.  
 
  Drug susceptibility tests were performed in the 'Mycobacteriology Unit' of the 
Institute of Tropical Medicine in Antwerp, Belgium, a supranational reference centre for 
susceptibility testing of tuberculosis drugs. In the 'TB Research Laboratory' in Manila, 
growth from cultures was transferred to screw cap tubes with 7H9 broth once a month. At 
the time of dispatch to Antwerp (which is approximately every two months) the vials were 
brought by airfreight to Antwerp. However, during the first seven months of the trial the 
samples were transported from Manila to Antwerp using skimmilk. Due to a high rate of 
contamination this kind of medium was no longer used; instead, 7H9 broth was used. 
 
  In Antwerp, culture re-growth on Löwenstein-Jensen medium was done. Drug 
susceptibility testing was performed according to the proportion method of Canetti et al. 
(1969). The antibiotics tested were isoniazid (H), rifampicin (R), ethambutol (E), 
streptomycin (S) and para-aminosalicyclic acid (PAS). Approximately 10% of the samples 
also underwent drug susceptibility testing in Manila, also according to the proportion 
method. In Manila, the drugs tested were H, R, E, S, and pyrazinamide (Z). Drug resistance 
of pyrazinamide was examined with the disc submerge method. 
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Follow-up of patients after treatment  
 
  To increase the likelihood of finding the relapse cases, all patients who completed 
treatment were asked to submit a sputum sample five, ten and fifteen months after the end of 
treatment. Only few patients followed this request. Thus, attempts were made to visit the 
patients in their homes five, ten and fifteen months after the end of their treatment to ask 
them to submit a sputum sample. In addition, patients who had some indication that they 
were treatment failures were also visited in their homes after the end of treatment. All the 
sputum samples that turned out to be positive for AFB underwent culturing. Culturing was 
done with all the sputum samples submitted fifteen months after the end of treatment.  
 
Definitions referring to treatment outcome 
 
  Completion of treatment: The third patient interview provided information about 
whether or not the patient had completed treatment. When the patient stated not to have 
completed treatment but the patient’s record in the health centre was ‘completed treatment’ 
the statement of the patient was accepted as more accurate. On the other hand, when the 
patient stated to have completed treatment but according to the patient’s record in the health 
centre the patient had not completed treatment, then the health centre record was accepted as 
more accurate. Treatment was considered to be completed if at least 22 of the prescribed 24 
weeks of treatment (or 30 of the 32 prescribed weeks of treatment for patients on the re-
treatment regimen) were taken.  
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  The following was considered to be a failure case: 
 
- The third follow-up sputum smear examination (at 5 or 7 months of treatment) was at 
least +1 (more than 10 AFB per 100 microscopy fields) and the corresponding culture 
result was not negative.  
 
- The third follow-up sputum examination (at 5 or 7 months of treatment) was only 
scantly positive (less than 10 AFB per 100 microscopy fields) or negative but sputum 
microscopy and/or culture in the 'TB Research Laboratory' was positive and the patient 
clearly still had signs and symptoms of tuberculosis. 
 
- The third follow-up sputum examination (at 5 or 7 months of treatment) was culture-
positive with more than 10 colonies and the patient clearly still had signs and symptoms 
of tuberculosis or - when the patient could no longer be re-visited after the third 
interview - the patient did not feel fully healed at the third interview. 
 
  The same criteria applied for relapse cases with the difference that the sputum 
positivity was at least two months after the end of treatment. In addition, patients who (after 
at least two months after the end of their treatment) were accepted as re-treatment cases in 
one of the health centres of Taguig were also considered to be relapse cases.  
 
 
Treatment  
  
 In the health centres with thrice-weekly therapy, new cases (and those classified as 
new cases) received 2 H3R3Z3E3 /  4 H3R3 (meaning: H, R, Z, and E for the first two months of 
treatment, and then H and R for another four months) and re-treatment cases received 2 
H3R3Z3E3S3 /  1 H3R3Z3E3  /  5 H3R3E3. Patients with "minimal TB" received a weaker regimen. 
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The patients of the other ten health centres received the same regimens but with daily drug 
intake. The dosages for patients under thrice-weekly therapy were as follows:  
 
a) with a bodyweight of up to 50kg:    600mg H,  450 mg R,  1500mg Z,  1200mg E,  1g S 
 
b) with a bodyweight of more than 50kg:  600mg H,  600 mg R,  2000mg Z,  1600mg E, 1g S. 
 
The dosages for patients under daily therapy were as follows:  
 
c) with a bodyweight of up to 50kg:    300mg H,  450 mg R,  1000mg Z,    800mg E,  1g S 
 
d) with a bodyweight of more than 50kg:  450mg H,  450 mg R,  1500mg Z,  1200mg E,  1g S. 
 
  In addition, the physicians of the health centres were advised to adjust dosages for 
patients weighing less than 35kg, especially for patients weighing less than 30kg.  
 
  All drugs were provided in single tablets (rifampicin is in capsule form). Thus, 
patients under thrice-weekly therapy had to swallow nine or twelve tablets, respectively, 
depending on their bodyweight. For patients under daily therapy, the corresponding figures 
were six and nine tablets, respectively. Except for ethambutol, the drugs were given in 
blister packs for those under daily therapy. For those under thrice-weekly therapy, a small 
plastic bag with the medication good for one day was prepared.  
 
Interviewing of patients  
 
  All AFB-positive patients were interviewed three times (almost all of them in their 
homes): during the first month of treatment (in exceptional cases also later), after 
approximately two months of treatment, and shortly after the end of treatment. AFB-
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negative patients that turned out to have a positive culture were commonly interviewed 
twice only: after approximately two months of treatment and shortly after the end of 
treatment. 
 
Discussions with health providers  
 
  Informal group discussions were held in four health centres where thrice-weekly 
therapy was given and in one health centre where daily therapy was given. The topic was a 
comparison of the daily and the thrice-weekly treatment approach, especially in terms of the 
advantages and disadvantages.  
 
Ethical considerations 
 
  The study received clearance from a review body of the Department of Health 
Manila. This review body is part of the office of 'Essential National Health Research'. And 
the Municipal Health Office of Taguig agreed to have the study performed in Taguig. On 
October 27, 2000, a 'Memorandum of Agreement' was signed with the Municipal Health 
Office of Taguig. Among other things, this document defined the responsibilities and stated 
ethical guidelines. In addition, a committee of the Swiss Tropical Institute that reviews study 
proposals in terms of ethical issues approved the study.  
 
Data management and statistical analysis  
 
 All data derived from the questionnaires were processed using Epi Info software 
package (version 6.04, USD Inc., Stone Mountain, GA, USA). Two of the authors did the 
encoding, and one of them (CA) re-checked the encoding of all the questionnaires.  
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Statistical analysis was performed using Chi-Square or Fisher's exact test (two-
tailed) for categorical factors. Treatment outcome was analysed using the intention-to-treat 
approach (Newell, 1992). There were some exceptions: several patients were not included in 
the analysis since they had a mix of daily and thrice-weekly therapy, for instance, a patient 
who – in spite of being in a health centre with daily therapy - first took treatment thrice 
weekly, then daily treatment, and then shifted back to thrice-weekly therapy. Multivariate 
logistic regression analysis was performed to account for the effect of possible confounders. 
STATA statistical software was used (Stata Corporation, 1999). Seven variables were 
included in the multiple regression analysis (596 observations, stepwise backward 
regression).  
 
 
RESULTS 
 
The study population 
 
We here present the findings from data of 806 patients that were interviewed shortly 
after initiation of treatment in the health centre (73% were interviewed within the first three 
weeks of treatment; mostly in the second or third week of treatment). We also make use of 
some data gathered from 668 patients at the second interview (at two months of treatment) 
and from 465 patients at the third interview (shortly after the end of treatment). The 
fieldwork of this study has not yet been completed, and data from approximately 900 
patients will be reported at a later stage.  
 
Majority (72%) were male, and 18.5% of the 806 patients had had previous anti-TB 
treatment for at least four weeks. For 333 of the 806 patients (41%), results from drug 
Chapter 8: Thrice-weekly vs. daily TB therapy 
 
 159 
susceptibility tests were available; 68% of the tested patients had strains susceptible to all 
tested drugs. Table 8.1 presents more data. Twenty-two percent of the new patients (58/260) 
and 39% of the re-treatment cases (27/69) had resistance to isoniazid (for 4 patients their 
status regarding previous anti-TB treatment was not clear; one of them had resistance to 
isoniazid). Multidrug-resistant tuberculosis (MDR-TB) was found in 7% of the patients 
(23/333); 2% of the new patients (5/260) had MDR-TB, and 26% of the re-treatment cases 
(18/69) had MDR-TB.   
 
TABLE 8.1: Drug resistance pattern before start of treatment at the health centre  
 
 
        All patients                Patients under            Patients under      p-value1 
               thrice-weekly therapy        daily therapy  
               (n = 806)                     (n = 451)              (n = 355)   
_________________________________________________________________________________ 
 
With results from drug  
susceptibility test:   41% (333/806)  44% (200/451) 37% (133/355)       0.05 
 
Among those with results: 
 
   No resistance found   68% (228/333) 65% (130/200) 74%  (98/133)    0.09 
 
   Any drug resistance   32% (105/333) 35%  (70/200) 26%  (35/133) 0.09 
 
   Any drug resistance other  
   than MDR-TB    25%  (82/333) 29%  (57/200) 19%  (25/133) 0.04 
 
   Resistance to isoniazid   26%  (85/333) 26%  (52/200) 25%   (33/133) 0.8  
 
   MDR-TB2      7% (23/333) 6.5% (13/200) 7.5%  (10/133) 0.7 
 
_______________________________________________________________________________ 
1 Comparing patients with thrice-weekly therapy with patients with daily therapy. 
2 Two percent of the new patients and 26% of the previously treated patients had MDR-TB. 
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Comparison of the two treatment arms  
 
Table 8.2 presents the frequency distribution of baseline data among those treated 
thrice weekly and among those treated daily. The two patient groups differed statistically 
significantly for four patient features. We also attempted to assess the quality of care 
provided in the health centres, comparing the health centres giving thrice-weekly therapy 
with those giving daily therapy. We looked at the perceived skill and kindness of the health 
centre personnel and the perceived sufficiency of explanation received. There were no clear 
differences between those treated daily and those treated thrice-weekly. Slightly more 
patients under thrice-weekly therapy were discontent with the perceived skill of the health 
centre personnel compared to patients under daily therapy (9% vs. 6%; p = 0.1). One of the 
researchers, the public TB co-ordinator and one research assistant graded the 20 health 
centres according to how they perceived the quality of the services in these 20 health 
centres. This assessment did not find differences between the two groups of health centres. 
Also, no difference was found in the extent of delay between sputum examination and 
initiation to treatment between the two groups of health centres. Nor was there a difference 
in the proportion of patients who were wrongly put on treatment for new cases (10% vs. 
12%) or who received a non-recommended dosage (12% vs. 9%). However, in the last 
interview at the end of treatment, more patients under thrice-weekly therapy compared to 
those under daily therapy stated to have received complete treatment all the time (95% vs. 
89%; p = 0.01).  
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TABLE 8.2: Baseline data among those treated thrice weekly and those treated daily  
 
                                                         Patients under              Patients under            p-value 
          thrice-weekly therapy             daily therapy  
                       (n = 451)      (n = 355) 
_______________________________________________________________________ 
  
Bodyweight below 35kg:        4.9% (22/448)    9.0% (32/355) 0.02 
 
High self-perceived degree   
of poverty ('poor', 'very poor'):     49.5% (181/366)  58.2% (173/297) 0.02 
 
Male and no job:        22.7% (102/450)  17.7% (63/355) 0.09 
 
High degree of sputum  
positivity (+31)        20.5% (91/443)  19.6% (68/347) 0.7 
 
 
Patients having co-morbidity: 
  Asthma           3.3% (15/449)   4.5% (16/355) 0.4 
 Hypertension          4.0% (18/449)   1.1% (  4/355) 0.01 
 Diabetes          5.6% (25/449)   5.1% (18/355) 0.8 
 
X-ray finding: 
    No X-ray or result   
    ill-defined or not known           50.6% (228/451)  59.2% (210/355) 0.01  
    Non-cav. TB        50.7% (113/223)  57.2% ( 83/145) 0.1   
    TB w/ at least one cavity       49.3% (110/223)  42.8% (62/145) 0.2 
 
Previous anti-TB treatment  
for a least 4 weeks:        18.3% (81/442)  18.6% (66/354) 0.9  
 
Haemoptysis:         53.7% (241/449)  46.0% (163/354) 0.03 
(before treatment started) 
_____________________________________________________________________ 
1 More than 10 acid-fast bacilli per microscopy field in at least 20 fields. 
 
 
Note:  In addition, our analysis did not indicate significant association between the mode of 
treatment (daily or thrice weekly) and other factors, such as sex, age group, civil 
status, level of attained education, degree of health seeking delay, presence of BCG 
scar, having stopped treatment more than once during the first two months due to 
feeling bad, and having had anti-TB treatment for at least one week before coming to 
the health centre (with an interruption of anti-TB treatment of not more than nine 
days before treatment was started in the health centre).  
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Experience of treatment 
 
How treatment is experienced has an impact on the treatment completion rate. One of 
the important features of treatment is the occurrence of side effects (adverse reactions to the 
anti-TB drugs). The patients were asked shortly after initiation to treatment and after two 
months of treatment regarding side effects they might experience. Reporting side effects was 
more common among those treated thrice weekly (Table 8.3 presents details). Also more 
common among patients under thrice-weekly therapy was difficulty swallowing the drugs 
(Table 8.4).  
 
Proper health facility-based DOT (directly observed therapy taking place in the 
health centre) was much more common among those treated thrice weekly (32% vs. 21%; p 
= 0.0008). Other factors did not differ in the two treatment groups, for instance self-reported 
missing and forgetting of drug intake. Table 8.4 presents details about how treatment was 
experienced.  
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TABLE 8.3: Frequency of occurrence of common side effects in the two treatment arms, 
                     as reported by the patients at two points in time 
 
_____________________________________________________________________________ 
 
A) Rate of patients who reported side effects when asked some weeks after the start of treatment  
      (806 patients were interviewed): 
        
Patients under thrice-weekly      Patients under daily        p- value  
        therapy (n = 451)                 therapy (n = 355)    
 
   Any kind:    44% (198/448)                          36% (128/355)        0.02      
   Feeling dizzy:   22%  ( 97/449)                           19% ( 67/355)        0.3 
   Nausea/vomiting:                  14% ( 64/449)                           11% ( 38/355)        0.13 
   Joint pains:                             0.9% (  4/448)                             1.1% ( 4/355)        0.71 
   Signs of jaundice:                    0.4% (  2/448)                               0.6% ( 2/353)            1.01 
   After probing:  
   Clearly feeling nauseous  
   while taking the drugs:        30%  (134/449)                          21%  ( 74/355)        0.004  
 
 
B) Rate of patients who reported side effects when asked at two months into treatment  
                 (668 patients were interviewed): 
  
   Patients under thrice-weekly      Patients under daily       p- value  
     therapy (n = 367)                    therapy (n = 301)    
 
  Any kind:            53%  (196/367)  38% (113/300)          < 0.0001      
  Feeling dizzy:            27%  (100/366)  19% ( 58/300)  0.02 
  Nausea/vomiting:            19%  ( 71/366)   13% ( 38/300)               0.02 
  Joint pains:             1.6% ( 6/367)    2% ( 6/300) 0.7 
  Signs of jaundice:                 0%    ( 0/367)       1%  ( 3/300)               0.09 1 
    
__________________________________________________________________________ 
 
   1 Fisher's exact test, 2-tailed.  
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TABLE 8.4: Experience of treatment in the two treatment arms 
 
   Patients under thrice-weekly     Patients under daily      p- value  
             therapy (n = 451)                 therapy (n = 355) 
_____________________________________________________________________________ 
 
Rate of patients who stated to have   
definite difficulty swallowing the drugs     16% (72/447)     11% (38/353)         0.03 
 
Rate of patients who expressed a strong or  
very strong fear regarding side effects  
at the start of treatment:                             13% ( 56/443)       9% ( 33/350)         0.15 
 
 
Mode of treatment supervision:            
Health-facility based DOT:       32% (143/451)     21% (75/355)         0.0008 
Partial health-facility DOT1:      38% (172/451)       25% (90/355)         0.0001 
Health volunteer DOT:                              2% (  9/451)         5% (17/355)         0.03     
Family DOT2:      17% (78/451)       26% (92/355)         0.003 
Self-administered treatment:        11% (49/451)     23% (81/355)           < 0.0001 
     
 
Rate of patients who reported more than  
two days of missed treatment during   
the first two months of treatment:                 8% (28/365)       9% (28/302)         0.5 
 
Rate of patients who had stopped treatment  
more than once during the first 2 months   
of treatment due to feeling bad:                   4% (14/366)       3% (8/300)         0.4 
 
Rate of patients who reported having forgotten   
treatment more than twice during treatment   
(6 or 8 months of treatment):                       5% (12/251)       8% (16/205)         0.2 
 
Rate of patients who expressed limited  
trust in the effect of treatment                      6% (16/259)       6% (12/205)         0.9 
 
Rate of patients who felt fully healed   
after the end of treatment                           70% (179/255)     72% (147/203)         0.6 
 
____________________________________________________________________________ 
       
1 Commonly health-facility based DOT for up to one month only or administration of medication in the 
health centre for some drugs only (e.g. for streptomycin only).      
2 A family member of the patient (or a close friend) has the responsibility to make sure and observe the 
patient's treatment intake. 
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Popularity of the two treatment approaches 
 
 The first 429 patients were asked what kind of treatment (daily or thrice weekly) they 
would prefer if they had the choice. Five of them stated to not have a preference. Most 
(86%) stated they would have chosen the treatment they actually had. However, 8% of the 
patients under thrice-weekly therapy preferred daily therapy (20/236) and 21% of the 
patients under daily therapy (39/188) preferred thrice-weekly therapy (p = 0.0003). 
 
 When asked for the reason(s) for their preference, most (140/255) of those who were 
happy with their thrice-weekly therapy (n = 216) or would have chosen thrice-weekly 
therapy (n = 39) mentioned that thrice-weekly therapy allowed them to have days without 
drug intake ("days of rest"). Also commonly mentioned was that compared to daily therapy, 
thrice-weekly therapy was easier or less tiring (n = 64), resulted in less transportation costs 
(n = 22), and saved time or interfered less with the duty of work (n = 15).  
 
 Common comments of those who were happy with their daily treatment (n = 149) or 
would have chosen daily treatment (n = 20) were that - compared to thrice-weekly therapy - 
daily therapy (i) made forgetting drug intake less likely (n = 49); (ii) was more effective (n = 
47); (iii) was a good routine (n = 37); and (iv) meant a lower number of tablets had to be 
swallowed (n = 35). 
 
 Among the health centre personnel, the following was expressed in all four health 
centres that had thrice-weekly therapy and where group discussions were held: (i) thrice-
weekly therapy results in reduced workload for the staff; (ii) the patients are content with 
thrice-weekly therapy. In one health centre it was said that some of their patients who had 
previously had daily therapy stated to prefer the current thrice-weekly therapy; (iii) a 
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preference for thrice-weekly therapy if the personnel themselves was in need of treatment of 
TB. Also, in three of the four health centres it was stated that with thrice-weekly treatment it 
is realistic to expect the patients to come to the health centre for drug intake. In one health 
centre it was pointed out that since on Tuesdays and Thursday there were no TB patients in 
their health centre, these two days with a reduced workload allowed them to make home 
visits of defaulting patients. 
 
 Disadvantages were also mentioned: in three health centres, it was said that under 
thrice-weekly therapy the patients have to swallow a larger number of tablets. Patients may 
feel like vomiting was said once. In one health centre, preparing and giving of drugs was 
perceived to be less easy than when blister packs are available (no blister packs were 
available for thrice-weekly therapy). 
 
 In the group discussion in the health centre with daily therapy, the advantages of 
thrice-weekly therapy were seen as follows: (i) patients have to go to the health centre less 
often; (ii) the health centre personnel is exposed to contagious TB patients only three times a 
week; and (iii) the patients have days of rest from treatment. But there were concerns that 
with thrice-weekly therapy forgetting drug intake might happen more frequently and that the 
number of tablets to be ingested was higher. All participants wanted daily therapy in case 
they themselves needed anti-TB treatment; the reason stated was that with daily therapy the 
number of tablets to be ingested was lower.  
 
 Interestingly, no one mentioned the reduced expenditures for drugs that go with 
intermittent therapy. We calculated that in comparison to daily therapy, thrice-weekly 
therapy resulted in savings of approximately 40% of the cost of drugs.  
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Sputum conversion rate 
 
An important indicator of the effect of treatment is the so-called sputum conversion 
rate at two months (or three months for re-treatment cases) of treatment. We found that the 
sputum conversion rate was lower for the patients treated thrice weekly when looking at 
sputum microscopy. When looking at the results of culturing, no difference was found. 
Table 8.5 presents the data. Drug resistance pattern, previous treatment, mode of treatment 
supervision and self-reported missing of drug intake were not found to act as confounders.  
 
Having had previous treatment was marginally associated with non-conversion of 
sputum: 30% of those previously treated were still positive while only 22% of the new TB 
patients were still positive (p = 0.06). Missing drug intake was also associated with non-
conversion of sputum (37% vs. 22%; p = 0.02). Cavities on a chest X-ray were not found to 
be associated with non-conversion of sputum (26% vs. 20%; p = 0.3). 
 
After four months (or five months for re-treatment cases) of treatment, sputum 
examinations were generally performed in Taguig only. Only 3% (12/349) of those under 
thrice-weekly therapy and 2% (6/263) of those under daily therapy were still positive (p = 
0.4).  
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TABLE 8.5:  Sputum conversion rates after two months (or three months for re-treatment cases) 
                    of treatment (n = 5981)     
a)  According to mode of treatment  
 
   Patients under              Patients under      
 thrice-weekly therapy         daily therapy         p-value 
  (n = 341)                       (n = 257) 
 
Sputum still positive2  26% (89/341)  19% (48/257) 0.03 
 
Sputum still positive, only results    
from Taguig considered   9% (32/341)    7% (18/257) 0.3 
 
Sputum still culture-positive3   15% (29/196)  16% (19/117) 0.7 
 
Sputum still positive2, 
only new patients included 24% (68/278) 18% (38/212) 0.08 
 
Sputum still positive2, only patients  
with fully sensitive strains included 23% (24/106) 17% (12/71) 0.35 
 
 
b)  According to mode of treatment and mode of treatment supervision 
                                     S p u t u m   s t i l l   p o s i t i v e 2, 4 
               Thrice-weekly        Daily therapy       Both groups  
         therapy                                            combined 
   
Patients under health centre-DOT    27% (34/124)  20% (12/ 61)  25% (46/185) 
 
Patients under less strict forms of  
supervision     25% (44/175)  17% (22/132) 21% (66/307) 
 
Patients under self-administered  
treatment   26% (11/ 42)  20% (12/ 60) 23% (23/102) 
 
___________________________________________________________________________ 
 
1 Sputum samples of patients who had at least one week of anti-TB treatment prior to starting anti-TB 
treatment at the health centre and whose treatment interruption before starting treatment at the health 
centre did not exceed 9 days were not included (n = 77).  
 
2 Be it AFB-positive in Taguig and/or in the 'TB Research Laboratory' and/or positive on culture.  
 
3 Not all sputum samples underwent culture since in the laboratories of Taguig not all sputum samples 
were set aside for dispatch to the 'TB Research Laboratory' . 
 
4 No significant differences were found between the three forms of treatment supervision. 
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Treatment outcome 
 
 Treatment outcome could be established for 705 patients. Treatment failure was 
slightly more common with thrice-weekly therapy (3% vs. 1%; p = 0.08), indicating that 
thrice-weekly therapy might be inferior to daily therapy. Also, among patients treated thrice 
weekly, adverse reactions to drugs were statistically significantly more frequently stated as 
reason to stop treatment. Table 8.6 presents the results in detail. To control for confounding, 
we included six factors whose distribution was not similar in the two treatment groups in our 
multivariate logistic regression model. The explanatory factors were (apart from mode of 
treatment) a bodyweight of less than 35 kg, a high or very high self-perceived degree of 
poverty, being male and jobless, suffering from hypertension, having had haemoptysis 
before the start of treatment and discontentment with the skills of the health centre 
personnel. One factor was shown to be marginally inversely associated with adverse 
treatment outcome (relapse, failure), namely a high or very high self-perceived degree of 
poverty (p = 0.08). Mode of treatment was clearly not associated with adverse treatment 
outcome (p = 0.7).  
 
Development of drug resistance while on treatment 
 
 It is important to examine whether intermittent therapy makes development of drug 
resistance while on treatment more likely. Excluding patients with resistance to more than 
two drugs at start of treatment, comparison of the drug resistance patterns at two points of 
time (commonly at start of treatment and two or five months later) has so far been possible 
for 29 patients. Five of 21 patients under thrice-weekly therapy and one of 8 patients under 
daily therapy developed drug resistance (p Fisher's  exact test; 2tailed = 0.6). Twenty of these 29 
patients were pan-sensitive at start of treatment. For eight of these 20 patients there was no 
result of the drug susceptibility test at start of treatment but since the result of the drug 
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susceptibility test at a later stage of treatment was pan-sensitivity to all drugs, it was 
concluded that no development of drug resistance had occurred (assuming that the same 
strain was in the sputum sample at both points of time). Patients with resistance to more than 
two drugs at start of treatment were not included in this analysis.     
 
TABLE 8.6: Treatment outcome (n = 7051)  
 
                           Of the 393 patients            Of the 312 patients      p-value 
                 under thrice-weekly therapy     under daily therapy 
 
___________________________________________________________________________ 
 
Successful treatment  
(87% of them were confirmed cured)         71%  (280/393)       75%  (234/312)        0.3 
 
Defaulted /Transferred-out2 23%  (90/393) 20%   (62/312)         0.3 
  
Defaulted due to side effects               5%  (19/393)   2%   (6/312)           0.04        
 
Relapse   2%  ( 7/393)               1%   ( 4/312)          0.83 
 
Failure     3%  (11/393)              1%   (3/312)           0.08 
 
Failure, relapse combined    5%  (18/393)              2%   ( 7/312)          0.1  
(‘adverse treatment outcome’)    
 
Died while on treatment    1%  (  5/393)              3%   (  9/312)         0.13  
__________________________________________________________________________ 
 
1 In addition to these 705 patients, a further 28 patients (17 under thrice-weekly therapy and 11 under 
daily therapy) completed treatment but their third follow-up sputum examination was scantly positive 
(e.g. microscopy was only scantly positive and culture was negative or microscopy was negative and on 
culture only few colonies grew) and as of mid-March 2003, no clear indices as to whether these patients 
were healed or treatment failures emerged. These 28 patients can be called 'potential failures'. Most of 
these 28 patients who are culture-negative are probably healed, as recent studies indicate (Tuberculosis 
Research Centre, 2002; Al-Moamary et al., 2000; Vidal et al., 1996).    
2 We decided not to differentiate between default and transferred-out since it was often difficult to find 
out if a patient had properly transferred out or left Taguig without proper notice at the health centre. A 
common reason for default was to have left Taguig. According to the assessment of the health centre 
staff, the proportion of people who are not permanent residents of Taguig is higher on an average in the 
health centres with thrice-weekly therapy compared to the health centres with daily therapy.  3 Fisher's exact test, 2-tailed.  
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DISCUSSION 
 
Limitations of the study 
 
Several factors may have affected the internal validity of this study. Since the 
patients were interviewed prospectively, recall bias is not expected to have occurred, but 
social desirability bias needs to be considered. Thus, in spite of efforts to relate to the 
interviewees in an informal and culturally appropriate way, some answers may not 
accurately reflect the patients' experiences. For instance, self-report about missing drug 
intake is known to be unreliable, underestimating the true incidence of missing drug intake 
(recently reviewed by Gorin & Stone, 2001 and found in many studies, e.g. Mwinga et al., 
2002; Meissner et al., 2002; Chaisson et al., 2001). Since we had to rely on patient self-
report (we did not attempt to monitor intake of treatment, e.g. through urine testing) we have 
no accurate data regarding regularity and completeness of treatment intake. Although it 
cannot be excluded, we do not believe that underreporting of missing drug intake was more 
common in one treatment group compared to the other treatment group.    
 
Our figure that 86% of the respondents preferred the mode of treatment they had is 
probably an overestimate: it is culturally expected that many respondents chose not to 
express discontentment with the free treatment they had. The greater popularity of thrice-
weekly therapy compared to daily therapy may thus be more pronounced than our data 
suggest. 
 
  Our ability to compare our two treatment groups regarding factors that may influence 
outcome of treatment was limited. For instance, we had results of drug susceptibility tests 
for only 41% of our patients, and 54% of our patients had no chest X-ray or the result of 
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their chest X-ray was ill-defined (e.g. 'Koch's infection') or not known. Thus, we did not 
include the results of drug susceptibility tests or those of chest X-rays in our logistic 
regression analysis. Having cavities in the lungs is a risk factor for adverse treatment 
outcome (ATS/CDC/IDSA, 2003; Benator et al., 2002; Oursler et al., 2002; Sonnenberg et 
al., 2001). Also, rigorous medical check-ups regarding co-morbidity are beyond the scope of 
what can be done in public health centres; we had to rely on self-report of the patients. We 
have no idea about HIV co-infection. It is believed that in the Philippines, TB patients are 
rarely co-infected with HIV (WHO estimates that in 2001, only 0.4% of adult TB patients 
were co-infected with HIV in the Philippines - WHO, 2003, p. 103).  
       
We also had to rely on self-report regarding occurrence of side effects. In addition, 
the health centre personnel also asked their TB patients about side effects. But there was no 
thorough professional assessing (including laboratory test) of occurrence of side effects. 
  
A point of contention can be the definition of failure and relapse cases. In view of the 
logistical limitations, we used non-stringent definitions. In several studies in special TB 
study sites, definitions were more stringent, e.g. repeated culture positivity with a growth of 
at least 10 or 20 colonies per culture (Tuberculosis Research Centre, 1997; Hong Kong 
Chest Service/British Medical Research Council, 1981). Other studies required one positive 
culture with more than 10 colonies (Bechan et al., 1997). In other places, culture 
examination was not used to determine failure or relapse, one smear-positive follow-up 
sputum examination being sufficient to become a relapse case (Cao et al., 1998). A review 
summarised the variations as follows: “Some studies required mycobacteriologic 
confirmation of failure, whereas others require only clinical evidence of failure or lack of 
response to therapy” (El-Sadr et al., 2001). Since the number of cases with adverse 
treatment outcome is low but crucial, variations in definition of failure and relapse can make 
a decisive difference.  
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Also important is to know whether a relapse case is due to endogenous reactivation 
or exogenous re-infection. DNA fingerprinting techniques (e.g. restriction fragment length 
polymorphism - Cohn & O’Brien, 1998) can be used to make this differentiation.  We have 
not used DNA fingerprinting (as of April 2003). Exogenous re-infection in relapse cases 
appears to be more common than was believed some years ago (De Boer et al., 2003; De 
Viedma et al., 2002; Caminero et al., 2001; Van Rie et al., 1999). In failure cases, 
exogenous re-infection seems to be rare (Sonnenberg et al., 2000). 
 
We did a cluster randomisation which has two disadvantageous effects. First, the two 
groups to be compared (in our case those treated thrice weekly and those treated daily) 
should be similar in terms of factors that may influence outcome of treatment. Such 
similarity is potentially less likely with cluster randomisation. Our multivariate analysis 
accounted for this. Secondly, cluster randomisation reduces the statistical power of the study 
(Campbell & Grimshaw, 1998). We did not account for the effect of clustering in our 
analysis which potentially overstates the found differences (i.e. p-values become too small). 
On the other hand, our sample size – though relatively large – can easily result in type II 
errors (existing differences are not detected), also because we used intention-to-treat analysis 
(Sommer & Zeger, 1991; Rubin, 1998; both cited in Fergusson et al., 2002). With a 
treatment outcome available for 705 patients (with slightly more having thrice-weekly 
therapy than daily therapy), we have - when choosing a 95% probability that the found 
difference presents a true difference - a statistical power of only 50% to detect an almost 
double difference in adverse treatment outcome (failure and relapse cases) between the two 
treatment groups, e.g. an adverse treatment outcome in 4% of those treated daily and 7.7% 
in those treated thrice weekly.  
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 Another limitation is that it was not possible to perform the trial in such a way that 
the investigators and those analysing the data would be blinded concerning mode of 
treatment of the patients. 
 
Advantages of intermittent therapy  
 
This study identified several advantages of thrice-weekly therapy over daily therapy. 
One, proper treatment supervision (DOT) is more feasible. In Taguig it meant that the 
patients who took all treatment in the health centres (which is the ideal situation according to 
WHO and the Philippine Department of Health) had to go to the health centre only three 
times a week, not five times a week, resulting in a reduced burden for patients and providers. 
The reduced work load of the health workers may lead health workers to invest more efforts 
(e.g. defaulter tracing) in achieving high treatment completion rates among their TB 
patients.  Home visits to defaulting patients can be successful (Chee et al., 2000; Baily et al., 
1974). Secondly, this reduction in the number of visits to the health facility also means that 
the likelihood that TB is transmitted to other people in the health facilities is reduced. Using 
thrice-weekly therapy may thus contribute to prevention of tuberculosis among health 
workers and also among users of health facilities, especially in places where health facilities 
are crowded. Thirdly, the cost reduction in terms of purchase of drugs is substantial. If 
thrice-weekly therapy were used all over the Philippines, the National TB Programme would 
save US $ 1.32 million each year; this would result in a budget reduction of 15% 
(infrastructure costs of shared staff and shared facilities not considered). (Calculation is 
based on figures presented in the latest WHO report on TB - WHO, 2003, p. 104.) Fourthly, 
thrice-weekly therapy is more popular among patients and also among providers. In the light 
of the distressing TB illness experience, treatment schemes that make treatment less 
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burdensome and more appealing to patients are crucial. Using a more popular treatment 
scheme may well result in more people with TB symptoms making use of the public 
facilities, thereby increasing the DOTS case detection rates.  
 
Disadvantages of intermittent therapy  
 
At two (or three) months of treatment, more patients under thrice-weekly therapy 
were still sputum-positive compared to patients under daily therapy. Such a difference could 
not be found when we looked at positivity on culture, suggesting that for many patients the 
acid-fast bacilli still released at two months of treatment were no longer viable and thus no 
longer contributed to the spread of TB. Our findings suggest that with thrice-weekly therapy 
it might take longer to stop a smear-positive TB patient from propagating viable TB bacilli. 
However, this was not found in a study where the sputum conversion rate at 1 month of 
treatment was known: In a study in Hong Kong (Hong Kong Chest Service/British Medical 
Research Council, 1981) culturing was done at 1 and 2 months of treatment. At 1 month of 
treatment, 53% of those treated thrice weekly and 51% of those treated daily (p = 0.6) were 
culture-negative. At 2 months of treatment the corresponding rates were 89% and 94%, 
respectively (p = 0.09).  
 
Patients under thrice-weekly therapy had to swallow a rather high number of pills 
(up to twelve pieces), and side effects (especially gastro-intestinal complaints) were 
commoner among them compared to those under daily therapy. This is in conformity with 
other studies comparing daily with intermittent therapy (Tuberculosis Research Centre, 
1997; Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical 
Research Council, 1989; Hong Kong Chest Service/British Medical Research Council, 
1981). It is of concern that among those treated thrice weekly, default from treatment due to 
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side effects was significantly commoner than among those treated daily. Using fixed-dose 
combination-tablets would reduce the number of pills to be swallowed and probably also the 
incidence of gastro-intestinal disturbances. However, the fixed-dose combination tablets 
available these days are not well fitted for intermittent therapy use (isonizaid would be 
under-dosed) and WHO does not recommend intermittent treatment with fixed-dose 
combination tablets (WHO/STOP TB, 2002).  
 
In contrast to what could be expected from the literature review (Tuberculosis 
Research Centre, 1997; Hong Kong Chest Service/Tuberculosis Research Centre, 
Madras/British Medical Research Council, 1989; Hong Kong Chest Service/British Medical 
Research Council, 1981; Hong Kong Chest Service/British Medical Research Council, 
1976) we did not find arthralgia and jaundice or hepatic reactions to be less common among 
those with intermittent therapy.  
 
 A problem of intermittent therapy is that a missed dose represents a bigger fraction 
of the total treatment. Concerns that thrice-weekly therapy might make forgetting drug 
intake more likely were not confirmed by our study.  
 
The effectiveness of intermittent therapy 
 
There are a number of observational studies that found thrice-weekly therapy from 
day one of treatment to be effective (Cao et al., 1998; Chaisson et al., 1996; China 
Tuberculosis Control Collaboration 19961; Yan et al., 1996; Neher et al., 1996). A recent  
        
_____________________ 
1 In China, intermittent therapy is given every other day, i.e. 3.5 times per week. 
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review comparing observational studies with randomised controlled trials indicates that 
evidence found from observational studies can be very robust (Concato et al., 2000). Well-
designed observational studies merit careful consideration (Ioannidis et al., 2001). Still, 
randomised controlled trials should be used to create a stronger evidence base and to 
demonstrate the comparative advantages and disadvantages of intermittent and daily 
therapy.  
 
We know of only one study performed with smear-positive patients that compared 
thrice weekly with daily therapy in a randomised controlled trial with mode of treatment 
(daily or intermittent) as the only difference of the regimens to be compared (Hong Kong 
Chest Service/British Medical Research Council, 1981). In this study in Hong Kong, 399 
patients were included for analysis of treatment outcome. The same drugs as in Taguig were 
used. However, pyrazinamide and ethambutol were used throughout treatment. Five of those 
under thrice-weekly therapy and one of those under daily therapy had a relapse (p-value = 
0.12). Similar to this study in Hong Kong, our study has not clearly answered the question 
whether thrice-weekly therapy is of equivalence to daily therapy. With our results we can 
argue that thrice-weekly therapy is not inferior to daily therapy (the p-value for mode of 
treatment as an explanatory variable for adverse treatment outcome was 0.7 in the 
multivariate logistic regression model). However, the bivariate analysis suggests there is a 
trend indicating intermittent therapy to be inferior to daily therapy. In countries with large 
number of TB patients small differences in the proportion of TB patients with adverse 
treatment outcome translate into thousands of additional relapse and failure cases when the 
regimen that is slightly inferior is chosen. These patients are not only in need of re-
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treatment, but continue to spread tuberculosis, and a substantial proportion of them may 
spread drug-resistant strains.                 
 
An interesting finding is that in the multivariate model, a high degree of self-
perceived poverty was shown to be inversely marginally associated with adverse treatment 
outcome (p = 0.08). More detailed studies would be needed to determine whether belonging 
to the very poor really does not hamper the chances of full recovery. In any case, apart from 
pursuing the search for the best possible use of existing tools, other issues being intrinsically 
linked to tuberculosis, such as poverty, need to be addressed urgently.  
 
 
 
CONCLUSION 
 
We believe that due to the potentially grave consequences of having more failure and 
relapse cases, using fully thrice-weekly therapy is warranted only if there is stronger 
evidence of its non-inferiority compared to daily therapy. It is hoped that our final report 
with treatment outcome from almost 900 patients will allow a firmer conclusion.  
Randomised controlled trials with larger sample sizes are needed; such trials should be 
carried out using fixed-dose combination tablets. Also, in view of the low sputum 
conversion rate we found after two months of treatment under thrice-weekly therapy, such 
trials should include a third treatment arm for patients taking two weeks of daily therapy 
before shifting to intermittent therapy.  
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CHAPTER 9: GENERAL DISCUSSION AND CONCLUSION 
 
9.1. Key findings 
 
Chapters 4 and 5 of this thesis described the illness experience of TB patients and 
their search for treatment. We found the TB illness burden to be substantial; ill-defined 
suffering, such as emotional and social distress as well as social stigma, was common and 
has considerable potential to complicate TB care. What significantly increases the burden 
of having TB is the widely found inefficient health seeking behaviour. Based on the 
knowledge gained, two approaches with considerable potential to make care of TB 
patients more effective and efficient were examined: to expand DOTS by introducing it to 
the private sector and establishing public-private collaboration, and to make treatment 
more efficient by using intermittent therapy. Thus, we wanted to know the diagnostic and 
treatment practices of private practitioners and their views towards public-private 
collaboration. Various aspects of the health seeking behaviour found in Malabon and 
various findings from our survey among the private practitioners strongly suggest that 
successful public-private collaboration offers the following benefits:  
   
1. Shortened case finding for people with symptoms of TB 
   
2. Considerable financial savings for patients over the course of diagnosis and treatment 
     
3. Improved diagnosis and treatment by private practitioners 
       
4. Stronger motivation for the public care providers to offer friendly and competent TB care 
     
5. Better epidemiological data for the local TB epidemic due to less non-reporting of cases 
     
6. Less drug resistance since inadequate treatment and repeated interruption of anti-TB  
treatment are less likely to occur. 
 
7. Fewer people wrongly treated for TB, since sputum microscopy is more accurate 
   than chest X-rays.  
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In our comparison of daily with thrice-weekly therapy in public health care clinics 
we found thrice-weekly therapy to be feasible, attractive to patients and providers, and 
effective but could not remove doubts about non-inferiority to daily therapy (see chapter 
9.4.). We identified the following benefits of intermittent therapy:  
 
1. Treatment is less burdensome for patients and providers 
2. Increased likelihood of properly supervised treatment 
3. Reduced cost of needed TB drugs   
4. Reduced emotional distress since intake of drugs – an act that has the unpleasant  
connotation of not being in the normal state of health – occurs not daily but only 
three times a week. And for patients who want to keep their illness a secret this 
goal is easier to achieve.  
   
5. Increased utilisation of the public TB programme since intermittent therapy is 
more popular than daily therapy.  
 
 
9.2. Methodological considerations 
 
a) Internal validity 
 
 We used carefully designed interview catalogues for our patient survey to identify 
help seeing and TB illness experience. Focus group discussions and a survey among the 
health care providers of Malabon yielded additional information about TB illness 
experience. However, as discussed more precisely in each of the chapters, our research 
had several limitations. More attention to qualitative data from the study of patients 
would have been useful to clarify quantitative findings. With a stigmatized disease such 
as TB, social desirability bias may be a problem, and the patient interviews in Malabon 
were performed retrospectively, so recall bias also needs to be considered. Thus, the 
validity of the index of stigma may not be very high (chapter 4). We believe our findings 
regarding help seeking and perceived causes of tuberculosis (chapter 5) are less prone to 
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have reduced validity. Unlike questions referring to sensitive personal issues such as 
emotional distress and social consequences of having TB, questions regarding help 
seeking and causes of TB are answered more candidly.  
 
 The main limitation in the survey among the private practitioners is that some of 
the findings are more likely to reflect knowledge rather than actual practices and that due 
to social desirability bias some findings may overestimate the willingness of the private 
practitioners for public-private collaboration.   
 
 Since the interviews in Taguig were carried out prospectively and less sensitive 
topics were covered we believe the internal validity of the patient findings in Taguig is 
high. An exception may be the issue of self-report on regularity of drug intake. A 
literature review and also our field experiences make it clear that some patients overstate 
regularity and completeness of their drug intake (Gorin & Stone, 2001). In spite of drug 
resistance being common in Taguig, we found adverse treatment outcome in only 3.5% of 
our patients. This low rate indicates that adherence to treatment was high. Thus, we do 
not believe that underreporting of missing of drug intake was substantial and that it 
strongly affected the internal validity of our study in Taguig. 
 
b) External validity 
 
To what degree can we generalise our findings for the whole of the Philippines 
and for other countries? Other studies from Manila and the Philippines have similar 
findings regarding health seeking behaviour (Tupasi et al., 2000a; Valeza et al., 1991), 
while findings regarding perceived causes of tuberculosis are more heterogeneous: our 
results are only partly similar to results from three studies in or near Metro Manila 
(Tiglao & Tempongko, 1991; Ortega et al., 1991; Cure TB Foundation, 1991). However, 
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it must be considered that several years have passed between these three studies and our 
patient survey in Malabon. Beliefs may change over time and become more congruent 
with medical knowledge. This may well have happened in the Philippines: The national 
TB programme in the Philippines has become stronger in the mid-1990’s. The general 
population has thus been exposed to health information about TB.  
 
Other studies of TB in the Philippines have emphasised the role of stigma 
(Nichter, 1994; Aresta, 1994; Ardales & Castel, 1992; Ortega et al., 1991; Sarmiento, 
1990). Some findings indicate that the effects of stigma can be far-reaching. For instance, 
in a study in a rural setting, Ardales and Castel (1992) encountered several patients who 
tried to keep their illness from their family members. In other countries, a large number 
of studies have found similar aspects of TB illness experience, including social stigma 
(Rangan & Uplekar, 1999).  
 
 The results of our survey among the private practitioners of Malabon are similar 
to a recent survey performed among private practitioners in five settings in and near 
Metro Manila1. In a recent telephone survey across the Philippines the private 
practitioners’ deficiencies in diagnostic and treatment practices were similar but appeared 
more pronounced, and a worrying finding was that more than three quarters of the private 
practitioners did not agree with the national TB programme. More than half (53% of the 
1355 respondents) did not agree with the policy that diagnosis was based on sputum 
smear microscopy (Portero & Rubio, 2003).  
 
_______________ 
1 Results were presented in Manila in 2002 but are not or not yet published: “Current Trends in TB Management 
by Private Physicians in the Philippines: A Survey in Five Private Health Settings”. Philippine Coalition Against 
Tuberculosis (PhilCAT) and Centers for Disease Control and Prevention, Atlanta, USA.   
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 Our studies were all performed within Metro Manila, a highly urbanised setting. 
The nationwide TB prevalence survey in the Philippines of 1997 showed that compared 
to other urban centres of the Philippines, TB is less common (i.e. lower rate of culture 
positivity as well as sputum smear positivity) in Metro Manila. When excluding Metro 
Manila, TB was found to be more common in urban areas compared to rural areas 
(Tupasi et al., 1999). It is hard to know if our findings can be generalised for rural areas 
in the Philippines. In some aspects, the form and quality of family life and social 
networks differ in urban and rural areas, and thus, TB illness experience may be different 
in rural areas. Studies from India suggest that in rural areas TB illness experience may be 
less distressing: rejection of the TB patients by their families was less common in rural 
than in urban areas (Ramachandran et al., 1997), and children discontinuing school as a 
result of parental TB was also less common in rural areas (Rajeswari et al., 1999).  
 
Health seeking behaviour may be less prolonged in rural areas due to a limited 
availability of health care providers. Establishing public-private collaboration in rural 
areas may prove more challenging, depending on the social dynamics prevailing in a rural 
place. The nationwide telephone survey of Portero and Rubio (2003) in the Philippines 
did not mention any rural-urban differences in their findings. Neither in the Philippines 
nor elsewhere have we heard of public-private collaboration initiatives in rural areas.  
 
 Several of our findings regarding health seeking and public-private collaboration 
are also valid for other countries, for instance an inefficient case finding process, 
diagnostic and treatment deficiencies among the private practitioners, and the existence of 
starting points for establishing public-private collaboration (Uplekar et al., 2001a).  
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 How would thrice-weekly therapy work in other settings? As discussed, several 
observational studies have found thrice-weekly therapy to be effective. We believe that 
generally our results in Taguig have a high external validity. However, in areas strongly 
affected by the HIV/AIDS pandemic, the situation may be different, as a study in Malawi 
suggested (Harries et al., 2001). Also, it is important that intermittent therapy be used 
only in settings where TB programmes work well. Good case holding mechanisms are 
important: under intermittent therapy missing of drug intake is more likely to have 
adverse consequences than under daily therapy (since a missed dose represents a larger 
fraction of the whole treatment). Due to the virtual non-existence of case holding 
mechanisms in the private sector concerns have been expressed about the effect of the 
recent occurrence of drug formulations for intermittent therapy in India (WHO, 2001e).  
 
 
9.3. Recommendations for public health action 
 
a) for TB programmes generally 
 
 The findings from the study of TB illness experience (Chapter 4) and the case 
studies presented in Chapter 5 illustrate the importance of giving correct, appropriate and 
patient-centred health advice. Clear guidelines from the central TB office and training of 
the health care providers should address the knowledge level, attitude, and skills of the 
health care providers. Consequently, misperceptions, such as the supposed need to 
separate eating utensils while on anti-TB treatment, need to be exposed and rectified. 
Training of TB health workers needs to make more explicit the balance of appropriate 
public health interests to prevent spread and the interests of preventing unwarranted 
social exclusion. Higher priority in the training of health care providers is needed to 
promote empathy for the TB patient and relating to the patient in such a way to enhance 
dignity, feelings of self-worth and emotional resilience of the patient. Such empathy 
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results, among other things, in giving health advice in an appropriate way. Attitudes and 
skills are often intertwined. Based on changed attitudes, communication skills of the 
health care providers can be improved. This includes the ability to maintain a balance 
between making clear how to avoid contagion and minimising the emotional burden and 
stigma of TB. Improving the skills of the health care providers must be supported by a 
wider effort from national governments and the international community to end the 
neglect of human resource development, as discussed in Chapter 1, section 3.3.  
 
 Our findings also suggest that case holding can be strengthened by involving the 
family of the patient. Emphasizing to the patients and their families that TB can be cured 
when treatment is taken correctly and completely also has the potential to reduce stigma 
and its adverse effects. By facilitating support for the patient, the often distressing 
experience of having TB and undergoing treatment becomes much more manageable 
which has great potential for decreasing drop-out rates. 
 
 Our research experience raised important questions about the relationship of 
policy and practice. We found in Taguig that contrary to the guidelines of the TB 
programme, a substantial proportion of TB patients was not receiving treatment under 
DOT. Our research in Malabon from the year 2001 (not reported in this thesis) also found 
considerable non-compliance with the principle of direct observation of treatment. 
Studies in Thailand and India have also found this (Pungrassami et al., 2002; 
Balasubramanian et al., 2000). Rather than insisting on a strict form of treatment 
supervision that is then not widely implemented 2,  the local health authorities and those  
________________ 
2 The new ’Manual of Procedures’ for the TB programme of the Philippine Department of Health (Philippine 
Department of Health, 2001) recommends daily DOT for the whole length of treatment (and no longer for the 
intensive phase of treatment only). Talking with people from the Department of Health responsible for the 
control of TB, I indicated that since daily DOT for two (or three) months apparently cannot be implemented 
fully, this new recommendation will probably not be followed. There was a shrugging of shoulders and the 
remark that WHO wanted this new emphasis on longer DOT. Wide gaps between what guidelines stored in 
offices and on desks state and what is actually happening in the field are problematic.  
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responsible for the implementation of the DOTS strategy need to take note of this non-
adherence and develop guidelines that facilitate a feasible decision-making regarding 
which form of treatment supervision is most appropriate for each TB patient. Important 
factors that need to be considered when deciding on the mode of treatment supervision 
are: distance from the patient’s home to the health facility; degree and quality of the 
relationship between the patient and the health facility (based on former visits to the 
health facility); the kind of work and working hours of the patient; work load at home (for      
some mothers with several small children, health facility-based DOT may not be 
feasible); physical and mental condition of the patient, including degree of self-perceived 
stigma; and degree of support in the patient’s household.  
 
b) regarding public-private collaboration 
 
  It is crucial that investments are made in the public sector for additional human 
resources to deal with public-private collaboration. At the central level, a person should 
be employed to handle policy issues related to public-private collaboration, develop 
indicators and a system that allows monitoring and supervision, and coordinate with local 
programmes (at district, city, or municipal level). At the local level, the health workforce 
has to be increased. On the one hand, establishing public-private collaboration is labour-
intensive and on the other hand, successful public-private collaboration may significantly 
increase the demand for the public TB programme. The physician in charge of a local TB 
programme should be released from clinical responsibilities to be able to perform 
frequent supervision in the public health facilities to ensure that each health facility 
implements DOTS well and does its part needed to establish and maintain public-private 
collaboration. This public TB physician should have an assistant to perform regular basic 
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tasks that are part of public-private collaboration, such as visiting the local private 
practitioners (e.g. for gathering their records to inform the public sector on patient load in 
the private sector and on the number of patients referred to the public health facility), 
ensuring proper functioning of logistic aspects (e.g. availability and distribution of TB 
drugs once a system has been set up that allows the private practitioners to make use of 
public TB drugs), and organising seminars and meetings. The public TB physician should 
be a member of a local committee that facilitates public-private collaboration. 
 
c) regarding intermittent therapy 
 
 Our findings do not warrant drastic recommendations. Since we do not have 
strong evidence of non-inferiority of intermittent therapy compared to daily therapy with 
the results available now we do not recommend a shift from daily to intermittent therapy. 
Our results suggest a trend towards inferiority of thrice-weekly therapy in terms of 
treatment outcome. Since this is only a trend, we do not recommend programmes using 
intermittent therapy to change to daily regimens. Programmes using intermittent therapy 
regimens should be especially aware of the importance of regular drug intake and of rigid 
evaluation of treatment outcome.  
 
9.4. Recommendations for further research 
 
A clear understanding of the patients and their behaviour is fundamental. What 
aspects of illness experience are particularly burdensome and what aspects of the illness 
burden are amenable through interventions that can easily be implemented in public TB 
programmes? In some places, enough is already known about the health seeking 
behaviour and the knowledge, attitude and practices of the general population regarding 
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TB. In other places, patient interviews and focus group discussions are needed to 
document these behaviours and the underlying attitudes, beliefs and experiences. The 
approach of cultural epidemiology facilitates generation of accurate knowledge. In-depth 
studies about health seeking behaviour, especially the switching of patients between 
private and public providers and their motives for doing so may provide further important 
insights and help identify the complex influences that determine patient behaviour. 
Patient behaviour should be explored on several levels: psycho-social and economic 
factors at the patient level; factors in the community and locality of the patient (focussing  
on the availability of health services, including folk healers); actors at the national level, 
such as existence and enforcement of laws related to health, availability of health 
insurance schemes, and health policies of the government; activities of and level of 
influence of pharmaceutical companies (such as advertising and promoting activities, 
sponsoring of medical meetings, and level of support for efforts to establish public-
private collaboration3); and international factors, such as trade liberalisation, globalisation 
and enforcement of structural adjustment programmes. Figure 9.1 gives an indication of 
the different levels and serves as an aid to keep the wider picture of TB in mind. 
 
 
 
 
 
 
 
 
__________________ 
3 The Philippine Coalition Against Tuberculosis (PhilCAT), a driving force in public-private collaboration 
in the Philippines, has several large pharmaceutical companies among its members. 
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Figure 9.1: The context and causal web of tuberculosis 
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 An area of research relevant to treatment (be it daily or intermittent) and how the 
patient experiences it, arises from the study in Taguig. Our finding that the mode of 
treatment supervision did not influence the sputum conversion rate is interesting. The 
question arises what kind of treatment supervision is needed and what the determinants of 
successful treatment supervision are. We did not in detail look at the factors that 
determined what kind of treatment supervision a TB patient received. One factor clearly 
was that in certain health centres the health care providers were more serious in following 
the concept of DOT than in other health centres. Also, narratives strongly indicate that in 
most health centres the TB patients have a kind of ‘bargaining power’, meaning that less 
rigid forms of treatment supervision are considered and negotiated when the patient 
expresses apprehension towards health facility-based treatment intake. In other words, the 
kind of treatment supervision a patient has is often a result of a negotiating process 
between the health care provider and the patient. This process also occurs in other places 
(Macq et al., 2003). Operational research should be carried out to create a stronger 
evidence base of the effects of the various modes of treatment supervision that result 
from such negotiating processes. Operational research may also be needed to finetune 
guidelines for the health care providers on how to go through such a process of 
negotiation.  
 
Operational research is needed to find ways of how to implement public-private 
collaboration. Additional support for such research is required. Finding ways of 
establishing public-private collaboration for TB control may also encourage valuable 
public-private collaboration for other diseases. Our survey in Malabon established 
common deficiencies among Malabon’s private practitioners. Such surveys need to be 
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carried out in other geographical areas where public-private collaboration is envisioned. 
These surveys and the questionnaires for them can be less elaborate than the one we 
performed in Malabon. The question of how identified deficiencies can be addressed is 
more difficult to answer; studies adopted to the local context have to address this 
question. Linked to this question are other questions referring to the private practitioner: 
What are the complex influences that determine provider behaviour? (E.g. what motivates 
the private practitioners apart from profit-maximisation? What encourages the private 
practitioners to collaborate with the public sector?) What kind of levers can be used to 
improve the practices of the private practitioners? 
 
Concerning the public TB programme, important questions are: What can the 
public sector learn from the private sector? What can the public sector offer to facilitate 
collaboration? How can the public sector be strengthened sufficiently so that the general 
public and the private practitioners trust in it? Focus group discussions with public and 
private health care providers as well as in-depth interviews with some key informants 
(e.g. physicians who work in both sectors) are useful tools to find answers to such 
questions. 
 
Other key questions are: What local mechanisms are already in place that can be 
used to facilitate collaboration? What kind of local mechanisms need to be put in place to 
facilitate collaboration? What kind of regulative mechanisms can realistically be put in 
place and enforced long-term? Who/what are the key local people and institutions whose 
support is needed? This last question indicates that a stakeholder analysis (Brugha & 
Varvasovszky, 2000) can be useful. A stakeholder analysis provides insights into the 
current and future organizational environment of a locality, leading to a deeper 
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understanding on how organizational changes can facilitate public-private collaboration 
in TB control. For instance, it clarifies the role a local medical society can play in 
establishing public-private collaboration and the steps the public health sector can 
undertake to strengthen health-related public-private relationships. A stakeholder analysis 
yields information about the relevant actors, i.e. it contributes to an increased 
understanding of the behaviour and intentions of private practitioners and the public 
providers and of the interrelations between the two kinds of health care providers. It also 
clarifies the influence and resources various stakeholders of a locality outside the health 
sector have (e.g. religious organisations) and how these can be tapped to facilitate public-
private collaboration. 
 
To establish public-private collaboration, research and public health action should 
go hand-in-hand. Findings from surveys (for instance regarding the practices of the 
private practitioners) should immediately be translated into remedial action. Thus, the 
research activities leading to public-private collaboration should involve the local players, 
i.e. health care providers from the public and the private sector. These local health care 
providers know best how remedial action can be implemented in their setting. A useful 
approach for such research is Research-Action-Capacity Building (Recherche Action 
Formation in French) to further the participation of these people and use their own 
experiences and creativity as an asset. Research-Action-Capacity Building sees research 
and action as two connected elements of one entity, stimulates a process of on-going 
exchanges between the various players, and sees social change as the ultimate purpose 
(Wyss et al., 2002). Public-private collaboration is often aided by social change and its 
successful implementation is an indicator of social change.    
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Our study showed intermittent therapy to have several advantages (compared to 
daily therapy). But since there is a lack of solid evidence that intermittent therapy is not 
inferior to daily therapy, further randomised controlled trials with a large statistical power 
comparing daily with intermittent therapy are warranted. Our concern stems not so much 
from considerations about limited external validity than from the fact that only much 
larger sample sizes would ensure that small differences in effectiveness are detected. It is 
vital that intermittent regimens are really non-inferior to daily regimens. Box 9.1 
illustrates how using a slightly less effective regimen can significantly affect individual 
and public health (calculations with figures from India, the country with the largest 
number of TB cases in the world, were used - Khatri & Frieden, 2002).  
 
Box 9.1: Hypothetical calculations of the detrimental effect of using a slightly less  
 effective regimen – the example of India 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is expected that in some years, DOTS reaches 100% of India’s population. This 
means around 1.4 million TB cases will be treated under DOTS every year. Assuming 
an adverse treatment outcome (failure and relapse cases) among 5% of new smear-
positive patients, 3% of new smear-negative patients, and 8% of re-treatment patients 
when using thrice-weekly therapy and an adverse treatment outcome among 3% of new 
smear-positive patients, 1% of new smear-negative patients, and 6% of re-treatment 
patients when using daily therapy results in 24,800 excess cases of pulmonary TB cases 
each year when thrice-weekly instead of daily therapy is used. If 4% of these excess 
cases turn out to have MDR-TB, then thrice-weekly therapy produces an excess 
number of 992 cases of MDR-TB each year in India under this scenario.  
 
For the calculations, we assumed that 39% are new smear-positive patients, 31% new smear-negative 
patients, and 18% re-treatment patients (and the remaining ones patients with extrapulmonary 
tuberculosis), based on the report by Khatri and Frieden (2002). The rates for adverse treatment outcome 
are partly based on the figures given for failure cases in Table 4 of Khatri and Frieden (2002). 
Observational studies of thrice-weekly therapy show that the rates here assumed are conservative. For 
instance, Cao and colleagues (1998) in China found an adverse treatment outcome rate of 6.4% for 306 
new patients and of 22.7% for 343 re-treatment patients. Another report from China (China Tuberculosis 
Control Collaboration, 1996) found a failure rate of 3.1% among 55,213 new patients and a failure rate 
of 10.2% among 57,629 re-treatment patients. And 3.2% of 4,037 patients that were followed-up became 
relapse cases (the relapse rate was not differentiated according to new or re-treatment patient).  
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9.5. Conclusion 
 
 With the goal to contribute to better TB care in the world, this thesis examined 
several aspects of TB illness experience and two approaches to enhance DOTS. The 
survey in Malabon to establish TB illness experience and clarify aspects of help seeking 
and treatment provided insights that served as a sound basis for our efforts to reach 
private practitioners and establish a bridge between the private and the public sector, and 
to study intermittent therapy.  Other research more rooted in basic science, invigorated by 
new money available for such research, provides cautious optimism that at the end of this 
decade, better diagnostic tools and new drugs making shorter therapy and treatment of 
highly resistant forms of tuberculosis possible will be available (Perkins & Kritski, 2002; 
Crabb, 2002; Freire & Roscigno, 2002; Young, 2001). Identifying and then applying such 
new tools could greatly simplify TB control. In the meantime, the challenge is to find 
ways to work more efficiently with what is available, and this is the contribution of this 
thesis. The thesis indicated the significant benefits that can result from bringing DOTS to 
the private sector and establishing public-private collaboration. A clear awareness of the 
need and benefits of public-private collaboration is needed to face the formidable 
challenges of establishing public-private collaboration in TB control. Additional 
resources, people on the ground dedicated to the task, and operational research to identify 
feasible approaches in various settings are required.   
 
 While public-private collaboration results in a wider use of sound principles of 
TB care, our study on intermittent therapy focussed on sharpening the main tool of 
DOTS, namely short-course chemotherapy. All possible means to make DOTS more 
efficient and convenient to patients and health care providers need to be pursued. 
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Intermittent therapy has considerable potential in this connection. Forty years ago, 
Canetti said: "On an international scale, among the efforts that are necessary to 
accomplish the eradication of tuberculosis, there is one absolute priority; the perfecting of 
chemotherapeutic methods adapted to conditions of 'developing' countries. In realising 
this objective, the 'developed' countries can give 'developing' ones considerable help.” 
(Canetti, 1962; emphasis added). There still is considerable room for perfecting therapy 
based on drugs available for more than 30 years. At the same time, it needs to be stressed 
that while using intermittent therapy instead of daily therapy can substantially improve 
TB care, better chemotherapy alone does not result in progress. Many aspects of TB care 
need improvement and many facets of treatment need to be considered. Our discussion in 
Chapter 1 on the limitations of DOTS highlights this reality. The growing support for TB 
control and research working towards controlling TB and the emerging awareness of the 
global community for the need of an all-embracing approach in confronting TB give rise 
to hope that this decade will see progress.    
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ANNEX: PATIENT QUESTIONNAIRE (used in Malabon)  
 
QUESTIONNAIRE  
 
HC:  _____________              GHC ____ 
 
Number:  ______           GNO ___ 
 
Re-Treatment?   _______         GRETX ____ 
 
UHNP? ________              GUHNP _____ 
 
 
 
This is a questionnaire about how one of the programs of the health centers can be improved. Your honest 
answers are very valuable and will help to improve one program of the health centers. We are not from the 
government. This questionnaire is part of a study performed by a student of the College of Public Health, 
UP Manila. 
Please try to give truthful answers. It is not bad or embarrassing if your answer is "I don't know" or "I 
can't remember" since we need to find out what the people know and what they do not yet know in order to 
improve the program.      
           Christian Auer, student of the College of Public Health, UP Manila  
 
 
 
 
 
 
a) General         
 
1. Gender   ________            GSEX  ____ 
        (1=male, 2=female) 
 
2. Age     _________      GAGE  _____ 
 
 
KINDLY ONLY ANSWER THOSE 
QUESTIONS WRITTEN IN BOLD 
AND LARGE LETTERS 
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3. Your civil status in the first half of 1996?     GCS  ____ 
 
      ___  Not yet having a partner      (=1) 
      ___  Having a partner then      (=2) 
      ___  I have a partner but she or he was absent in the first half of 1996   (=3) 
      ___  I had a partner but we are separated      (=4) 
      ___  Widowed        (=5) 
 
 
4. Since when have you been living in this place?            _____________ GAREA ____ 
 
      
5. Generally, do you more often go to a private doctor or to a health center?       PRIVORHC  ____ 
        ___  to a health center      (=1) 
     ___  to a private doctor        (=2) 
     ___  To both (private doctor and health center)    (=3) 
     ___  Other: __________________________________ (=4,5) 
 
 
6.  What are common serious illnesses of people aged 13 years   GCOMDIS ____ 
      and older in this place? 
 
      If possible, mention three illnesses:  1.  ________________________ 
2.  ________________________ 
3.  ________________________ 
 
7.  In your opinion,  when a person is sick, can he or she do a lot to become   GCONTROL ____ 
      healthy again or only a little bit? 
      ___  Really a lot    (=1) 
      ___  A lot    (=2) 
      ___  Quite a bit     (=3)   
      ___  A little bit     (=4) 
      ___  Almost nothing    (=5) 
      ___  I don't know    (=8) 
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b) Case finding     
 
The following questions (Nos 9 to 32) are regarding the time span when you first noticed that your 
health was not fine up to the time when it became clear what your illnes was. Therefore, try to 
remember what you did when your symptoms began. 
  
8.  In your opinion, what was the illness you had last year?   FSAKIT ___ 
   ___  "Sicknees on the lungs"      (=1) 
   ___  "Weak lungs"      (=2) 
   ___  TB       (=3) 
   ___  Other; what?  __________________________   (=4) 
   ___  I don't know       (=8) 
 
 
 
9.  When you were not yet sick on your lungs did you then    FDANGER  ___ 
     consider TB to be a dangerous disease?                
   ___  Yes, really dangerous    (=1) 
   ___  Yes, somewhat dangerous    (=2) 
   ___  Only slightly dangerous    (=3) 
   ___  No. Not dangerous     (=4) 
   ___  I don't know      (=8) 
 
 
10. When you were not yet sick on your lungs did you believe   FTBGET ___ 
      that you could get sick on your lungs? 
 
   ___  Yes, really      (=1) 
   ___  Yes, somewhat     (=2) 
   ___   Not really                         (=3) 
   ___   Definitely not    (=4) 
   ___  I don't know      (=8) 
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11. Before getting sick on your lungs, did you believe then that there exists    FCURE  ___ 
      an effective cure for TB?    
   ___  Yes, really      (=1) 
   ___  Yes, I thought it probable    (=2) 
   ___   Rather not                          (=3) 
   ___   Definitely not     (=4) 
   ___  I don't know/ I can' t remember   (=8) 
 
 
12. If yes, what was the cure according to your believe at that time ?     FCUREANO ____ 
 
      _____________________________________________________________ 
 
      _____________________________________________________________ 
 
 
13. What was the very first thing you did when you got concerned about your symptoms?   FFIRST  ____ 
___  Self-treatment                            SHOW IT AND PROBE!!   (=1) 
___  Asked advice at relatives/family/friends      (=2) 
  ___  Asked advice at the relatives/family/friends and then got self-treatment (=3)   
___  Went to a folk healer (albularyo)       (=4) 
___  Went to a health center      (=5) 
___  Went to a private doctor      (=6) 
___  Other: _______________________________________   (=7) 
 
   
14. Did someone invite you or tell you to have a medical checkup?   FENCOUR ___ 
     ___ Yes     (=1) 
     ___  No     (=0) 
     ___ I can't remember    (=8) 
 
 
     15. If yes: Who?  _____________________________________   FENCWHO ___ 
                                              (E. g. health center staff, someone from your house, neighbour) 
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16. Where did it become clear what your illness was?      FDIAGWO 
 
  ___  At the health center      (=1) 
  ___  At the private doctor      (=2) 
  ___  At both (health center and private doctor)     (=3) 
  ___  Somewhere else: _______________________    (=4) 
 
 
       IF APPLICABLE: 
17. If at the private doctor: Did the private doctor tell you that you can get treatment for    FDRSABIHC ____ 
       sickness on the lungs at the health center? 
      ___  No    (=0) 
      ___  No, I don't think so   (=1) 
      ___  Yes, I think so    (=2) 
      ___  Yes    (=3) 
      ___  I don't know     (=8) 
 
 
18. What was the result or what came up at the first check-up you had?  _________________ FFIRSANO ____ 
              (X-ray? Prescription? Buying drugs for how long? .....) 
       _____________________________________________________________________________ 
 
       _____________________________________________________________________________ 
 
 
19.  After that, did you still go somewhere else or do something else?    FTHENGO ____  
 
 
20. What were the symptoms that made you go to check for sickness on the lung?    FSYMP ____ 
 
 1.  ___________________________________________________________________   
 
       2. AFTER PROBING: ___________________________________________________ 
      
                HEMOPTYSIS? ___________ 
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21. Approximately, how many weeks or months did you first have symptoms    FTIME  ___ 
       before you went to a private doctor or health center (or NGO)? 
       __________________   
 
      IF APPLICABLE: 
22. What was the reason for your waiting to get a check-up?      FDISCOU ____ 
      Or in other words:  Why did you wait for _______________ before having a check-up? 
  
      __________________________________________________________________________ 
 
23. How many times had you gone to the health center before you got sick on your lungs?  FMANY ____ 
 
    Around _____  times 
 
           
24. Did you undergo a sputum test, an X-ray, both or even    FHOWDIA  ___ 
      something else?       
    
                    __  Sputum test only    (=1) 
           __  X-ray only     (=2) 
                   __  Both (sputum test and X-ray)   (=3) 
                   __  Something else: ____________________ (=4, 5 evt)                                     
                                          (Write down here what) 
                                __  I can't remember    (=8) 
 
 
25.  If you had a sputum test:  What was the result of the sputum test??     SPUTEST  ____ 
           (PROBE!!)    __  positive     (=1) 
     __  negative     (=0) 
     __  I can't remember    (=8) 
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26. Is giving of sputum embarrassing?     FSPUEMB  ___ 
              __  No     (=0)   
     __  I little bit        (=1) 
      __  Somehow yes     (=2) 
      __  Yes     (=3) 
   __  I don't know      (=8) 
 
 
 
27.  Was there someone with sickness on the lungs in your household  FHHSICK  ___ 
      during the time when you went for a check-up? 
 
           __  No    (=0) 
         __  Yes    (=1) 
        __  I can't remember   (=8) 
 
 
28. How many people who had had sickness on the lungs or had sickness on the lungs did   FHADTB ____ 
       you know of during the time when you went for a check-up??  
   
           Around _______ people. 
 
       29.  How many of them are your relatives or close friends?      Around  ____   FHADTBRF   ____ 
           
 
30. How many people who had sickness on the lungs and who were treated successfully    FTREAT  ____ 
       did you know of during the time when you went for a check-up??  
   
           Around _______ people. 
 
31. How many of them are your relatives or close friends?      Around  ____   FTREATRF   ____   
 
   
32.  How many people had died of TB did you know of during the time when you went   FDIED ____ 
        for a check-up??  
   
           Around _______ people. 
 
33. How many of them are your relatives or close friends?      Around  ____   FDIEDRF   ____    
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c)  Case holding 
 
 
The following questions refer to the time when you were treated, i.e. they refer to the time span when 
your illness was clearly diagnosed up to the end of treatment. Therefore, try to remember what you did 
while you were taking medications.  
 
 
34. When the result of the sputum examination came out, were you then   HINFEC ____  
     told that your disease was contagious?    
         
 
       __  Yes    (=1)   
     __  Yes, I think so         (=2) 
     ___   I do not think so     (=3) 
     __  No     (=4) 
     __  I can't remember    (=8) 
  
 
35. Were you also told how to prevent that other would get infected? HPREV  ___ 
                                           __  Yes         (=1)   
     __  Yes, I think so     (=2) 
          __  No     (=3) 
     __  I do not think so    (=4) 
     __  I can't remember    (=8) 
 
              IF APPLICABLE: 
      36. If yes: What were you told? _______________________________________ HPRWHAT ____ 
                  ______________________________________________________________ ....... 
           ______________________________________________________________ 
 
 
37. For how long must TB be treated?      HLENGTH  ____ 
      For around  _________ months  
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38. When the result of the sputum examination became known were you then immediately   HTXWAIT ___ 
       treated or did you have to wait?               
     __  I was immediately treated        (=0) 
             __  I had to wait for  ____________        (1=1 wk, 2=2wks, ect) 
               __  I can't remember          (=8) 
  
       IF APPLICABLE: 
39. If treatment was not yet available at the health center when the result of the sputum   HHCGAWA ___ 
       examination came out, what did you do then?                
               __  I really just waited      (=1) 
     __  I bought treatment even though is was incomplete   (=2) 
     __  I bought treatment. And it was complete.    (=3) 
     __  I was looking for treatment somewhere else and I succeeded. (=4) 
     __  I was looking for treatment somewhere else but in vain.  (=5) 
     __  Something else; what?  __________________________ (=6)   
     __  I can't remember              (=8) 
     
40. When the result of the sputum examination became known were you then told that the other  HHHCOME ___ 
       members of your household should have a check-up at the health center? 
         
     __  No        (=0)  
     __  Yes       (=1)  
           __  Yes, all of them.     (=2) 
         __  Yes, those with symptoms       (=3)          
            (cough, fever, weight loss etc.)     
 
     __  I can't remember      (=8)  
 
 Comment: _______________________________________________________________    
 
 
41.  Was there someone in your household that got sickness on the lungs HHHTBAF  ____ 
       after you had been diagnosed?         
                                __  Yes     (=1) 
      __  No     (=2) 
      __  I can't remember     (=8) 
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42. How much is the transportation fee from your house to the health center? (both ways)  HTRSP  _____ 
   ___  None, because I just walked to the health center                      (0=none, 1= up to P 5, 
   ___  Pesos         2=P 6-10,  3=P 11-15,  
                                     4= 16 plus)    
 
 
43. How many minutes does it take to go to the health center (one way)?     TIMEHC  ____ 
               Around  ______ minutes       
                   
 
 
44.  How many minutes did you have to wait in the health center to get your medication?  HHCWAIT  ___ 
     
   ___   Around _____  minutes        
 ___   It depended, varied:  _________________________________________   
   
 
 
 
45. Was there someone who picked up the medication from the health center for you?   HPICKUP  ___ 
     __  Yes                 (0=no, 1=yes, mw/bhw, 
     __  No                                 2=yes, relat., 3=friend,  
 __  I can't remember                  4=k'bahay, 5=other) 
      
        If yes: Who?  ____________________________________________ 
  
 
 
 
46.  Did it happen that sometimes the medications were not complete when you went to the  HNOTCOMP ____ 
              health center to get them? 
 
     __  No                (=0) 
  __  It happened; around  _____ times              (=1,2,3...) 
     __  It happened, but I can't remember how many times           (=55) 
     __  I can't remember                         (=88) 
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        IF APPLICABLE: 
47. What did you do if there was no medication or incomplete medication at the health center?    HDOTHEN ____ 
 __  The medication was always complete      (=9) 
 __  There was nothing I could do but wait. This meant that my treatment was   (=1) 
       interrupted..        
 __  I bought medication even though incomplete.     (=2) 
 __  I bought medication. And it was complete.      (=3) 
 __  I was successfully looking for medication somewhere else.     (=4) 
 __  I was looking for medication somewhere else. But I had no success.    (=5) 
 __  Something else? If yes: what? _____________________________________  (=6, 7) 
       _____________________________________________________________ 
 __  I can't remember        (=8) 
 
 
48.  Did you have to show the empty 'blister pack' of the medication when you went to the   HBLIPACK __ 
        health center to get your medication?  
        
     __  No      (=0) 
     __  Yes, but only in the beginning    (=1) 
     __  Yes, but not always      (=2) 
     __  Yes, always      (=3) 
     __  I can't remember      (=8) 
 
 
49.  How did you help yourself in order not to forget to take your daily medication?  HCLUES ____ 
        (reminders, clues) 
      __________________________________________________________________   
      __________________________________________________________________ 
 
 
50. For how many months did you take your medication?      For ____  months   HTXMOS _____ 
 
           If for less than 6 months: Why did it happen that you did not finish six months?    ________________ 
 
        ____________________________________________________________________________ 
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51. Did your take your medication daily during the months of being  HTXDAILY ____ 
      on medication? 
 
 __  Yes, during all the months of taking my medication          (=1) 
 __  Yes, but only during the first few months          (=2) 
 __  Not really. There were months when I took my medication daily, but there were  
        also months with interruption(s)     (=3) 
 __   Almost every month there were interruption(s)       (=4) 
 __   Every month there were interruption(s)     (=5) 
   __   Something else: _______________________________________________ (=6) 
 
    
52. In your opinion,  if we compare the TB drugs that can be bought in the drug stores with  HDRUGSEF ____ 
       those that we get in the health centers: which ones are better? Or are they the same?  
        
     __  They are the same     (=0)  
     __  Those in the drug stores are better    (=1)  
     __  __________________________________________________ (=2)   
     __  I don't know      (=8) 
 
53.  Were you asked in the health center whether you experienced side effects?   HSIDEEFA ____ 
      __  No     (=0)  
      __  Only once     (=1)  
      __  Around ______ times    (=2, 3, 4...) 
      __  I can't remember                  (=8) 
 
 
54. Was it only one person who gave you the medication in the health center?   HONEGAVE  ___      
      __  No. different ones    (=0) 
       __  Mostly     (=1) 
       __  Often    (=2) 
       __  Always      (=3) 
      __  I can't remember     (=8) 
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55. Did you experience side effects when you were taking your  HSIDEEF  ____ 
     TB medication? 
     __  No      (=0)   
      __  Yes, but only in the beginning. And it was harmless (=1) 
      __  Yes, but it was harmless     (=2) 
      __  Yes.     (=3) 
      __  Yes. And I had to change my medication  (=4) 
      __  Yes. And I had to stop my medication   (=5) 
      __  I can't remember                   (=8) 
     
 
56. Did you sometimes stop taking your medication because you felt unwell?     HBAD  ___ 
           
      __  Quite frequent    (=1) 
 __   Only sometimes    (=2) 
 __   Seldom    (=3) 
 __   No    (=4) 
    __   I can't remember     (=8) 
  
57. It is rather difficult to take medication every day, isn't it.  Probably it happened to you   HFORGOT  ___     
that you forgot to take your daily drugs. Did this happen? How frequent? 
  
               __  No      (=0) 
 __  Around once a month    (=1) 
 __  Twice or three times a month    (=2) 
 __  Around once a week     (=3) 
      __  More than once a week     (=4) 
      ___   Something else:  _____________________________  (=5) 
    __  I can't remember     (=8) 
 
58.  Did it happen that for more than two weeks you could not take your medication?   HTXMISS  ___ 
        (i.e. your treatment was interrupted for more than two weeks?) 
      __  No     (=0)  
    __  Yes, but only once          (=1) 
    __  Yes, ____ times    (=2, 3, 4....) 
    __  I can't remember     (=8) 
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59. After how many weeks or months of taking your medication regularly did you feel well again?  HFEEL  ____ 
                   (1=after 1week, 2=after 2wks  
                                          etc.) 
              After    _____________________________         
 
60. Was there someone who encouraged you to keep on taking your medication?    HENCOUR  ____ 
       
      __  Yes    (1=yes) 
__  No    (0=no) 
       If yes: Who?  _____________________________________     (2= MW/BHW,   
     (e.g. someone in your household, a neighbour, a health worker)    3=relative, 4=friend,  
          5=k'bahay, 6=other) 
 
61. If yes:  How important was this encouragement for you to continue to get and take   HENCHELP  ___ 
                  your medication?   
            
      __  Definitely not important    (=0) 
      __  A little bit important     (=1) 
      __  Quite important    (=2) 
      __  Important    (=3) 
      __  Really important    (=4)  
      __   I don't know     (=8) 
      
 
 
What can you say about the personnel in the health center during the time of getting 
your medication? 
 
62.  Were they competent?         __  Yes, really competent   HHCSKIL  ____ 
      __  Yes, competent     (1=no, 2=somehow,  
      __  Somehow competent      3=quite,.....) 
        __  A little bit competent                            
         __  Not competent 
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63. Did they explain you well?      HHCEXPL___  
      __  Yes, really well    
      __  Yes, well       
      __  Somehow well    
        __  A little bit well                           
         __  Not well 
   
 
64. Were they kind to you?      HHCKIND ____ 
      __  Yes, really kind    
      __  Yes, kind       
      __  Somehow kind      
        __  A little bit kind                           
         __  Not kind 
 
 
 
65. What did they tell you in the health center why you had to come and get medication for  HTOLD  ___ 
      six months? 
      ______________________________________________________________    
      ______________________________________________________________ 
 
 
66. What can happen to someone who has TB if his or her time of medication is stopped  HTXSTOP  ____ 
      too early?     (PROBE!)                           (1= he won't get cured,  
                                        2=he'll die 3= ...    
                   [not now]) 
      __________________________________________________________________          
      _______________________________________________________________________ 
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67. When you started to have medication - meaning to say after the result of the sputum  HSPUTUM ____ 
       examination came out - how many times more did you have to give sputum?  
       In other words: Apart from your giving sputum at the beginning of your treatment  
       how many times more did you give sputum ? PROBE!!    
     __  No more     (=0) 
     __   No more, but X-ray after  ___ months   (=1) 
         __  Only once; after ______ months    (=2) 
         __  Twice     (=3) 
         __  Three times     (=4) 
         __  Four time or more      (=5) 
         __  I can't remember          (=8) 
    
 
 68. Did it happen to you that someone asked you to give him or her HASKED  ____       
                       medication?        
      __  No            (=0) 
          __  Seldom    (=1) 
      __  From time to time       (=2) 
       __  Quite often     (=3)   
                            __   Really often     (=4) 
            __  I can't remember    (=8) 
 
 
69. If it happened: Did you give medication to those who asked you?   HGAVE  ____ 
      
     __  No, because no-one asked me  (=9) 
     __  No    (=0) 
     __  Seldom; around ____ times  (=1) 
     __  From time to time; around ___ times  (=2) 
           __  Quite often; around ___ times (=3)   
                                   __  Really often    (=4) 
                  __  I can't remember     (=8) 
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70. If a TB patient starts to take medication regularly: For how many days or weeks or  HINFDAY ____ 
       months more will he or she still be contagious?  
          ....... 
           For around  ______________________                 ___  I don't know  
 
------------------------------------------------------------------------------------------------------------ 
 
d) Social effects 
 
 
71.  Did you have a job before you had sickness on the lungs?   ASOK ____ 
    __  Yes     (=1) 
    __  Only in between    (=2) 
    __  No        (=0) 
 
72. If yes: What kind of job did you have then?     PJOBANO  ____ 
        __  I was employed as a ______________________________ (=...) 
       __  I had my own work:  ______________________________ (=...) 
 
 
     
73.  To those with a job: What was the effect of your illness on your job?     SJOB  ___ 
          __  It had no effect       (=0,  
 __  I interrupted my work for  ____________________  (weeks or months)  (=1,2,3,4,....) 
 __  I stopped my work up to now.        (=44) 
 __  I lost my job, but found a new one after  _________ (weeks or months)    (=55) 
 __  I lost my job and hav enow job up to now    (=66) 
 __  Something else: ______________________________________________  (=77) 
             (Write down what) 
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       To those with a job:   
74.   Did the six months of getting medication become an obstacle for  HCONFL ____ 
       your work?  
     __  No, because I didn't have a job then . (=9) 
     __  No    (=0) 
     __  Only a little bit    (=1) 
     __  Yes, somehow     (=2) 
     __  Yes    (=3) 
 
75.  Were you the only one in your household who had an income  SBREADW  ___ 
      before you fell sick on the lungs? 
       
          __  Yes, I only      (=1) 
           __  Yes, but not only I had an income   (=2) 
          __  No-one counted on my income because it was small (=3) 
          __  I did not earn       (=4) 
 
    
76.  Did you - because of your sickness on the lungs -  have separate  SEATAFF  ___ 
      eating utensils?         
       __  Yes     (=1) 
                  __  No      (=2) 
    __  I can't remember     (=3) 
 
        77. If yes: for how long?      SEATLONG ___  
                     Mga  _________________________                 (1= <1 mo., 2= < 2mos...) 
            
        78. If you had separate eating utensils: Who told you to do this? SEATWHO  ___ 
                                _______________________________________                (1=mw/BHW, 2=relat. 
              (e.g. Someone in your household, neighbour, health worker)                       3=friend, 4=k'bahay,  
                                       5=other)  
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79. Did you - because of your sickness on the lungs - change your way  SSLEAFF  ___ 
      of sleeping?   (for instance: you slept on your own)  
        
      __  Yes    (=1) 
         __  No    (=2) 
     __  I can't remember    (=8)   
 
         80. If yes: What kind of change? __________________________ SLEANO ____ 
                ______________________________________________________________ 
 
          81.  If there was change: for how long?      SSLELONG ___ 
                   For around ________                    (1= <1 mo., 2= < 2mos.etc) 
                   
 82. If there was change: Who told you to change?     SSLEWHO ___    
 
                      (1=mw/BHW, 2=relat. 
            ____________________________________                              3=friend, 4=k'bahay,  
                                5=other) 
               (e.g. Someone in your household, neighbour, health worker)  
 
 
83. If you are married or have a partner : Did you - because of your  SSEAFF  ___ 
      sickness on the lungs - change your marital life?  
 
       __  Yes    (=1) 
         __  No    (=2) 
     __  I can't remember    (=8)   
 
 
       84. If yes: What kind of change?   _______________________________ SSEANO ____ 
               _______________________________________________________________ 
 
       85. If there was change: for how long?     SSELONG ___ 
           (1= <1 mo., 2= <   
                   For around _____________      2mos.etc 
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              86.  If there was change: Who told you to change?     SSEWHO ____ 
 
                                        _______________________________________ 
    (e.g. Someone in your household, neighbour, health worker) 
 
 
 
 
87.  In your opinion, who from or what from did you get your sickness on the lungs?    SWHFROM  __ 
           SHOW IT!!   __  From the dirty environment      
               __  From the dirty water 
     __  From too heavy work 
       __  From cold wheather 
     __  From sudden change of temperature 
        __  Inherited 
     __  From vices  
     __  From something else: ______________________________ 
     __  From someone who had TB 
                 If from someone: Who from did it come?  
      __  from a household member 
      __  from a friend 
      __  from a neighbour 
      __  from a work-mate 
      __  from someone else 
                   __  I don't know who it came from   
        __  I don't know  
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In your opinion, what are the reasons why someone gets TB?  
        
 
 
                           Is not a reason    Is somehow    Is really a    I don't know 
    Hand it over and tell the patient that                              a reason         reason 
    this is not regarding him/her  
                      
 
88.   Fatigue, too hard work ('overwork') 1            2                3    8            TBWORK ___ 
89.   Dirty environment  1 2  3  8 TBDIRT   ____ 
90.   Lack of food  1 2  3  8 TBFOOD ____ 
91.   Poverty  1 2  3  8 TBPOV    ____ 
92.   Microbe  1 2  3  8 TBMICROB ___ 
93.   There is often drying sweat on the back  1 2  3  8 TBPAWIS  ___ 
94.   He is cllse to someone with TB  1 2  3  8 TBCATAO ___ 
95.   Inherited  1 2  3  8 TBMANA ___ 
96.   He had already often had pneumonia  1 2  3  8 TBPULM  ___ 
97.   He is often drinking alcohol  1 2  3  8 TBALAK  ____ 
98.   He is often smoking   1 2  3  8 TBZIGI   ____ 
99.  He has many 'sex partners'   1 2  3  8 TBSEX  ____ 
100. He is often sleeping on cold floor  1 2  3   8 TBCOLD  ____ 
 
 
 
101. When you found out that you had TB: were you then very sad  
       or in other words very depressed? 
     __  No       (=0) 
        __  A little bit    (=1) 
        __  Somewhat yes    (=2) 
      __  Yes      (=3) 
       __  I can't remember    (=8) 
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         102. Were you afraid to die when you found out that you had TB?  SDIE  ____  
        
     __  No       (=0) 
        __  A little bit     (=1) 
        __  Somewhat yes   (=2) 
      __  Yes     (=3) 
       __  I can't remember    (=8) 
 
103. Did you feel that your self-worth or self-esteem became smaller  
       when you found out that you had TB? 
  
     __  No       (=0) 
        __  A little bit     (=1) 
        __  Somewhat yes   (=2) 
      __  Yes     (=3) 
       __  I can't remember    (=8) 
 
        
104. Did you feel embarrassed or ashamed when you found out  SHIYA  ____ 
       that you had TB?   
 
     __  No       (=0) 
        __  A little bit     (=1) 
        __  Somewhat yes   (=2) 
      __  Yes     (=3) 
       __  I can't remember    (=8) 
 
 
105. Did you feel kind of sinful when you found out that you had TB? SGUILT  ____ 
        
           __  No       (=0) 
        __  A little bit     (=1) 
        __  Somewhat yes   (=2) 
      __  Yes     (=3) 
       __  I can't remember    (=8) 
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106. In your opinion, were there some people who changed their   SBAD ____ 
       attitude towards you when they heard that you had sickness on the lungs?  
 
     __  No       (=0) 
        __  A little bit    (=1) 
        __  Somewhat yes    (=2) 
      __  Yes      (=3) 
       __  I don't know     (=8) 
 
107.  Did you feel that some people avoided you when you had TB?       SOSTRA  ____ 
     __  No       (=0) 
        __  A little bit    (=1) 
        __  Somewhat yes    (=2) 
      __  Yes      (=3) 
       __  I don't know    (=8) 
 
--------------------------------------------------------------------------------------------------------------------    
 
e) Personal items 
108.  How many persons were living in your household while   PPEOPLE  ____ 
        you were taking? 
     ______  person       
 
109. How big was the monthly income of all those together who had  PINCOME  ____ 
       an income in your household before you got sick on your lungs?  
 
     __  less than P 3000       (=1)   
 __  less than P 4000:       (=2) 
 __  between P 4000 and 6000      (=3) 
 __  between P 6000 and 8000      (=4) 
 __  between P 8000 and 10,000       (=5) 
 __  between P 10,000 and 14,000        (=6) 
 __  more than  P 14,000       (=7) 
 __  It's hard to say /  I don't know         (=8) 
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110.  In your opinion, to what group of people does your family belong?  PPERCPOV  ____ 
         
                 __  quite rich      (=1) 
  __  not rich, but a good income (=2) 
  __  has a bit more than just needed (=3) 
  __  quite poor  (=4) 
  __  poor (=5) 
  __  very poor (=6) 
 __  I don't know       (=8) 
 
 
111. How often did you go to church in 1996?       PCHURCH _____ 
 __  very seldom     (=1) 
 __  around once every second month      (=2) 
 __  around once a month        (=3) 
 __  around twice a month       (=4) 
 __  around once a week        (=5) 
 __  more than once a week           (=6) 
     __  I don't know          (=8) 
 
112. Normally, in which church do you go?     PRELI  ____   
                   __  in the Catholic Church    (=1) 
            __  in a Protestant church   (=2) 
   __  in a "born-again" church (=3)     
  __  in the "Iglesia ni Cristo" church   (=4)    
  __  in another church; what kind?________________  (=5) 
__  it depends                 (=6) 
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113. What kind of education did you have?    PEDUC  ____ 
      __  None     (=0) 
         __  Elementary school              (=1) 
 __  Graduate of elementary school   (=2) 
 __  High School     (=3) 
 __  graduate of High School     (=4) 
             __  Vocational training    (=5)  
 __  Graduate of a vocational training   (=6) 
 __  College level     (=7) 
 __  College graduate     (=8) 
 __  Post-graduate     (=9) 
                 
 
114. Do you feel that your TB is now totally healed?     PHEALED  ____ 
        
     __  No     (=0) 
     __  Not really     (=1) 
     __  Yes, almost     (=2)   
     __  Yes, fully healed     (=3)    
     __  I don't know       (=8) 
 
115. Are you afraid that your TB might come back?     PFEAR ____ 
     __  No     (=0) 
     __  A little bit      (=1) 
     __  Somehow yes      (=2) 
     __  Yes, I am really afraid     (=3) 
     __  I don't know      (=8) 
 
116.  Was it the first time when you had sickness on the lungs in 1996?      PTBULIT ___ 
           
          PROBE!!    __  Yes, the first time       
     __  No; it was the  ______ time. 
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117. Did you smoke before you got diagnosed?                 PSMKBEF  ____ 
     __  No      (=0) 
     __  From time to time      (=1) 
__  Often     (=2) 
__  Always and quite heavily    (=3) 
     
118. And while you got medication, did you smoke?    PSMKTX  ____ 
     __  No      (=0) 
     __  From time to time      (=1) 
__  Often     (=2) 
__  Always and quite heavily    (=3) 
 
 
119. And now, do you smoke?     PSMKNOW  ____ 
     __  No      (=0) 
     __  From time to time      (=1) 
__  Often     (=2) 
__  Always and quite heavily    (=3) 
 
 
120. Did you drink alcohol before you got diagnosed?    PALCBEF  ___ 
     __  No      (=0) 
     __  From time to time      (=1) 
__  Around once a week     (=2) 
__  More than once a week    (=3) 
 
 
     
121.  And while you got medication?     PALCTX  ____ 
     __  No      (=0) 
     __  From time to time      (=1) 
__  Around once a week     (=2) 
__  More than once a week    (=3) 
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122. And now, do you drink alcohol?     PALCNOW  ____ 
     __  No      (=0) 
     __  From time to time     (=1) 
__  Around once a week     (=2) 
__  More than once a week    (=3) 
 
 
g) Re substudy 3 
 
 
 
What can you say about the giving of explanations of the health center staff to you?   
 
123. Were the explanations sufficient CCSAPAT ____  
 __  Yes, very sufficient (=1) 
 __  Yes, sufficient (=2) 
 __  Only somehow sufficient (=3) 
 __  Not sufficient (=4) 
     __  I don't know      (=8) 
 
124. Were the explanations clear (easy to understand)?            CCCLEAR ____  
 __  Yes, very clear (=1) 
 __  Yes, clear (=2) 
 __  Only somehow clear (=3) 
 __  Not clear (=4) 
     __  I don't know      (=8) 
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125.  Was it easy to remember the explanations?  CCEASY ____ 
 __  Yes, very easy (=1) 
 __  Yes, easy (=2) 
 __  Only somehow easy (=3) 
 __  Not easy (=4) 
     __  I don't know      (=8) 
 
 
 
126.  Was your belief or trust in the drugs (that they were effective) firm while you were  CCDRUGS ____ 
          receiving medication?   
   
       SHOW IT AND PROBE! __  Yes, very firm  (=1) 
 __  Yes, firm  (=2) 
 __  Only somehow firm (=3) 
 __  No. It was small (=4) 
     __  I don't know      (=8) 
 
 
127. Was your belief that treatment was lacking if it did not last six months strong  CCSIXMOS ____ 
         while you were receiving medication?   
         (Or in other words that treatment was really needed for six months?)  
    
       SHOW IT AND PROBE! __  Yes, very strong (=1) 
 __  Yes, strong (=2) 
 __  Only somehow strong (=3) 
 __  No. It was weak (=4) 
     __  I don't know      (=8) 
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128.  Was your sickness very serious or dangerous in your view when you started to get medication?     CCGRABE ___ 
   
       SHOW IT AND PROBE! __  Yes, very serious (=1) 
 __  Yes, serious (=2) 
 __  Only somehow serious (=3) 
 __  No (=4) 
     __  I don't know      (=8) 
 
 
 
129.  Were you afraid of the 'side effects' while being on medication? CCSIDEF ____ 
 
       SHOW IT AND PROBE! __  Yes, very much afraid (=1) 
 __  Yes, I was afraid (=2) 
 __  I was only somehow afraid  (=3) 
 __  No, I was not afraid  (=4) 
     __  I don't know      (=8) 
 
 
 
130. Do you know of someone who was not healed of his or her TB even though he or she       CCDIGALI____ 
         was receiving medication?               If yes: How many do you know? 
 
 
             
 
 
 
        131. If yes: Why were they not getting well?         ____________    CCWHY ____ 
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